Sub-Nuclear Localization and Tumorigenic Function of the Oncoprotein Dek. by Khodadoust, Michael S.
 












A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
(Immunology) 










 Professor David M. Markovitz, Chair 
 Professor David R. Engelke  
 Professor Bruce C. Richardson 
 Associate Professor Colin Duckett 







































 I would like to thank the National Science Foundation and the University of 
Michigan Rackham Graduate School for funding.  There have been several important 
contributions made to this work by others.  Kajal Sitwala and Joanne Cleary initially 
described the acetylation of DEK and its relocalization following acetylation as presented 
in Figures 2 and 3.  Roland Kwok performed the in vitro acetylation of DEK presented in 
Figure 2.  Philip Cole and Marek Cebrat provided us with the acetylase inhibitors.  Nirit 
Mor-Vaknin constructed the DEK-GFP vector.  The Bcl-XL expression lentivirus was 
created by Kary Oetjen.  The mcl-1 luciferase reporter plasmids were a kind gift of 
Douglass Cress.  TW-37 was provided by Shaomeng Wang.   I thank Ron Koenig and 
Keith Bishop for their support and advice.  Special mention is deserved of Ellen Elkin, 
Penny Morris, Zarinah Aquil and Dianna Banka for their tremendous help.   
 Many others have assisted in less direct ways, but this work would not have been 
possible without their assistance.  I thank Monique Verhaegen for her assistance and her 
always helpful advice and ideas that have helped shape this work.  I also thank MaryBeth 
Riblett for her frequent assistance in providing cell cultures.  I would like to thank all of 
the members of the Markovitz lab for providing me with such an enjoyable workplace for 
these several years.  I am especially indebted to Ferdinand Kappes who has served as an
advisor, a colleague, and a dear friend.  He has provided me with a steady supply of 
interesting and insightful discussion, both scientific and not-so-scientific.   
iv 
 I have benefited from a wealth of intellectual assistance throughout my graduate 
student career.  I thank the members of my dissertation committee, Colin Duckett, David 
Engelke, Roland Kwok, and Bruce Richardson, for continuing to provide valuable 
direction and criticism even as the direction of research veered far from its starting point.  
Maria Soengas deserves special recognition for her role in the completion of this 
dissertation.  This work was made possible by her unwavering commitment to my 
success, and I have benefited greatly from my opportunity to learn from her.  Finally, I 
have to thank my mentor, David Markovitz.   Both scientifically and personally, it has 
been a gift to have worked with him.  His passion for science combined with his genuine 
compassion for those around him have made him the ideal mentor. 
  Lastly, I thank Susie and my family.  Their love and support gave me strength in 
the most difficult of times.  For that, I will always be grateful.  
 







As of the submission of this dissertation, Chapter II has been published in modified form. 
 
Cleary, J., Sitwala, K.V., Khodadoust, M.S., Kwok, R.P., Mor-Vaknin, N., Cebrat, M., 
Cole, P.A., Markovitz, D.M.,  2005.  p300/CBP-associated factor drives DEK into 
interchromatin granule clusters. J Biol Chem 280: 31760-7.
vi 
TABLE OF CONTENTS 
DEDICATION................................................................................................................... ii 
ACKNOWLEDGEMENTS ............................................................................................ iii 
FORWARD ....................................................................................................................... v 
LIST OF FIGURES ....................................................................................................... viii 
LIST OF TABLES ............................................................................................................ x 
CHAPTER I ...................................................................................................................... 1 
INTRODUCTION 
Structure of DEK............................................................................................. 1 
Functions of DEK ........................................................................................... 6 
DEK Expression and Cancer ........................................................................ 15 
DEK Functions in Cancer ............................................................................ 21 
Summary........................................................................................................ 29 
CHAPTER II................................................................................................................... 31 
P300/CBP-ASSOCIATED FACTOR DRIVES DEK INTO 
INTERCHROMATIN GRANULE CLUSTERS 
Abstract .......................................................................................................... 31 
Introduction ................................................................................................... 32 
Results............................................................................................................ 35 
Discussion...................................................................................................... 49 
Materials and Methods.................................................................................. 55 
vii 
CHAPTER III ................................................................................................................. 62 
DEK EXPRESSION INHIBITS SENESCENCE IN MELANOMA 
Abstract .......................................................................................................... 62 
Introduction ................................................................................................... 63 
Results............................................................................................................ 66 
Discussion...................................................................................................... 75 
Materials and Methods.................................................................................. 82 
CHAPTER IV.................................................................................................................. 86 
DEK PROMOTES CHEMORESISTANCE IN MELANOMA THROUGH 
UPREGULATION OF MCL-1 EXPRESSION 
Abstract .......................................................................................................... 86 
Introduction ................................................................................................... 87 
Results............................................................................................................ 89 
Discussion.................................................................................................... 101 
Material and Methods ................................................................................. 106 
CHAPTER V ................................................................................................................. 110 
CONCLUSION 
DEK and mRNA processing ....................................................................... 110 







LIST OF FIGURES 
 
 
FIGURE 1.  STRUCTURE OF THE HUMAN DEK PROTEIN.................................................... 2 
FIGURE 2.  DEK IS ACETYLATED IN VIVO AND IS ACETYLATED IN VITRO BY CBP, P300, 
AND P/CAF.. ............................................................................................................. 37 
FIGURE 3.  TREATMENT OF T98G CELLS WITH TSA RESULTS IN THE CONCENTRATION 
OF DEK IN PUNCTATE BODIES WITHIN THE NUCLEAR SPACE, WHICH ARE IGCS.  41 
FIGURE 4. TREATMENT OF T98G CELLS WITH THE P/CAF-SPECIFIC INHIBITOR H3-
COA-20-TAT PREVENTS TSA-MEDIATED ACCUMULATION OF DEK IN IGCS....... 42 
FIGURE 5.  OVEREXPRESSION OF P/CAF, BUT NOT CBP, DRIVES DEK INTO IGCS...... 44 
FIGURE 6. INHIBITION OF TRANSCRIPTION ALTERS DEK SUB-NUCLEAR LOCALIZATION
................................................................................................................................... 46 
FIGURE 7. TSA DOES NOT ENHANCE DEK ASSOCIATION WITH RNA.. .......................... 48 
FIGURE 8.  RNA IMMUNOPRECIPITATION OF DEK. ....................................................... 50 
FIGURE 9.  OVEREXPRESSION OF DEK IN METASTATIC MELANOMA LINES................... 67 
FIGURE 10.  KNOCKDOWN OF DEK EXPRESSION REQUIRES TWO DISTINCT SHRNAS.. 70 
FIGURE 11.  SHRNA INTERFERENCE OF DEK AFFECTS CELL PROLIFERATION............. 72 
FIGURE 12.  SENESCENCE ASSOCIATED Β-GALACTOSIDASE ACTIVITY OF SHDEK-
TRANSDUCED MELANOMA LINES.. ............................................................................ 74 
FIGURE 13.  IMMUNOBLOTTING OF SHDEK-TRANSDUCED MELANOMA LINES FOR 
SENESCENCE MARKERS ............................................................................................ 76
 
ix 
FIGURE 14.  DEK IS EXPRESSED BY MELANOCYTES DURING ONCOGENE-INDUCED 
SENESCENCE. ............................................................................................................ 77 
FIGURE 15.  DEK DOES NOT CO-LOCALIZE WITH SENESCENCE ASSOCIATED 
HETEROCHROMATIN FOCI. ....................................................................................... 78 
FIGURE 16.  INTERFERENCE WITH DEK EXPRESSION SENSITIZES SK-MEL-19 
METASTATIC MELANOMA CELLS TO PRO-APOPTOTIC STIMULI. ............................. 91 
FIGURE 17.  KNOCKDOWN OF DEK DECREASES MCL-1 EXPRESSION, BUT DOES NOT 
AFFECT THE P53 RESPONSE TO DOXORUBICIN......................................................... 93 
FIGURE 18.  DIMINISHED MCL-1 EXPRESSION IN DOXORUBICIN SHDEK-TRANSDUCED 
CELLS IS NOT CASPASE-3 DEPENDENT.. .................................................................... 95 
FIGURE 19.  DIMINISHED MCL-1 EXPRESSION IN SHDEK-TRANSDUCED SK-MEL-19 
AND SK-MEL-29 CELLS IS NOT SHRNA OR VECTOR SPECIFIC. ............................. 97 
FIGURE 20.  KNOCKDOWN OF DEK DECREASES MCL-1 PRODUCTION, BUT DOES NOT 
AFFECT MCL-1 PROTEIN STABILITY ........................................................................ 98 
FIGURE 21.  DECREASED ACTIVITY OF THE MCL-1 PROMOTER IN SHDEK-TRANSDUCED 
CELLS. ....................................................................................................................... 99 
FIGURE 22.  MCL-1, BUT NOT BCL-XL, EXPRESSION CONFERS DOXORUBICIN 
CHEMORESISTANCE IN MELANOMA. ...................................................................... 102 
FIGURE 23.  MCL-1 EXPRESSION, BUT NOT BCL-XL, EXPRESSION RESTORES 







LIST OF TABLES 
 
 
TABLE 1.  INHIBITORY PROPERTIES OF H3-COA-20-TAT AND H3-AC-20-TAT 
(CONTROL) CONJUGATES AGAINST P300 AND P/CAF. ............................................ 42 
TABLE 2.  MELANOMA-ASSOCIATED EVENTS IDENTIFIED WITHIN METASTATIC 








 The human DEK gene encodes a structurally unique protein that has been 
implicated in a diverse set of cellular processes, including regulation of transcription, 
chromatin architecture, mRNA processing, and cell signaling.  The participation of DEK 
in these disparate processes is most likely regulated through extensive post-translational 
modification by phosphorylation, acetylation, and poly (ADP)-ribosylation.  DEK has 
been associated with both autoimmunity and cancer, though its contribution to 
pathogenesis of either disease is unclear.  This chapter will address the known structural 
and functional features of the human DEK protein.  The link between DEK and cancer 
will also be explored in detail. 
Structure of DEK 
 Structurally, DEK is a unique protein that shares little homology with any other 
known proteins.  DEK exhibits high sequence conservation among higher eukaryotes, 
with ~91% sequence conservation between human and mouse DEK.  Notably, there are 
no known DEK homologs in either Saccharomyces cerevesiae or Caenorhabditis elegans 
genomes.  The SAP box is the only region of DEK with known homology to other 
proteins (Figure 1).  The SAP box domain is named for three proteins initially found to 
















PIAS (Protein Inhibitor of Activated Stat) (Aravind and Koonin 2000).  The initial search 
for proteins containing sequence similarity to SAF-A and SAF-B yielded 29 other 
proteins and identified the SAP box as a 34 residue motif with a number of highly 
conserved residues.  The SAP box functions as a DNA-binding domain and also mediates 
attachment of SAP-containing proteins to AT-rich chromosomal regions of the nuclear 
matrix (Romig, Fackelmayer et al. 1992; Bohm, Kappes et al. 2005).   Additionally, SAP-
containing proteins frequently also possess a separate RNA-binding domain (Aravind and 
Koonin 2000) and some, like SAF-B, display interactions with both RNA polymerase and 
mRNA processing factors  containing serine-arginine repeats (SR proteins) (Nayler, 
Stratling et al. 1998), suggesting a possible role as a bridge between transcription and 
pre-mRNA processing.  Finally, several SAP box containing proteins, such as poly(ADP-
ribose) polymerase (PARP) and Ku70,  have emerged as high profile members of the 
cellular DNA repair machinery  (Schreiber, Dantzer et al. 2006; Morio and Kim 2008).   
 There exists only one other recognizable motif within the DEK sequence: a 
bipartite nuclear localization sequence (NLS).  The bipartite NLS is composed of two 
adjacent basic residues followed by a stretch of basic residues 10 amino acids 
downstream of the initial pair of basic residues (Dingwall and Laskey 1991).  The second 
stretch of basic residues must contain at least 3 basic residues out of five total residues.  
As the name suggests, the bipartite NLS localizes proteins to the nucleus (Dingwall and 
Laskey 1991).  Although DEK is almost exclusively restricted to the nucleus (exceptions 
discussed below and in Chapter II), the contribution of the bipartite NLS to its 
localization has never been experimentally tested.   
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 In fact, it is likely that this bipartite NLS is not necessary for targeting of DEK to 
the nucleus.  In silico analysis of the effect of deleting the bipartite NLS reveals no 
change in the probability of nuclear localization as compared to wild type DEK (Horton, 
Park et al. 2007).  The more significant factor may be its overall basic charge, a 
characteristic feature of nuclear proteins.  The predicted isoelectric point of human DEK 
is 8.6, and at a pH of 7, DEK would be estimated to have a net charge of +6.3.  
Strikingly, of the total 375 amino acids of DEK, 82 are strongly basic (~22%).  This is 
offset in large part by three large acidic stretches, one N-terminal and two C-terminal.  In 
total there are 76 strongly acidic residues, and thus 42% of DEK carries a charge, and 
another 25% of DEK is composed of polar residues.   
 One of the most remarkable features of the amino acid composition of DEK is 
that there are 67 lysine residues.  In addition to being a basic residue, lysine is also 
significant in that it is a frequent acceptor of post-translational modifications.  These 
include acetylation, mono-, di-, tri-methylation, Nε-lysine formylation, ubiquitination, 
SUMOylation, glycation, and ADP-ribosylation (Imamura, Neildez et al. 2004; Krueger 
and Srivastava 2006; Hunter 2007; Povey, Howard et al. 2008; Wisniewski, Zougman et 
al. 2008).  DEK has long been suspected to be a target of post-translational modification.  
Indirect evidence of possible post-translational modification was inferred by the 
discrepancy between DEK’s predicted and observed molecular weight.  Based on its 
amino acid composition, DEK is predicted to be a 43 kilodalton protein, yet by SDS-
PAGE analysis, DEK is almost invariably observed to migrate as an approximately 50 
kilodalton protein (Alexiadis, Waldmann et al. 2000; McGarvey, Rosonina et al. 2000; 
Faulkner, Hilfinger et al. 2001; Kappes, Burger et al. 2001).  Subsequent studies have 
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confirmed that DEK is substantially post-translationally modified in vivo.  Radiolabeling 
with 
32
P-orthophosphate first demonstrated that DEK was a phosphoprotein (Fornerod, 
Boer et al. 1995). Detailed quadrupole ion trap mass spectrometry analysis later mapped 
several phosphorylation sites of human DEK, and CK2 was identified as the primary 
kinase involved in phosphorylation of DEK (Kappes, Damoc et al. 2004).  We and others 
have additionally found that DEK is a target of poly(ADP)-ribosylation by PARP 
(Gamble and Fisher 2007; Kappes, Fahrer et al. 2008).  Finally, in chapter II of this work, 
we demonstrate that DEK is also an acetylated protein.  Importantly, all three of these 
described modifications have also been shown to have important implications in the 
regulation of DNA-binding activity and sub-cellular localization of DEK. 
 X-ray crystallography structures have not been determined for DEK. However, H. 
Matsuo and colleagues have provided NMR based structures of two important domains: 
amino acids 68-226 and amino acids 309-375 (Devany, Kappes et al. 2008).   The 
structure of the 68-226 fragment of DEK revealed that there exists a second domain N-
terminal to the SAP box that exhibits structural similarity to the SAP box, despite sharing 
little sequence similarity.  Interestingly, this region had previously been found to be 
important in enhancing the DNA-binding affinity of the SAP box and also conferred 
upon DEK DNA-supercoiling activity (discussed below) (Bohm, Kappes et al. 2005).  A 
similar agreement between form and function was observed with the C-terminal fragment 
of DEK.  The NMR structure of this portion of DEK revealed a winged helix DNA-
binding motif similar to that of the E2F/DP transcription factor family (Devany, Kotharu 
et al. 2004), and Kappes et al. (Kappes, Scholten et al. 2004) experimentally determined 
that this region represents a second, previously unidentified DNA-binding domain of 
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DEK.  In addition to DNA-binding, this region was also shown to be critical to the ability 
of DEK to form multimers in a phosphorylation-dependent manner (Kappes, Scholten et 
al. 2004).   
Functions of DEK 
Transcriptional regulation  
 The first described functional activity of DEK was as a transcriptional repressor 
of the HIV-2 virus.  DNase footprinting studies had identified a cellular factor that 
protected a 10 base pair region of the HIV-2 transcriptional enhancer adjacent to a 
purine-rich ets binding site (termed peri-ets or pets) (Markovitz, Smith et al. 1992).  
Subsequent studies identified a 43 kilodalton protein capable of protecting this region (Fu 
and Markovitz 1996).  Using a Southwestern screen of a Jurkat T cell phage library, DEK 
was determined to be the unknown factor (Fu, Grosveld et al. 1997).  Its role as a 
transcriptional repressor was inferred by its presence in transcriptionally inactive protein 
complexes binding to this site, and its absence in transcriptionally active complexes that 
are induced upon 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment (Faulkner, 
Hilfinger et al. 2001).   
 Several studies have since found evidence supporting a role for DEK as a 
transcriptional repressor.  DEK was found to be a transcriptional co-repressor in a 
complex composed of the transcriptional repressor Daxx, the core histones H2A, H2B, 
H3, and H4, and histone deacetylase II (HDAC2) (Hollenbach, McPherson et al. 2002).  
DEK has also been shown to potently repress NF-κB transcriptional activity via 
interactions with the p65 subunit (Sammons, Wan et al. 2006).  In addition to NF-κB 
repression, DEK is also capable of repressing activity of the androgen receptor, p53, and 
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Stat5b (Sammons, Wan et al. 2006; Wise-Draper, Allen et al. 2006).  Finally, DEK was 
described as an element present on chromatin that must be displaced by either SET (a 
histone chaperone) or PARP1 prior to transcriptional activation (Gamble and Fisher 
2007).   
 The mechanism of transcriptional repression by DEK has not been elucidated, but 
there are three likely possibilities.  First, DEK may act to inhibit histone acetylation at the 
promoters of target genes.  Ko et al. (Ko, Lee et al. 2006) found that DEK can interact 
with histones and inhibits their acetylation by the histone acetyltransferases p300 and 
p300/CBP-associated factor (P/CAF).  Second, because DEK has been shown to be 
present in a complex with HDAC2, DEK may act to recruit this histone deacetylase, and 
possibly others, to target promoters (Hollenbach, McPherson et al. 2002).  Both of these 
activities result in the same outcome, hypoacetylation of promoter-associated histones.  
Thus, it is very possible that DEK represses transcription by maintaining promoter 
hypoacetylation.  The third possible mechanism of transcriptional repression by DEK 
may be a consequence of DEK’s ability to alter chromatin architecture, a function that 
will be described later in this chapter. 
   Conversely, DEK has also displayed characteristics of a transcriptional co-
activator.  The first example of this ability was a study that identified DEK as an 
interaction partner for the inducible transcription factor AP-2α (Campillos, Garcia et al. 
2003).  DEK was found to promote activity of the APOE promoter by enhancing the 
DNA-binding affinity of AP-2α.  Other studies have demonstrated the presence of DEK 
in transcriptionally active chromatin regions.  During active transcription, the WSTF-
SNF2h chromatin remodeling complex interacts with several nuclear proteins, including 
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DEK (Cavellan, Asp et al. 2006).  Additionally, DEK was present at promoter-proximal 
regions of the CD21/complement receptor 2 (CR2) gene in the B cell lymphocytic Ramos 
cell line that expresses CD21/CR2, but not in another B cell-derived cell line, Nalm-6, 
that does not express CD21/CR2 (Hu, Illges et al. 2005).  By chromatin 
immunoprecipitation (ChIP) of DEK, DEK was found to be enriched in euchromatic, 
acetylated histone H4-containing chromatin fractions of HeLa cells (Hu, Scholten et al. 
2007).  A promoter-proximal element of the actively transcribed human topoisomerase I 
(TOPI) was enriched in chromatin fractions precipitated with anti-DEK antibodies.  
When transcription was inhibited with α-amanitin, this region was no longer enriched 
following ChIP analysis with anti-DEK antibodies, suggesting that DEK was only present 
at this promoter during active transcription.  Thus, DEK may also be capable of 
promoting gene transcription in certain circumstances. 
Modifying chromatin architecture 
 Although initial findings suggested that DEK’s affinity for its DNA targets was 
sequence dependent (Fu, Grosveld et al. 1997; Adams, Cha et al. 2003), other data have 
pointed to preferential binding to certain DNA structures.  Specifically, DEK has 
increased affinity for supercoiled and four-way junction DNA (also present in Holliday 
junctions or cruciform DNA) (Waldmann, Baack et al. 2003; Waldmann, Scholten et al. 
2004).  Because several other proteins with high affinity for these DNA structures, such 
as the high mobility group proteins (HMGs) and the linker histone H1, have been shown 
to play prominent roles in altering chromatin architecture (JR, Norman et al. 1998; 
Zlatanova and van Holde 1998)(Varga-Weisz, van Holde et al.; Thomas), this has been 
proposed as a potential function of DEK as well. 
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 Indeed, DEK has also been shown to exert direct effects on chromatin structure.  
This function is distinct from the roles in chromatin remodeling previously mentioned.  
Whereas chromatin remodeling is an ATP dependent process that alters access to DNA 
through nucleosome manipulation (Saha, Wittmeyer et al. 2006), the chromatin 
modifying activities of DEK do not utilize ATP hydrolysis and do not affect or require 
nucleosomes.  This function of DEK was identified after DEK was purified from nuclear 
extracts as a factor capable of reducing the number of negative supercoils present in 
circular SV40 minichromosomes (Alexiadis, Waldmann et al. 2000).  Further 
investigations demonstrated that this activity of DEK was also seen, albeit to a lesser 
degree, with naked DNA targets lacking histones (Waldmann, Eckerich et al. 2002).  
Detailed studies revealed that the reduction of negative supercoils was in fact due to the 
ability of DEK to induce constrained positive supercoiling of both naked and 
nucleosomal DNA in the presence of topoisomerase (Waldmann, Eckerich et al. 2002).  
Positive supercoiling activity was observed with a truncated form of DEK (a.a. 68-250) 
that contained only the SAP box and the regions immediately N-terminal and C-terminal 
to the SAP box (Bohm, Kappes et al. 2005).   Interestingly, a peptide limited only to the 
SAP box region of DEK (87-137) exhibited negative supercoiling activity.  
 The implications of this positive supercoiling activity are unclear.    Physiological 
examples of positive supercoiling include DNA unwinding during transcription and 
replication (Varga-Weisz, van Holde et al. 1993).  In these processes, positive 
supercoiling is induced ahead of the advancing polymerase, and the resulting positive 
supercoils are generally considered a necessary side effect of DNA unwinding, although 
recent data suggests that torsional stress caused by these processes may function to 
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transmit signals through the genome (Kouzine, Sanford et al. 2008).  Excessive positive 
supercoiling can create resistance that can stall advancing polymerases (Wang, Schnitzer 
et al. 1998), and thus in prokaryotes enzymes such as DNA gyrase exist to dissipate 
positive supercoils (Duguet 1997).  Eukaryotes do not have an equivalent mechanism, but 
are thought to use DNA/nucleosome interactions to absorb this torsional stress (Bancaud, 
Conde e Silva et al. 2006).  Few proteins capable of promoting positive supercoils have 
been identified.  The best known example of an enzyme with positive supercoiling 
activity is that of condensin.  Supercoiling by condensin during mitosis compacts the 
mitotic chromosomes and is required for proper chromosome segregation (Hagstrom and 
Meyer 2003).  Recently, positive supercoiling has also been implicated in formation of 
the complex DNA structure of eukaryotic telomeres.  Telomere repeat factor-2 (TRF2) 
had been shown to promote formation of a lasso-like DNA structure termed the t-loop 
(Griffith, Comeau et al. 1999).  The free guanine-rich DNA end (G-tail) of the telomere 
can invade this structure and by doing so, protects itself from nuclease degradation and 
from exposure to DNA strand break machinery (Stansel, de Lange et al. 2001).  Although 
the precise mechanism is still speculative, it was found that TRF2 also possessed positive 
supercoiling ability (Amiard, Doudeau et al. 2007).  Using a panel of TRF2 mutants, the 
authors found that the ability to induce positive supercoils correlated with the ability to 
promote t-loop formation and strand invasion.   
 Recently, we have discovered a role for DEK in global chromatin organization 
(Kappes, Khodadoust, et al., in preparation).  Using minimal and reconstituted chromatin 
templates and micrococcal nuclease as a tool, we found a significant decrease in 
chromatin accessibility and altered nucleosomal repeat length upon addition of 
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recombinant DEK in vitro. Furthermore, investigation of lentiviral shRNA-mediated 
inhibition of DEK in HeLa S3 cells by micrococcal nuclease digestion revealed a more 
accessible and open chromatin structure accompanied by changes in global histone 
acetylation and methylation in vivo. Furthermore, these cells exhibited reduced 
nucleosomal repeat length, chromosomal defects, altered cell cycle behavior, and a higher 
susceptibility to HDAC inhibitors. However, no increased apoptosis or senescence was 
observed upon DEK depletion. Interestingly, by electron microscopic imaging we found 
a significant loss of pericentric heterochromatic areas in cells lacking DEK. This 
observation is further supported by altered localization of HP1-α and aberrant 
organization of heterochromatic satellite DNA markers in DEKi cells.  These results 
point to a significant function of DEK as an essential factor required for the maintenance 
of heterochromatin, possibly by tethering HP1-α to pericentric chromatin. 
mRNA Processing 
 Although most cellular DEK is found tightly bound to chromatin, a role for DEK 
in pre-mRNA processing has also been suggested.  Digestion of HeLa nuclei with RNase 
results in the release of approximately 10% of DEK from the nucleus, implying a direct 
or indirect association between DEK and RNA (Kappes, Burger et al. 2001).  An 
experiment to discover novel SR-related proteins and associated factors identified DEK 
in a splicing complex containing these SR proteins (McGarvey, Rosonina et al. 2000).  
This study utilized a monoclonal antibody specific for a phosphoepitope present within 
the RS domains (rich in alternating arginines and serine residues) of many SR proteins to 
purify SR proteins in a multi-step fractionation.  In the final SR protein-enriched fraction, 
the authors found an approximately 50 kilodalton protein.  Mass spectrometry analysis 
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identified this protein as DEK.  DEK was found to co-immunoprecipitate with the 
splicing coactivator SRm160/300.  Furthermore, immunoprecipitation of DEK also 
precipitated splicing complexes.  Additionally, it was shown by immunofluorescence that 
~15% of HeLa cells exhibited co-localization of DEK and SR proteins. However, in 
characterizing the interaction between DEK and components of the splicing complex the 
authors discovered that DEK was not required for splicing, and that DEK did not have 
direct interactions with RNA splicing substrates.   
 DEK has also been posited as a member of the exon-exon junction complex.  The 
exon-exon junction complex is a complex of splicing proteins, including SRm160, that 
remain associated with recently spliced mRNA (Le Hir, Izaurralde et al. 2000).  This 
protein complex was originally identified in an attempt to identify the factors responsible 
for the protection from RNase of a conserved region 20-24 nucleotides upstream from the 
site of exon-exon linkage.  Immunoprecipitation with DEK-specific antibodies was able 
to precipitate this complex along with spliced mRNA, but not an identical RNA fragment 
that had been transcribed from a cDNA template and therefore had not undergone 
splicing.  Some members of the exon-exon junction complex remain associated with 
mRNA that has been transported to the cytoplasm, however DEK is not found in the 
cytoplasmic complex (Le Hir, Gatfield et al. 2001).    
 Since these initial studies, DEK’s participation in the exon-exon junction complex 
has been challenged.  Several other investigations focusing on the assembly of the exon-
exon junction complex and its interaction with the spliceosome failed to identify DEK as 
a component of the exon-exon junction complex (Lejeune, Ishigaki et al. 2002; Reichert, 
Le Hir et al.; Kataoka and Dreyfuss).  Furthermore, a detailed proteomic analysis of the 
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spliceosome C and H complexes failed to identify DEK as a component (Reichert, Le Hir 
et al. 2002).  It has been suggested that the initial observation of DEK associated with the 
exon-exon junction complex was a spurious result that was attributable to a cross-
reactivity of the only available anti-DEK antisera used in those experiments.  As evidence 
for this possibility, one group noted that the anti-DEK antisera reacted with an 
unidentified 20 kilodalton protein found in the complex (Reichert, Le Hir et al. 2002; 
Waldmann, Scholten et al. 2004).  However, there are several alternative explanations of 
the inconsistent findings regarding the association of DEK with ribonucleic protein 
(RNPs) complexes.  First, the association of DEK with RNPs may be transient or 
unstable under experimental conditions.  Second, given the array of potential post-
translational modifications of DEK, it is possible that the antisera used in early 
experiments demonstrated limited reactivity to certain modified forms of DEK that 
preferentially interact with RNPs.  The multitude of potential post-translational 
modifications of DEK also makes its identification by mass spectroscopy technically 
challenging, and thus may limit its identification in many proteomic-based studies.   
 The original observations linking DEK with RNPs never found DEK to be 
required for splicing reactions and never delineated any role for DEK in pre-mRNA 
processing.  However, a breakthrough study revealed a putative role in mRNA splicing.  
Metazoan 3’ splice sites are marked by a pyrimidine-rich tract and a conserved AG, 
which are recognized by the RNA-binding proteins U2AF65 and U2AF35, respectively 
(Zamore, Patton et al. 1992; Merendino, Guth et al. 1999; Wu, Romfo et al. 1999; Zorio 
and Blumenthal 1999).  If the polypyrimidine tract is sufficiently long, only U2AF65 is 
required to initiate the splicing reaction (Reed 1989; Wu, Romfo et al. 1999; Guth, Tange 
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et al. 2001).  However, shorter polypyrimidine tracts require U2AF35 binding to promote 
this reaction (Wu, Romfo et al. 1999; Guth, Tange et al. 2001).  Although previous 
studies had concluded that U2AF35 was sufficient to recognize the 3’ AG signal, 
experiments by Soares et al. (Soares, Zanier et al. 2006) have demonstrated that DEK can 
act as a proofreader of the 3’ splice site and confers specificity of U2AF35 to the AG 
signal.  Depletion of DEK eliminated this proofreading ability resulting in inability of 
U2AF35 to discriminate between 3’ AG and 3’ CG signals.  This ability of DEK required 
its phosphorylation at two specific serine residues.  The implications of this proofreading 
activity are significant, however further work and verification of DEK’s role in 
maintaining 3’ splice site fidelity is warranted. 
Chemoattraction 
 DEK has been repeatedly described as a strictly nuclear protein in multiple cell 
lines and lineages.  However, our group had noted that upon TPA stimulation of U937 
monocytic cells, DEK is absent from the nucleus (Faulkner, Hilfinger et al. 2001).  We 
subsequently found that DEK migration out of the nucleus could be seen in activated 
primary human monocyte-derived macrophages (MDMs) (Mor-Vaknin, Punturieri et al. 
2006).  Activation with 40% human serum resulted in translocation of DEK in to the 
cytoplasm.  Remarkably, we found that after several days of stimulation, DEK could be 
found extracellularly in MDM cultures.  We demonstrated that DEK was actively 
secreted via a non-classical secretion pathway and was not released as a result of cell 
death.  Extracellular DEK was found in a freely soluble form, but a significant portion of 
DEK was also found to be contained within exosomes.  Exosomes are small membrane-
bound vesicles that are released from certain cell types, most notably antigen presenting 
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cells (Chaput, Flament et al. 2006).  These vesicles have been shown to be capable of 
presenting antigen to cells without requiring cell-cell contact (Raposo, Nijman et al. 
1996).  Because DEK has been found to be an autoantigen in a number of autoimmune 
diseases, most prominently juvenile idiopathic arthritis, this finding has important 
implications in the pathogenesis of those diseases (Szer, Sierakowska et al. 1994; 
Murray, Szer et al. 1997; Dong, Michelis et al. 1998; Dong, Wang et al. 2000).   
 We additionally examined whether the freely soluble form of DEK may exhibit 
pro-inflammatory function.  Intriguingly, recombinant DEK was found to be a potent 
chemoattractant for CD8+ lymphocytes, CD56+ natural killer cells, and neutrophils.  
Thus, it appears that activated macrophages may secrete DEK to promote inflammation.  
In support of this possibility, we found anti-inflammatory treatment with dexamethasone 
and cyclosporine A could block DEK secretion.  Notably, inhibitors of classical golgi-
secretion pathways, such as brefeldin A and monensin, did not block secretion, but 
treatment with an inhibitor of the kinase CK2 did inhibit secretion.  Therefore, it appears 
that post-translational modification of DEK may be an important factor in the release of 
DEK from MDMs.  The contributions of the more recently identified post-translational 
modifications of DEK, namely acetylation and poly(ADP)-ribosylation, to its secretion 
are currently being investigated. 
DEK Expression and Cancer 
DEK-NUP214 
 DEK was initially discovered as part of a chromosomal translocation, 
t(6;9)(p23;q34), observed in a subset of acute myeloid leukemia (AML) patients (von 
Lindern, Fornerod et al. 1992; von Lindern, van Baal et al. 1992).  Its name derives from 
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the initials of one such patient: D.K.  This translocation event occurs most often in the 
M2 subset of AML (acute myeloblastic leukemia with maturation), but can occur in other 
subtypes as well (Soekarman, von Lindern et al. 1992; Lowenberg, Downing et al. 1999).  
The translocation results in a fusion of the N-terminal 359 amino acids of DEK with the 
C-terminal 1278 amino acids of the nucleoporin NUP214 (also called CAN) (von 
Lindern, van Baal et al. 1992).  The potential oncogenic function of this fusion protein 
has been poorly described.  However, the fusion of a nuclear factor with a nucleoporin 
has been seen in other translocation events associated with AML.  Notably, NUP214 also 
forms a similar fusion protein production with SET in acute promyelocytic leukemia 
(APL) (von Lindern, van Baal et al. 1992).  This is of particular interest, given the 
recently described interaction between SET and DEK (Gamble and Fisher 2007).   
DEK overexpression in cancer 
 DEK has since been found to be overexpressed in a number of malignancies, 
independent of the t(6;9) translocations.  The list of cancers in which DEK is 
overexpressed continues to grow and currently includes retinoblastoma, hepatocellular 
carcinoma, bladder carcinoma, glioblastoma, acute myeloid leukemia, lung carcinoma, 
breast cancer, colon cancer, uterine cervical cancer, and melanoma (Kondoh, Wakatsuki 
et al. 1999; Grottke, Mantwill et al. 2000; Kroes, Jastrow et al. 2000; Larramendy, Niini 
et al. 2002; Sanchez-Carbayo, Socci et al. 2003; Lu, Luo et al. 2005; Wu, Li et al. 2008).  
Overexpression in almost all of these tumors has been evaluated solely by DEK mRNA 
expression.  The exceptions are retinoblastoma and lung carcinoma, in which DEK 
overexpression has been validated by immunoblotting or immunofluorescence (Carro, 
Spiga et al. 2006; Orlic, Spencer et al. 2006).  Overexpression of DEK does not appear to 
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be ubiquitous in these tumors, but is instead found in a subset of each malignancy.  The 
percentage of these cancers displaying increased DEK expression has not been rigorously 
examined, but the best estimations have been provided by the work of Carro et al. (Carro, 
Spiga et al. 2006)  Using tissue microarray analysis of 460 total tissue samples, including 
both tumors and normal tissue counterparts, the authors identified melanoma as the 
cancer with the greatest proportion of DEK-expressing tumors (72%).  Additionally, 
bladder cell carcinoma and colon cancer showed a high incidence of DEK overexpression 
(50% of each).   
 The tissue microarray analysis also found that expression of DEK correlated with 
other tumor characteristics.  Importantly, DEK expression in melanoma and colon cancer 
appeared to correlate with tumor grade (Carro, Spiga et al. 2006).  In colonic tissue DEK 
expression was higher in adenomas than in hyperplastic polyps.  Moreover, colon 
carcinomas expressed much higher levels of DEK than adenomas.  Similarly, analysis of 
melanoma revealed higher expression of DEK in primary melanoma samples than in skin 
nevi.  Additionally, metastatic melanoma tumors had markedly increased DEK 
expression over primary sites of melanoma formation.  In addition to a correlation 
between DEK expression and tumor grade, the authors also described a direct correlation 
between expression of DEK and Ki67.  Ki67 is a nuclear antigen present in actively 
dividing cells that is frequently used as a measure of proliferative activity (Scholzen and 
Gerdes 2000).  This association between expression of DEK and proliferation has been 
seen in normal tissue as well.  In cells of hematopoeitic lineage, DEK also appears to be 
expressed to a higher degree in dividing cells.  Bone marrow cells expressing CD34 have 
greater expression of DEK than CD34-negative cells (Ageberg, Gullberg et al. 2006).  
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CD34 is a marker that is used in the enrichment of hematopoietic stem cells as well as 
undifferentiated progenitor cells.  Finally, stimulation of lymphocytes with the mitogenic 
lectin phytohemagglutinin and IL-2 also causes upregulation of DEK (Ageberg, Gullberg 
et al. 2006). 
Chromosome 6p gain     
 The mechanism responsible for increased DEK expression is not known in the 
majority of these tumors.  However, studies of retinoblastoma and bladder cell carcinoma 
suggest a likely cause.  These cancers, like many others, frequently exhibit gain of the 6p 
chromosome arm (Squire, Phillips et al. 1984; Bruch, Wohr et al. 1998; Mairal, Pinglier 
et al. 2000; Evans, Gallie et al. 2004).  Though the majority of these gains are a result of 
whole arm gains (commonly from acquisition of an isochromosome of 6p), comparative 
genomic hybridization (CGH) and quantitative multiplex polymerase chain reaction 
(PCR) studies have identified minimal regions of 6p gain and amplification in these two 
malignancies (Chen, Gallie et al. 2001; Chen, Pajovic et al. 2002; Evans, Gallie et al. 
2004; Wu, Hoffmann et al. 2005).  These alterations are focused in a narrow region 
located with the 6p22.3 band that comprised only seven genes.  In retinoblastoma, gene 
dysregulation in this region was examined and only three genes were found to be 
upregulated: DEK, NUP153, and E2F3 (Orlic, Spencer et al. 2006).  A separate group 
identified DEK and E2F3 as the targets of 6p22.3 gain (Grasemann, Gratias et al. 2005).  
Thus, it appears likely that chromosomal alterations are at least partially responsible for 
the overexpression of DEK in these cancers.   
 Although minimal regions of gain have not been identified in other cancers, 6p 
gain is frequent chromosomal abnormality found in tumors, including colorectal 
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carcinoma, hepatocellular carcinoma, breast carcinoma, basal cell carcinoma, Merkel cell 
carcinoma, osteosarcoma, and several lymphoid tumors (Aalto, Nordling et al. 1999; Al-
Mulla, Keith et al. 1999; Ashton, Weinstein et al. 2001; Seute, Sinn et al. 2001; Ozaki, 
Schaefer et al. 2002; Larramendy, Koljonen et al. 2004; Moinzadeh, Breuhahn et al. 
2005; Santos, Zielenska et al. 2007).  Interestingly, gain of 6p has been associated with 
increased tumorigenicity of many of these tumors.  For example, 6p22 gain in carcinomas 
is associated with higher histological grade, greater proliferative activity, and metastases 
(Prat, Bernues et al. 2001; Tomovska, Richter et al. 2001).  Gains of 6p are also 
associated with transformation from low to high-grade non-Hodgkin’s lymphoma 
(Hough, Goepel et al. 2001).  Not surprisingly, 6p gain has also been shown to correlate 
with poor prognosis as well (Tarkkanen, Elomaa et al. 1999).   
Transcriptional upregulation 
 Although alterations in copy number appear to be a likely cause of DEK 
overexpression, this does not exclude other possible mechanisms of DEK upregulation.  
Because overexpression of DEK has been most frequently identified at the mRNA level, 
deregulation of DEK transcription must also be considered.  The DEK promoter has been 
characterized and appears to be driven by the transcription factors Yin Yang-1 (YY1) and 
Nuclear Factor-Y (NF-Y) (Sitwala, Adams et al. 2002).  The only other transcription 
factors that have been shown to directly bind and affect the DEK promoter are the E2F 
family of transcription factors (Carro, Spiga et al. 2006).  The activity of the E2F 
transcription factors is regulated through binding by the pocket protein family members: 
retinoblastoma tumor suppressor protein (pRb), p107, and p130.  Hyperphosphorylation 
of pRb occurs during the G1 phase of the cell cycle and results in the release of the E2F 
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proteins, which in turn are required for progression into S-phase.  Interestingly, pRb has 
also been shown to regulate YY1 activity (Petkova, Romanowski et al. 2001).  Thus, 
inactivation of the pRb tumor suppressor checkpoint would be predicted to result in 
upregulation of E2F and YY1, and consequently DEK.  Indeed, this regulation by pRb 
has been confirmed experimentally.  Using a conditional tetracycline-responsive 
repressor, it was shown that expression of a constitutively active form of pRb resulted in 
downregulation of DEK transcript (Vernell, Helin et al. 2003).  
 The pRb tumor suppressor pathway is a major barrier to tumorigenesis.  In normal 
cells, the pRb/E2F pathway is regulated in part by the cyclin dependent kinase (CDK) 
inhibitor, p16
INK4a
.  Through a poorly understood mechanism, repetitive cell division can 
increase p16
INK4a
 expression, resulting in activation of the pRb checkpoint and thus cell 
cycle arrest at the G1 stage.   Predictably, this pathway has been found to be frequently 
inactivated in cancer, with melanoma being a prime example.  Through a variety of 





suppressor pathway is almost invariably inactivated in this cancer (Bartkova, Lukas et al. 
1996; Walker, Flores et al. 1998).  As stated above, this inactivation would be predicted 
to result in increased DEK expression.  Furthermore, since E2F activity is regulated by 
cell division, it would be expected that rapidly proliferating cells would have increased 
E2F activity and thus higher DEK expression, potentially explaining the correlation 
between proliferation and DEK expression. Taken together, a compelling argument can 
be made that DEK overexpression is secondary to the frequently observed inactivation of 
the p16
INK4a
/pRb pathway in many cancers.  It is also certainly plausible, given the 
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heterogeneity of most tumors, that both 6p chromosomal gain and transcriptional 
upregulation are mechanisms of achieving DEK overexpression. 
 
DEK Functions in Cancer 
Inhibition of senescence 
 Based upon its overexpression in cancers, DEK has long been a suspected 
oncogene.  However, the potential cancer-promoting functions of DEK have only 
recently been examined.  The discovery of one such oncogenic property of DEK arose 
from studies of human papillomavirus infection (HPV).  HPV infection is an important 
cause of carcinogenesis of cervical cancer.  Two viral oncogenes, the HPV early genes 
E6 and E7, can cooperate to immortalize infected cells (Hawley-Nelson, Vousden et al. 
1989).  The HPV E6 protein binds and promotes degradation of the tumor suppressor 
p53, whereas HPV E7 binds to and inactivates pRB (Mantovani and Banks 2001; 
Munger, Basile et al. 2001).  However, another HPV gene, E2, can repress the activity of 
the E6/E7 promoters (Tan, Gloss et al. 1992; Demeret, Desaintes et al. 1997).  Loss of E2 
expression is frequently observed in malignant carcinomas transformed by HPV 
infection, and if E2 expression is restored, these cells undergo senescence (Francis, 
Schmid et al. 2000; Goodwin and DiMaio 2000; Goodwin, Yang et al. 2000; Wells, 
Francis et al. 2000; Wells, Aronow et al. 2003).  Senescence is the irreversible loss of 
ability to proliferate and is naturally induced in normal somatic cells after completion of a 
finite number of cell divisions (replicative senescence).  In addition to cell death, 
senescence represents an additional important barrier to the transition of normal cells to 
cancerous cells.   
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 Gene array analysis of E2-mediated senescent cells, where E2 was reintroduced 
into HPV positive HeLa cells, revealed that DEK expression was diminished in these 
cells (Wells, Aronow et al. 2003).  Subsequently, it was found that overexpressing DEK 
in these cells could oppose the senescence response (Wise-Draper, Allen et al. 2005).  
Furthermore, it was shown that DEK was upregulated by the HPV E7 protein.  This 
upregulation of DEK by E7 required expression of the pRb pocket protein family, 
suggesting that DEK overexpression is a result of inactivation of pRb and the consequent 
increase in E2F activity.  The control of DEK expression by HPV E7 has also been 
separately confirmed (Johung, Goodwin et al. 2007).  Through microarray studies, 19 
E2F gene targets, including DEK, were found to be repressed during E2 induced 
senescence.  To determine if repression of DEK was sufficient to induce senescence, 
short hairpin RNAs (shRNA) targeting DEK expression were used to knockdown DEK 
expression in primary HPV-negative human fibroblasts.  Notably, even in the absence of 
HPV infection, interference with DEK expression alone resulted in senescence.  It should 
be noted that interference with expression of another E2F-regulated gene, B-MYB, also 
induced senescence.  In contrast to previous findings showing that overexpression of 
DEK could delay senescence, this group found that constitutive expression of DEK did 
not inhibit or delay the induction of senescence in response to E2.  Because these data 
were not shown, they should be considered with some caution.  We and others have 
observed that most methods of enhancing DEK expression result in, at best, modest 
transient expression of DEK.  In our experience, the most effective method of achieving 
DEK expression is through the use of adenoviral vectors, the method utilized by Wise-
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Draper et al.  Without data to evaluate, it is reasonable to suspect that the lack of 
senescence-inhibition observed by Johung et al. was due to insufficient DEK expression. 
 Replicative senescence represents the ultimate fate of most dividing normal 
somatic cells.  In contrast, tumor cells are capable of undergoing unlimited divisions, and 
thus appear to possess a means of bypassing the senescence response.  In addition to 
replicative senescence, cancer cells must also overcome another form of senescence, 
termed oncogene-induced senescence.  This refers to the observation that introduction of 
certain oncogenes into otherwise normal somatic cells results in the rapid onset of 
senescence.  One of the classic examples of this phenomenon is the rapid induction of 
senescence in fibroblasts following the artificial introduction of an oncogenic mutant 
form of the ras oncogene (Serrano, Lin et al. 1997).  Within days these cells cease 
division and begin to display hallmarks of senescence.  If, however, oncogenic ras is 
introduced into rodent cells with defects in either the p16
INK4a
/pRb or ARF/p53 tumor 
suppressor pathways, cells do not senesce.  Interestingly, human cells appear to display 
an important difference to their rodent counterparts in that both the p16
INK4a
/pRb and 
ARF/p53 senescence pathways must be inactivated to avoid senescence (Serrano, Lin et 
al. 1997).   
 A final important connection between DEK and senescence is the recently 
discovered link between chromatin structure and senescence.  Both replicative and 
oncogene-induced senescence result in dramatically altered chromatin.  Specifically, 
chromosomes condense and form dense heterochromatin foci, termed senescence-
associated heterochromatic foci (SAHF) (Narita, Nunez et al. 2003).  It is believed that 
these foci are responsible for the irreversible nature of senescence.  Interestingly, this 
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heterochromatic change was shown to result in the silencing of E2F target genes (Narita, 
Nunez et al. 2003).  Once heterochromatin foci are formed, ectopic E2F1 expression fails 
to restore expression of these genes.  One hypothesis suggests that pRb and E2F recruit 
factors to these genes that initiate heterochromatin formation.  In this model, these genes 
act as nucleation sites for the heterochromatization of the entire chromosome (Adams 
2007).  Importantly, DEK has been described to be downregulated during senescence of 
human primary keratinocytes and fibroblasts.  It is possible, therefore, that the DEK gene 
represents one of the targets of heterochromatin formation and gene silencing in 
senescencing cells. 
 The localization of DEK in senescent cells is also of particular interest.  We have 
discovered that interference with DEK expression has the remarkable effect of 
maintaining proper global chromatin structure (Kappes, Khodadoust, et al., in 
preparation).  Specifically, cells lacking DEK have diminished heterochromatin, and 
consequently, greater chromatin accessibility.  Furthermore, we have identified an 
interaction between DEK and heterochromatin protein-1α (HP1α).  The three HP1 
isoforms, HP1α, HP1β, and HP1γ, are components of heterochromatin thought to play an 
important role in the formation and maintenance of heterochromatin.  All three HP1 
isoforms were found to co-localize with SAHFs (Narita, Nunez et al. 2003).  
Surprisingly, the HP1 proteins were not found to be required for SAHF formation 
(Zhang, Chen et al. 2007).  Given DEK’s association with HP1α and its role in 
heterochromatin maintenance, it is plausible that DEK may also localize to SAHF or even 
may contribute their formation.  However, the finding that DEK expression is diminished 
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in senescing cells argues that DEK may not be associated with SAHFs and may not even 
be present during SAHF formation.  
Apoptosis and DEK 
 In addition to senescence, apoptosis represents an important barrier to cancer 
formation.  Many known oncogenes that are capable of promoting cell proliferation also 
simultaneously render cells more susceptible to death by apoptosis (Lowe, Cepero et al. 
2004).  For example, deregulation of Myc expression results in the activation of the 
ARF/p53 pathway and ultimately results in the induction of apoptosis (Evan, Wyllie et al. 
1992; Harrington, Fanidi et al. 1994).  Other oncogenes that display pro-apoptotic 
potential include E2F1 and Ras (Qin, Livingston et al. 1994; Wu and Levine 1994; Rak, 
Mitsuhashi et al. 1995; Arber 1999).  Thus, it seems the development of pro-apoptotic 
signals may be inherent in the transformation of a normal cell to a cancerous one.   
 The failure of tumor cells to undergo apoptosis despite their expression of 
oncogenes known to induce apoptosis in normal cells intimated the existence of defects 
in underlying apoptotic pathways.  Indeed, a myriad of survival mechanisms utilized by 
tumor cells has been uncovered (Sharma and Settleman 2007; Letai 2008).  A thorough 
description of these mechanisms is beyond the scope of this discussion, but events 
leading to the evasion of apoptosis can be crudely divided into two categories: 
enhancement of pro-survival signals/factors and inhibition of pro-apoptotic 
signals/factors.  Clearly, these same events also contribute to the ability of cancer cells to 
withstand chemotherapeutic interventions (chemoresistance) (Soengas and Lowe 2003; 
Eberle, Kurbanov et al. 2007).  Because of the clinical implications in overcoming 
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chemoresistance, identification of these anti-apoptotic alterations has been an extremely 
active, and fruitful, area of investigation.   
 One recurring survival mechanism utilized by many malignancies is the 
upregulation of the Bcl-2 family of anti-apoptotic proteins.  Through their binding to two 
related pro-apoptotic proteins, BAX and BAK, the Bcl-2 protein family protects against 
mitochondrial depolarization, the initiating event of the intrinsic apoptotic pathway.   
Initiation of apoptosis is induced through the displacement of the Bcl-2 family proteins 
from BAX and BAK by another class of pro-apoptotic proteins, the BH3-only proteins 
(Youle and Strasser 2008).  The BH3-only proteins are so-named because they possess a 
BH3 domain, but not BH1, BH2, or BH4 domains.  BH3-only proteins are activated, 
either transcriptionally or in some cases post-translationally, in response to apoptotic 
signals.  Examples of such signals include DNA damage (induces NOXA and PUMA), 
growth-factor deprivation (induces BIM and BAD), and endoplasmic reticulum stress 
(induces BIM) (Zha, Harada et al. 1996; Dijkers, Medema et al. 2000; Oda, Ohki et al. 
2000; Nakano and Vousden 2001; Yu, Zhang et al. 2001; Puthalakath, O'Reilly et al. 
2007).  By overexpressing the Bcl-2 family of proteins, tumor cells can accommodate 
stress or drug-induced activation of BH3-only proteins without triggering apoptosis.  
Chapter IV will demonstrate that, in the case of melanoma, increased expression of DEK 
can augment expression of one such Bcl-2 family member, Mcl-1, and thereby enhance 
chemoresistance. 
 The tumor suppressor protein p53 is an important mediator of apoptosis induced 
by many anti-neoplastic agents, particularly those that induce DNA damage.  Because of 
its critical role in both apoptosis and senescence, p53 is frequently mutated or deleted in 
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many cancers.  Interestingly, DEK has been shown to inhibit the action of p53, and 
consequently, to also inhibit apoptosis.  Using adenoviral delivery of shRNAs, Wise-
Draper et al. found that interference with DEK expression in HPV-positive HeLa cervical 
carcinoma cells resulted in apoptosis (Wise-Draper, Allen et al. 2006).  Conversely, 
adenoviral delivery of DEK inhibited HeLa apoptosis.  The anti-apoptotic function of 
DEK was also observed with primary human keratinocytes, but not with SAOS-2 
osteosarcoma cells.  Importantly, SAOS-2 cells carry a deletion of the p53 gene.  Due to 
the presence of the HPV E6 protein, HeLa cells do not have detectable levels of p53 
despite possessing intact wild type p53 gene.  Following interference with DEK 
expression, HeLa cells and keratinocytes exhibited increased p53 expression.  
Additionally, the activity of the promoters of several p53 target genes was enhanced.  The 
authors concluded that DEK inhibited p53-mediated basal apoptosis through repression 
of p53 protein stability and activation. 
 These data present a remarkable role for DEK in the suppression of p53-mediated 
apoptosis, however several experimental details complicate the interpretation of these 
results.  First, while the data demonstrate a clear enhancement of apoptosis following 
shRNA-mediated inhibition of DEK, the empty adenovirus that serves as a control 
appears to have a significant, but poorly examined effect.  In particular, growth curves of 
infected cells were never exponential, and in some experiments, control-infected cells 
either did not proliferate for several days or actually diminished in number.  Strangely, 
these control-infected cells displayed a remarkably high rate of basal apoptosis (6-14%) 
that appears to increase with time after infection, and most of the data is presented as 
“fold apoptosis,” making it difficult to discern the absolute level of background 
 
 28 
apoptosis.  Therefore, it appears that adenoviral infection itself is a potent apoptotic 
stimulus in these experiments.  Accordingly, this effect demands rigorous assessment of 
the multiplicity of infection (MOI) for each virus.  Although identical MOIs of each 
vector were used, there is no means of evaluating the degree of infection.  Indeed, the 
sole figure depicting the efficiency of infection appeared to demonstrate different 
transfection efficiencies for each vector.  It is noteworthy that attempts by our group to 
recapitulate these results using lentiviral vectors in lieu of adenoviral vectors failed to 
demonstrate the same effects (unpublished results).  As a final caveat, estimation of 
RNAi-mediated interference with the monoclonal antibody used in this study 
dramatically overestimates the degree of inhibition, again complicating interpretation.  
An example of this effect will be presented in Chapter III.    
DNA Repair 
 A final putative role for DEK in the promotion of cancer is that of a DNA damage 
repair protein.  Before the DNA damage repair gene atm had been identified as the 
mutated gene in ataxia-telangiectasia patients, a complementation screen identified the C-
terminal portion of DEK as being able to complement the phenotypic defects of ataxia-
telangiectasia fibroblasts (Meyn, Lu-Kuo et al. 1993).  Recently, we demonstrated that 
DEK promotes repair of DNA damage caused by the radiomimetic neocarzinostatin, the 
topoisomerase I inhibitor camptothecin, and the topoisomerase II inhibitor etoposide.  
shRNA interference with DEK expression sensitized HeLa cells to these DNA damage 







 The function of DEK in the context of both normal and malignant cells remains 
unclear.  Conflicting data exist regarding DEK’s participation in certain cellular 
processes, most notably the proposed function of DEK in mRNA processing.  Although 
multiple studies have implicated DEK as a member of mRNA splicing complexes, 
several others have concluded that DEK is not a prominent component of the cellular 
splicing machinery.  This discrepancy may be a result of differential regulation of DEK 
in the various model systems examined.  As noted above, post-translational modification 
has emerged as an important regulatory mechanism of DEK activity.  We hypothesized 
that one or more of DEK’s 67 lysine residues may be acetylated in vivo, and that 
acetylation of DEK may regulate its interactions with splicing factors and/or RNA.  The 
first aim of this study was to determine whether DEK is a target of acetylation in vivo¸ 
and to determine if acetylation alters the sub-nuclear localization of DEK.  This aim will 
be addressed in Chapter II. 
 While there have been many proposed functions of DEK in normal cells, the 
contribution of increased expression of DEK to the malignant phenotype of cancer cells 
has not been previously examined.  The second aim of this study is to determine whether 
overexpression of DEK promotes or is required for maintenance of tumor formation.  To 
address this, we focused on the contribution of DEK to the phenotype of malignant 
melanoma.  Gain of 6p has frequently been identified as one of the most common 
chromosomal alterations in all subtypes of melanoma, yet the target(s) of 6p gain in 
melanoma have not been identified.  We hypothesized that overexpression of DEK may 
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be a frequent event in melanoma progression and that this overexpression may serve to 
promote proliferation and/or cell survival in melanoma.  This aim will be 





P300/CBP-ASSOCIATED FACTOR DRIVES DEK INTO INTERCHROMATIN 
GRANULE CLUSTERS  
 
Abstract 
 DEK is a mammalian protein that has been implicated in the pathogenesis of 
autoimmune diseases and cancer, including acute myeloid leukemia, melanoma, 
glioblastoma, hepatocellular carcinoma, and bladder cancer. In addition, DEK appears to 
participate in multiple cellular processes, including transcriptional repression, mRNA 
processing, and chromatin remodeling. Sub-nuclear distribution of this protein, with the 
attendant functional ramifications, has remained a controversial topic. Here we report that 
DEK undergoes acetylation in vivo.  Furthermore, deacetylase inhibition results in 
accumulation of DEK within interchromatin granule clusters (IGCs), sub-nuclear 
structures that contain RNA processing factors. Overexpression of P/CAF acetylase 
drives DEK into IGCs, and addition of a newly developed, synthetic, cell-permeable 
P/CAF inhibitor blocks this movement.  The acetylation of DEK does not promote in vivo 
interactions with RNA.  Finally, transcriptional inhibition results in DEK migration into 
both IGCs and non-IGC nuclear speckles.  To our knowledge, this is the first reported 
example of acetylation playing a direct role in relocation of a protein to IGCs, and this 
may explain how DEK can function in multiple pathways that take place in distinct sub-
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nuclear compartments. These findings also suggest that DEK-associated malignancies 




 The mammalian nuclear protein DEK is associated with the pathogenesis
 
of 
autoimmune diseases and cancer (Kondoh, Wakatsuki et al. 1999; Kroes, Jastrow et al. 
2000; Larramendy, Niini et al. 2002). Autoantibodies
 
specific for DEK are present in 
patients with juvenile rheumatoid
 
arthritis and other inflammatory diseases (Sierakowska, 
Williams et al. 1993; Dong, Wang et al. 2000), and fusion
 
of dek and nup214 by 
translocation of chromosomes 6 and 9 results
 
in acute myeloid leukemia (von Lindern, 
van Baal et al. 1992).  DEK expression is also increased
 
in multiple malignancies, 
including bladder cancer, hepatocellular
 
carcinoma, glioblastoma, melanoma, T-cell large 
granular lymphocyte
 
leukemia, and acute myeloid leukemia, independent of the t(6,9)
 
chromosomal translocation (Kondoh, Wakatsuki et al. 1999; Grottke, Mantwill et al. 
2000; Kroes, Jastrow et al. 2000; Daibata, Matsuo et al. 2004; Evans, Gallie et al. 2004).  
 DEK does not belong to any characterized protein family, and
 
sequence similarity 
with other factors is limited to the SAF
 
(scaffold attachment factor) box (Gohring, 
Schwab et al. 1997; Kipp, Schwab et al. 2000), also known as the
 
SAP domain (from 
SAF-A/B, acinus and PIAS) (Aravind and Koonin 2000), a 34-amino
 
acid motif found in 
nuclear factors that participates in chromatin
 





DEK has been implicated in all three of these nuclear events.
 
We have previously shown that DEK binds to the TG-rich peri-ets
 
(pets) site from the 
human immunodeficiency virus type 2 (HIV-2)
 
promoter and that this binding is 
responsive to cellular signals
 
(Fu, Grosveld et al. 1997; Faulkner, Hilfinger et al. 2001). 
In the case of HIV-2, DEK appears to function in transcriptional
 
repression (Faulkner, 
Hilfinger et al. 2001). Subsequently, DEK has also been isolated in
 
a complex containing 
both Daxx and HDAC2, essential proteins
 
involved in transcriptional repression 
(Hollenbach, McPherson et al. 2002), lending further
 
support to the role of DEK in this 
process. In addition, DEK
 
has been shown to play an active role in DNA and chromatin 
architecture
 
and to bind preferentially to supercoiled and four-way junction
 
DNA 
(Alexiadis, Waldmann et al. 2000; Waldmann, Baack et al. 2003; Waldmann, Scholten et 
al. 2004). Moreover, DEK has been found in complexes
 
with a number of mRNA splicing 
and export factors and spliced
 
transcripts themselves (McGarvey, Rosonina et al. 2000; 
Le Hir, Gatfield et al. 2001). Although the direct role of
 
DEK in the exon-exon junction 
complex, as originally proposed,
 
remains controversial (Reichert, Le Hir et al. 2002; 
Kataoka and Dreyfuss 2004), there is considerable evidence
 
supporting its association 
with one or more SR proteins that
 
function in pre-mRNA splicing through protein-protein 
interactions
 
(McGarvey, Rosonina et al. 2000).
 
 
 There is a growing body of evidence suggesting that separate
 
steps along the 
pathway of gene expression are integrated (Maniatis and Reed 2002; Proudfoot, Furger et 
al. 2002). As DEK has defied categorization as a single function protein,
 
it is likely 
poised at the interface of multiple components
 
of the gene expression pathway; however, 
this poses the question
 




sub-nuclear compartments. The majority of endogenous DEK is
 
associated with 
chromatin and DNA, whereas only 10% of DEK is
 
released with RNase treatment 
(Kappes, Burger et al. 2001). Nonetheless, DEK has been
 
found in association with RNA 
and RNA-processing factors by
 
separate groups using multiple experimental approaches.
 
 
 One mechanism by which a single polypeptide can exhibit different
 
properties is 
through post-translational modifications. Acetylation
 
can modify protein function in a 
number of ways. The most well
 
known example is that of histone acetylation, which by 
altering
 
the charge and size of specific lysine residues results in
 
a loosened association 
with DNA and a subsequent increase in
 
local gene expression (Sterner and Berger 2000). 
It has recently become clear that
 
many transcription factors are acetylated, which often 
results
 
in an enhancement of function (Gu and Roeder 1997; Sterner and Berger 2000). 
Mechanisms mediating
 
this increase in transactivating potential include alterations
 
in 
DNA-binding affinity (p53, GATA-1, GATA-2, E2F, and c-Myb)
 
(Gu and Roeder 1997; 
Boyes, Byfield et al. 1998; Martinez-Balbas, Bauer et al. 2000; Marzio, Wagener et al. 
2000; Tomita, Towatari et al. 2000; Hayakawa, Towatari et al. 2004), affinity for 
negative regulators (NF- B and B-Myb)
 
(Chen, Fischle et al. 2001; Schubert, Horstmann 
et al. 2004) or positive cofactors (p53) (Barlev, Liu et al. 2001), and localization
 
(CIITA 
and HNF-4) (Soutoglou, Katrakili et al. 2000; Spilianakis, Papamatheakis et al. 2000). 
We report that DEK is acetylated
 
in the cell, and in vitro it is a substrate for the 
acetyltransferases
 
CBP (CREB-binding protein), p300, and P/CAF (p300/CBP-associated
 
factor).  In addition, we find that acetylation markedly alters the localization
 
of DEK. 
Inhibition of deacetylase activity triggers redistribution
 
of DEK from a diffusely nuclear 
to a punctate pattern within
 




accumulation of DEK in structures known as nuclear speckles
 
or interchromatin granule 
clusters (IGCs), which are well characterized
 
sub-nuclear domains containing RNA-
processing and transcription
 
factors. Importantly, DEK can be driven into the IGCs by 
overexpression
 
of P/CAF, but not CBP/p300, and this movement can be prevented
 
by 
specifically blocking the activity of P/CAF with a newly
 
developed, synthetic, cell-
permeable inhibitor.  We further show that inhibition of transcription also causes DEK 
accumulation in nuclear speckles.  Finally, we find that acetylation results in diminished 
DEK-RNA interactions.  Our results indicate that acetylation represents a key regulatory 
post-translational modification that controls its sub-nuclear localization.   
Results 
DEK is an Acetylated Protein 
 To determine whether DEK
 
is acetylated in vivo, T98G human glioblastoma cells 
were infected
 
with an adenoviral vector encoding for N-terminally tagged FLAG-DEK.
 
Glioblastoma is one of several tumors that exhibit increased
 
expression of DEK, as 
compared with its tissue of origin (Kroes, Jastrow et al. 2000).
 
FLAG-DEK was 
immunoprecipitated with anti-FLAG antibodies and
 
separated by SDS-PAGE. Staining 
for total protein revealed that
 
one major band is recovered in the immunoprecipitate at 48 
kilodalton
 
and a minor protein band at 35 kilodalton (data not shown). N-terminal
 
sequencing has previously demonstrated that the 35-kilodalton band
 
corresponds to a 
truncated form of DEK (amino acids 70–375)
 
(Sierakowska, Williams et al. 1993). 
Importantly, immunoprecipitated DEK is reactive with a
 
monoclonal antibody that is 
specific for acetylated lysine residues
 






 In vitro acetylation assays were used to determine whether DEK
 
could serve as a 
substrate for the well characterized acetyltransferase
 
proteins CBP, p300, and P/CAF. 
Figure 2B indicates that all three
 
enzymes acetylate recombinant DEK purified from 
baculovirus-infected
 
insect cells. In the absence of an acetyltransferase enzyme,
 
DEK 
remained unlabeled. Similar in vitro acetylation reactions
 
using FLAG-DEK 
immunoprecipitated from T98G cells gave identical
 
results (data not shown). These data 
suggest that acetylation
 
does not occur solely on the tag, because one recombinant
 
protein 
is FLAG-tagged while the other is polyhistidine-tagged,
 
and the His-tag contains no 
lysines. These results also indicate
 
that in mammalian cells there are available CBP/p300 
and P/CAF
 
acetylation sites within native DEK, which validates the use
 
of deacetylase 
inhibitor treatment to shift the equilibrium
 
toward more highly acetylated forms of the 
protein. To confirm
 
that treatment with a deacetylase inhibitor alters the acetylation
 
state 
of DEK in vivo, T98G glioblastoma cells were treated or
 
mock-treated overnight with the 
deacetylase inhibitor trichostatin
 
A (TSA). Indeed, FLAG-DEK immunoprecipitated from 
TSA-treated
 
T98G cells demonstrates considerably more reactivity toward
 
the 
monoclonal anti-acetylated lysine antibody than similar amounts
 
of FLAG-DEK isolated 
from untreated cells (Figure 2A, lane 3 versus
 
lane 4). These data demonstrate that 
treatment of DEK-infected
 
cells with the deacetylase inhibitor TSA directly affects the
 











Figure 2.  DEK is acetylated in vivo and is acetylated in vitro by CBP, p300, and 
P/CAF. In A, untreated FLAG-tagged DEK (arrowhead) immunoprecipitated with anti-
FLAG antibodies is detected by anti-FLAG antibody (lane 2) or monoclonal anti-acetyl 
lysine antibody (lane 4). FLAG-DEK isolated from cells treated with the histone 
deacetylase inhibitor TSA shows increased reactivity to anti-acetyl lysine antibody (lane 
3) with similar reactivity to anti-FLAG antibody (lane 1), as compared with FLAG-DEK 
isolated from untreated cells. In B, purified recombinant DEK is incubated in vitro with 
radiolabeled acetyl-CoA and either P/CAF (lane 1), p300 (lane 2), CBP (lane 3), or no 
acetyltransferase (lane 4). An arrowhead marks the position of DEK; CBP, p300, and 




Deacetylase Inhibitors Alter the Localization of DEK 
 Recent
 
reports have demonstrated that acetylation alters the localization
 
of certain 
transcription factors (Soutoglou, Katrakili et al. 2000; Spilianakis, Papamatheakis et al. 
2000). Therefore, TSA treatment
 
was used to investigate whether acetylation would 
change the
 
location of DEK. T98G glioblastoma cells were treated or mock-treated
 
with 
TSA overnight and fixed for immunocytochemistry. Comparison
 
with 4,6-diaminido-2-
phenylindole (DAPI) staining confirmed that, in
 
untreated T98G cells, DEK is distributed 
diffusely throughout
 
the nucleoplasm as reported previously (Figure 3A). However, the
 
pattern of DEK localization is dramatically altered in TSA-treated
 
cells (Figure 3D): in 
particular, DEK staining adopts a punctate
 
pattern, suggesting that significant amounts of 
protein have
 
accumulated in specific sub-nuclear structures in response to
 
deacetylase 
inhibition. These data also indicate that DEK acetylation
 
is dynamic; in other words, 
DEK is normally a substrate for
 
deacetylase enzymes as well as acetylases.  
  
DEK Relocates to the Interchromatin Granule Cluster 
 There
 
are many distinct structures within the nuclear space, a number
 
of which 
appear as collections of small, round dots when stained
 
(Lamond and Earnshaw 1998). 
McGarvey et al. (McGarvey, Rosonina et al. 2000) have previously demonstrated that
 
in  
approximately 15% of cells, DEK appears to be enriched in the nuclear speckles, which 
they speculate to be interchromatin granule clusters (IGCs) based on their observation 
that DEK associates with splicing
 
factors. In contrast, acetylation of the oncoprotein 
EVI1 results
 
in its relocalization to punctate structures that are enriched
 
in CBP, which 
identifies them as promyelocytic leukemia protein
 
oncogenic domains (PODs) (LaMorte, 
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Dyck et al. 1998; Chakraborty, Senyuk et al. 2001). To determine whether the
 
punctate 
structures in Figure 3 are either IGCs or PODs,
 
cells were stained with antibodies specific 
for either SC35
 
or CBP, respectively. Figures 3B and 3E
 
depict staining of SC35. Figure 
3F indicates substantial
 
colocalization between the DEK-containing bodies and the IGC,
 
whereas Figure 3C shows that the colocalization signal
 
does not result simply from the 
overlap of SC35 staining with
 
diffuse nuclear DEK. Colocalization was not seen with 
anti-CBP
 
staining of PODs, which revealed a set of nuclear bodies distinct
 
from the DEK-
containing structures (Figures 3G-3I). Thus,
 
by preventing deacetylation, TSA shifts the
 
equilibrium toward the more acetylated form of DEK, which causes
 
this protein to 
accumulate in IGCs. Our data suggest that, in
 
normal cells, the more acetylated fraction 
of DEK interacts
 
with mRNA processing proteins within IGCs, which are thought
 
to be 
accumulation sites of transcriptional factors and mRNA
 
processing factors (Spector 1996; 
Lamond and Spector 2003).  Indeed, previous data have supported
 
the association of 
DEK with spliceosome proteins, most notably
 
in complexes important for the coupling of 
pre-mRNA splicing
 




Acetylation by P/CAF Drives DEK into IGCs 
 To investigate
 
which histone acetyltransferase is responsible for the movement
 
of 
DEK into IGCs, cells were transfected with a vector encoding
 
GFP-DEK and treated with 
newly developed, specific inhibitors
 
of P/CAF (Table I) or CBP/p300 (Polesskaya, 
Naguibneva et al. 2001; Guidez, Howell et al. 2005). These inhibitors have
 
a significant 
advantage over previously employed synthetic histone
 





and therefore do not require transfection. Inhibition constants
 
were determined as previously described and are shown in Table
 




 Treatment of GFP-DEK-transfected cells with the selective cell-permeable
 
inhibitor of CBP/p300, followed by treatment with TSA, does
 
not block the movement of 
GFP-DEK to IGCs (Figure 4B). In contrast,
 
treatment of cells with the P/CAF inhibitor 
H3-CoA-20-Tat, prior
 
to TSA treatment, blocks the movement of GFP-DEK to IGCs 
(Figure
 
4C). However, treatment of cells with the control peptide (lacking
 
only the acetyl-
CoA functional group), followed by the addition
 
of TSA, has no effect on the localization 
of DEK (Figure 4D).
 
These data suggest that, although both P/CAF and CBP/p300 can
 
acetylate DEK in vitro, it is the specific acetylation by P/CAF
 
that results in the 
movement of DEK to the IGC.
 
 
 To further investigate the role of P/CAF and CBP in the sub-nuclear
 
movement of 
DEK, cells were co-transfected with GFP-DEK and
 
a vector encoding either CBP or 
P/CAF.  DEK remains pan-nuclear
 
with the overexpression of CBP (Figure 5A), whereas 
overexpression
 
of P/CAF with DEK results in the movement of DEK to IGCs (Figure
 
5B). This relocalization can be blocked with the addition of
 
the P/CAF-specific inhibitor 
(Figure 5C), but not the P/CAF inhibitor
 
control molecule (data not shown), following co-
transfection
 
of plasmids expressing GFP-DEK and P/CAF. These data support
 
the 
hypothesis that it is the specific acetylation of DEK, or
 
an associated protein, by P/CAF 
that causes DEK to move to an
 




Figure 3.  Treatment of T98G cells with TSA results in the concentration of DEK in 
punctate bodies within the nuclear space, which are IGCs.  A–C show an untreated 
cell, while panels D–I depict cells treated with TSA. A, D, and G show staining with 
polyclonal antibodies to DEK, B and E show staining with monoclonal antibodies to the 
splicing factor SC35 (a protein known to be concentrated in IGCs), and H shows staining 
with anti-CBP (a protein known to localize to PODs). C, F, and I show the merged 
image, with yellow indicating colocalization. Images were captured with a confocal 




Table 1.  Inhibitory properties of H3-CoA-20-Tat and H3-Ac-20-Tat (control) 
conjugates against p300 and P/CAF.  These assays were carried out with recombinant 
human P/CAF and p300 as described previously (Lau, et al., 2000; Poux, et al., 2002) and 
contained 10 µM acetyl-CoA and 10 µM peptide substrate (H3-20) for P/CAF, and 20 
µM acetyl-CoA and 50 µM peptide substrate (H4-20) for p300.  The measurements 
showed standard error < 20%.  H3-CoA-20-Tat was shown to be a linear competitive 
inhibitor of P/CAF versus acetyl-CoA (150 µM H3-20 substrate) with Ki 2.1±0.7 nM 









Figure 4. Treatment of T98G cells with the P/CAF-specific inhibitor H3-CoA-20-Tat 
prevents TSA-mediated accumulation of DEK in IGCs. A shows a cell after overnight 
treatment with TSA. B shows a cell pretreated with the CBP/p300 inhibitor Lys-CoA-Tat 
at a concentration of 50 µM, followed by overnight treatment with TSA. C shows a cell 
pretreated with the P/CAF-specific inhibitor H3-CoA-20-Tat (50 µM), followed by 
overnight treatment with TSA. D depicts a cell pretreated with a control inhibitor, H3-
(Ac)-20-Tat (50 µM), followed by overnight treatment with TSA.  
3.2 NA H3-(Ac)-20-Tat 
0.04 12 H3-CoA-20-Tat 





this is the first demonstration that a specific acetylase can
 
control the 
movement of a protein into the IGC. 
Inhibition of transcription induces DEK accumulation in nuclear speckles 
 IGCs are nuclear bodies that comprise primarily RNA splicing factors.  Given 
DEK’s previously described association with SR proteins, we sought to examine if 
DEK’s migration to the IGC could be induced in a manner similar to other known 
splicing factors.  Classically, SR proteins and splicing factors such as SC35 and U2AF 
are redirected into IGCs upon treatment with an inhibitor of transcription (Gama-
Carvalho, Krauss et al. 1997; Melcak, Cermanova et al. 2000).  We tested whether 
actinomycin D, a transcriptional inhibitor, could similarly drive DEK into IGCs.  We 
found that treatment with actinomycin D did indeed cause DEK to aggregate in punctate 
bodies (Figure 6A).  We next used SC35 co-staining to determine if the DEK aggregates 
co-localized with IGCs.  Interestingly, we found that DEK did co-localize with SC35 in 
most cells (Figure 6B, top panels), but in other cells DEK aggregates only partially 
coincided with SC35 staining (Figure 6B, bottom panels).  Additionally, we occasionally 
identified DEK bodies that appeared to be cytosolic (Figures 6A and 6B, bottom panels 
arrowheads). 
 We have previously observed DEK movement into the cytosol following phorbol 
12-myristate 13-acetate (PMA) treatment of the U937 monocytic cell line (Faulkner, 
Hilfinger et al. 2001).  To confirm the extranuclear localization of DEK after actinomycin 
D treatment, U937 cells treated with TSA, PMA, or actinomycin D were fractionated into 











Figure 5.  Overexpression of P/CAF, but not CBP, drives DEK into IGCs. A shows a 
cell co-transfected with vectors encoding GFP-DEK and CBP. B shows a cell co-
transfected with vectors encoding GFP-DEK and P/CAF. C shows a cell co-transfected 
with GFP-DEK and P/CAF-expressing vectors followed by treatment with the P/CAF-







that TSA, PMA and actinomycin D all induced translocation of a small but significant 
amount DEK into the cytosol (Figure 6C).  Intriguingly, actinomycin D treatment also 
resulted in the expression in the nucleus of a low-mobility form of DEK (~70 kilodaltons) 
that was not observed with other treatments (Figure 6C, lane 4).   This form was 
recognized by both monoclonal and polyclonal anti-DEK antibodies (data not shown).  
These data show that, like many mRNA processing factors and SR proteins, DEK 
translocates to IGCs in response to transcriptional inhibition. 
Deacetylation inhibitors do not promote association of DEK with RNA 
 Taken together with previous associations of DEK with SR protein complexes, 
the migration of DEK into IGCs in response to transcriptional inhibition suggested a role 
for DEK in mRNA processing.  Because acetylation reduced DEK’s DNA-binding 
affinity and altered its sub-nuclear localization, we hypothesized that acetylation of DEK 
may also function to regulate the RNA-binding activities of DEK.  We tested this 
possibility by assessing DEK-RNA interactions in the presence of TSA.  We digested 
untreated or TSA-treated HeLa nuclei with either DNase or RNase.  We then separated 
the released fractions and the nuclear retained fractions and assessed the amount of DEK 
contained in each fraction by immunoblotting.  As has been described previously 
(Kappes, Burger et al. 2001), we found that the vast majority of nuclear DEK was 
released upon treatment with DNase (Figure 7, lanes 2 and 5).  This was true for both 
untreated and TSA-treated HeLa nuclei.  In contrast, we observed that RNase treatment 


















Figure 6. Inhibition of transcription alters DEK sub-nuclear localization. A shows a 
cell transfected with a vector encoding GFP-DEK and treated with 1 µg/ml actinomycin 
D for 12 hours. B, cells were treated as in A, and subsequently were stained for SC35. C, 
immunoblotting for DEK expression of nuclear and cytoplasmic fractions of U937 cells 
treated with either 1 µM trichostatin A (TSA), 32 nM phorbol 12-myristate 13-acetate 





is in agreement with previous observations that estimated approximately 10% of nuclear 
DEK is released following RNase digestion of HeLa nuclei (Kappes, Burger et al. 2001). 
However, TSA treatment resulted in a decrease in the amount of DEK released following 
RNase digestion (Figure 7, lanes 3 and 4).  This suggests that acetylation of DEK results 
in reduced DEK-RNA interactions. 
RNA Immunoprecipitation of DEK 
  We next attempted to identify pre-mRNA and mRNA targets of DEK.  RNA 
immunoprecipitation (RIP) of ribonuclear protein (RNP) complexes is a useful method of 
dissecting RNA-protein interaction in vivo and is particularly useful in identifying 
biologically relevant RNAs.  RIP is technically similar to chromatin immunoprecipitation 
(ChIP), with the obvious difference being that the target of the former is RNA and the 
target of the latter is DNA.  Like ChIP, RIP requires the use of a reversible crosslinker, 
since most RNA-protein interactions are not sufficiently stable.  
 The procedure is outlined in Figure 8A.  HeLa cells were infected with either an 
adenoviral vector expressing Flag-DEK or a control vector expressing GFP.  Three days 
after infection, cells were collected and fixed with formaldehyde.  Cells were lysed by 
sonication, and the lysates were immunoprecipitated with anti-Flag antibodies.  HeLa 
cells infected with the control vector did not express any Flag-tagged proteins, and thus 
were used a control for non-specific background determination.  Following precipitation, 
beads were washed, crosslinks were reversed and precipitated RNP complexes were 
processed for protein or RNA analysis.  Immunoblotting confirmed successful 












Figure 7. TSA does not enhance DEK association with RNA. Untreated or 1 µM TSA 
treated nuclei were digested with either DNase or RNase, or received no treatment (NT).  
Proteins released with treatment, and those retained in the nuclear fraction were 








immunoprecipitated samples using an Agilent Bioanalyzer 2100 revealed nearly identical 
electropherograms, indicating similar RNA composition (Figure 8C).  Additionally, area 
under the curve analysis estimated a negligible amount of RNA co-precipitating with 
DEK (Figure 8D).  These results indicate that conventional RIP of DEK does not 
precipitate DEK-bound RNA targets.    
Discussion 
 We show here that DEK is an acetylated protein whose nuclear localization can 
be regulated by the acetylase P/CAF.  We find that non-specific inhibition of histone 
deacetylases results in the accumulation of DEK in IGCs.  This relocalization of DEK is 
dependent on the activity of P/CAF, which appears to be both necessary and sufficient to 
cause migration of DEK to IGCs.  We additionally find that DEK accumulates in both 
IGC and non-IGC nuclear speckles in response to transcriptional inhibition.  Finally, we 
show that acetylation of DEK does not promote interactions with RNA, and direct DEK-
RNA interactions cannot be observed with conventional RIP.   
 We demonstrate for the first time that acetylation
 
alters the sub-nuclear 
localization of DEK, as deacetylase inhibition
 
results in the redistribution of DEK from 
being diffusely nuclear
 
to being concentrated into IGCs. To our knowledge, this is the
 
first demonstration that movement of any protein into the IGC
 
is under the control of 
acetylation changes. We have not strictly
 
shown that acetylation of DEK is the cause, 
rather than the
 
consequence, of its relocation into the IGC. Attempts to address
 
this issue 
using protein transfection have proven unrewarding,
 
as we have been unable to transduce 
DEK into cells. This may
 

























































































































































































































































































































































































































































































































































































































DEK, or to the propensity of this protein to multimerize. However, it appears that the 
most straightforward
 
explanation for the translocation of DEK into the IGC is that
 
this 
movement follows acetylation. There are several reasons
 
to assume that this is the case. 
First, when DEK is bound to
 
DNA, it is tightly associated with chromatin, and acetylases
 
are also known to act on chromatin, so this would be a logical
 
place for DEK/acetylase 
interaction. Further, because it is
 
the addition of deacetylase inhibitors or transfection of a
 
vector expressing P/CAF that is the first step in our experiments,
 
the simplest explanation 
is that an acetylation event drives
 
DEK into IGCs.  Additionally, we show that acetylation 
reduces the affinity of DEK for DNA, thus it seems likely that acetylation would alter the 
sub-nuclear localization of this predominately chromatin-bound protein.  Therefore, it 
appears most likely that acetylation
 
events precede the relocalization of DEK into the 
IGC, rather
 
than DEK first entering IGCs and then undergoing acetylation.
 
  
 Importantly, DEK is driven into the IGCs by overexpression of
 
P/CAF, but not 
CBP, even though both histone acetyltransferases
 
can acetylate DEK in vitro. In contrast, 
the majority of studies
 
to date have demonstrated that it is the acetylation by CBP/p300
 
that has important functional consequences in vivo, including
 
DNA binding, chromatin 
remodeling, and protein-protein recognition
 
(Boyes, Byfield et al. 1998; Marzio, 
Wagener et al. 2000; Tomita, Towatari et al. 2000; Barlev, Liu et al. 2001; Chen, Fischle 
et al. 2001; Hayakawa, Towatari et al. 2004; Schubert, Horstmann et al. 2004). 
Interestingly, one of the few examples
 
of an in vivo role for acetylation by P/CAF is for 
the Class
 
II transactivator protein, CIITA: acetylation results in relocalization
 
of the 
protein from the cytoplasm to the nucleus (Spilianakis, Papamatheakis et al. 2000). The 
sub-nuclear
 




molecule inhibitor, but not by a similar CBP/p300 inhibitor
 
or a control molecule. These 
compounds and other similar small
 
molecule inhibitors of various acetylases have 
considerable
 
advantage over previously described acetylase inhibitors, because
 
they are 
cell-permeable and therefore do not require transfection.
 
We believe these compounds 
will have significant and broad application
 
in the identification of proteins that are 
acetylated in vivo
 
and further the understanding of the functional consequences
 
of 
acetylation in controlling gene regulation.
 
 
 IGCs are dense collections of proteins that have been shown to have a high 
concentration of pre-mRNA processing factors (Misteli and Spector 1997; Lamond and 





nucleic acid (Hendzel and Bazett-Jones 1995; Mintz, Patterson et al. 
1999).  Multiple studies have concluded that mRNA processing does not occur in IGCs, 
leading to the notion that IGCs represent a storage depository of inactive mRNA 
processing factors (Fakan, Leser et al. 1984; Zeng, Kim et al. 1997; Cmarko, Verschure 
et al. 1999).  In support of this, treatment with transcriptional inhibitors results in a 
depletion of pre-mRNA products and causes the subsequent accumulation of mRNA 
processing factors, such as U2AF and SC35, to the IGCs (Gama-Carvalho, Krauss et al. 
1997; Zeng, Kim et al. 1997).  Accordingly, DEK’s migration into IGCs following 
transcriptional inhibition suggests a role in pre-mRNA processing.  DEK has
 
previously 
been found to be associated with spliced mRNA and with ribonucleic protein (RNPs) 
complexes, although a proteomic analysis of the spliceosome did
 
not identify DEK 
(Zhou, Licklider et al. 2002).  We found that acetylation of DEK results not only in 
migration to IGCs, but also reduced interactions between DEK and RNA.  Thus, the DEK 
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found in IGCs upon acetylation may contain a fraction of DEK that was previously 
involved in active mRNA processing, in addition to DEK that may be released from 
chromatin.  Our results support a model in which acetylation reduces DEK’s affinity for 
both DNA and RNA interactions, resulting in release of DEK from its normal nucleic 
acid-bound, sub-nuclear location, and as a result, DEK subsequently accumulates in 
IGCs.  It remains unclear whether accumulation of released DEK in the IGCs contributes 
to an alternate function, or if the IGCs are merely acting as a storage area for inactive 
DEK.    
 Finally, we found that while DEK redistributed from a diffuse to a punctate 
pattern in response to both transcriptional inhibition and acetylation, there were some 
significant differences.  Notably, the punctate pattern of DEK did not always colocalize 
with IGCs following transcriptional inhibition.  Although we have clearly shown that in 
response to acetylation DEK migrates into IGCs and not PODs, it is possible that 
following transcriptional inhibition DEK may additionally enter other sub-nuclear 
compartments, such as PODs or Cajal bodies.  Notably, inhibitors of transcription, such 
as actinomycin D, have been shown to induce chromatin retraction and the induction of 
new PML bodies (Eskiw, Dellaire et al. 2004).   
 We find that, in striking contrast to treatment with deacetylation inhibitors, 
transcriptional inhibition resulted in the expression of a novel low-mobility form of DEK.  
As this report and others have shown that DEK is the target of extensive post-
translational modifications (Kappes, Damoc et al. 2004; Gamble and Fisher 2007; 
Kappes, Fahrer et al. 2008), it is very likely that this represents a post-translationally 
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modified form of DEK.  If DEK is indeed redirected to PODs in response to 
transcriptional inhibition, an interesting candidate for this modification would be 
sumoylation.  Sumoylation is a post-translational modification that involves the covalent 
attachment of small ubiquitin-like modifier peptides (SUMO) to lysine residues of a 
target protein.  In contrast to ubiquitination, sumoylation tends to enhance protein 
stability and has been shown to be an important factor in regulating sub-nuclear 
localization, particularly in targeting of factors to PODs.  This SUMO-dependent 
recruitment to PODs has been best described for the transcriptional co-repressor Daxx 
(Ishov, Sotnikov et al. 1999; Li, Leo et al. 2000; Lin, Lai et al. 2003).  Like Daxx, DEK 
has multiple putative sumoylation sites (Xue, Zhou et al. 2006), and it is worth noting 
that Daxx is one of the few verified protein interaction partners of DEK (Hollenbach, 
McPherson et al. 2002).  Taken together, these findings show that in the context of 
transcriptional inhibition DEK may exhibit both radically altered form and function. 
 In summary, we identify acetylation as a post-translational modification of DEK 
that regulates its sub-nuclear localization.  Our results suggest a potential mechanism of 
regulating the participation of DEK in the disparate processes of transcriptional 
repression, chromatin maintenance, and mRNA processing.  Our findings suggest that 
P/CAF activity may both relieve transcriptional repression by releasing chromatin bound 
DEK and may also regulate the poorly understood interaction between DEK and RNP 
complexes.  These results support the notion that DEK is a versatile nuclear protein 




Materials and Methods 
Cell Culture and Transfection 
 T98G and U937 cells were purchased
 
from ATCC and passaged in Dulbecco's 
modified Eagle's medium
 
with 10% fetal bovine serum and antibiotics. GFP-DEK was 
constructed
 
as a fusion protein between DEK and an enhanced variant of Aequorea
 
victoria green fluorescent protein. Primers with EcoRV (5')
 
and EcoRI (3') restriction 
sites were designed for PCR-based
 
subcloning of the dek coding region into the pGNVL3 
mammalian
 
GFP vector (gift of T. Glaser, University of Michigan). Cells
 
were 
transfected with 2.5 µg of GFP-DEK, P/CAF, or CBP
 
plasmid using Lipofectamine 2000 
(Invitrogen). After transfection,
 
cells were treated overnight with 1 µM TSA (Sigma) or 
left untreated, and fixed for immunocytochemistry
 
on the following day. Alternatively, 
untransfected cells were
 
treated overnight with 330 nM TSA or left untreated and fixed
 




Construction of DEK-encoding Adenovirus 
 FLAG-tagged DEK
 
was excised from pCMV-Tag1 (Stratagene) using HindIII and 
BamHI
 
and introduced via those sites into the adenoviral shuttle plasmid
 
pACCMVpLpA(-)loxP-SSP. This vector was linearized with SfiI,
 
and the transgene was 
recombined into E1A/E1B-deficient adenovirus
 
by the University of Michigan Vector 
Core. Virus was harvested
 
from E1A/E1B-positive producer cells, purified by cesium 
chloride
 





concentration. T98G cells were transduced at a multiplicity
 
of infection of 100 by 





Immunoprecipitation and Western Blotting 
 Immunoprecipitation
 
of FLAG-DEK from transduced T98G cells was performed 
using agarose-conjugated
 
anti-FLAG M2 monoclonal antibodies (Sigma) by following 
the
 
manufacturer's instructions with regards to cell lysis, incubation,
 
and washing, and 
elution by competition with 3xFLAG peptide (Sigma).  Fractionation into nuclear and 
cytosolic components was performed as described previously (Kappes, Burger et al. 
2001).  
 
For Western blotting, proteins were transferred from the gel
 
to polyvinylidene 
difluoride membrane, blocked in 5% milk, and probed with either horseradish 
peroxidase-conjugated
 
anti-FLAG antibody at a dilution of 1:1000 (Sigma), or 
monoclonal
 
anti-acetylated lysine antibody at a dilution of 1:1000 (Cell Signaling
 
Technologies) or monoclonal anti-DEK antibody (Biosciences),
 
followed by horseradish 
peroxidase-conjugated anti-mouse IgG
 




Production of Recombinant His-DEK in Baculovirus 
 DEK coding
 
sequence was subcloned into the pBacPAK-His3 vector for 
recombination
 
into the baculovirus genome. Recombination, virus production,
 
cell 
transduction and harvesting, and protein purification were
 
performed as indicated in the 
manufacturers' instructions for
 
the BacPAK Baculovirus Expression System (Clontech) 
and HIS-trap
 





In Vitro Protein Acetylation Assay 
 Recombinant His-DEK
 
was dialyzed overnight at 4 °C into acetylation buffer (10
 
mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol,
 
0.5 mM 
phenylmethylsulfonyl fluoride, and 5% glycerol). DEK
 
was then incubated at 30 °C for 1 




(Amersham Biosciences), 10 mM sodium butyrate, 
and 50 nM of
 
either CBP, p300, or P/CAF, which had been purified as previously
 
described (39). Reactions were resolved by SDS-PAGE; gels were
 
stained with 




was detected using a phosphorimaging 






 Three phosphate-buffered saline (PBS)
 
washes were performed in between each 
of the following steps;
 
when indicated, PBS washes contained 0.1% saponin. Cells were
 
washed and fixed for 10 min in 4% paraformaldehyde. Fixed cells
 
were washed, blocked 
for at least 1 hour with 0.2% bovine serum
 
albumin in PBS, rewashed with PBS/saponin, 
and incubated for
 
1 hour with mouse monoclonal anti-SC35 (23 µg/ml; Sigma)
 
in 
PBS/saponin. If cells were not transfected with GFP-DEK,
 
then the incubation included 
polyclonal anti-DEK serum at a
 
1:200 dilution (gift of G. Grosveld). Cells were then 
rewashed
 
in PBS/saponin and reblocked with goat serum in PBS/saponin
 
at a 1:50 
dilution for 1 hour, followed by PBS/saponin washing
 
and a 1 hour incubation with Alexa 
fluor 594-conjugated goat anti-mouse
 
IgG (20 µg/ml; Molecular Probes) in PBS/saponin. 
If cells
 
were not transfected with GFP-DEK, then incubation included
 
Alexa fluor 488-
conjugated goat anti-rabbit IgG (20 µg/ml;
 





for 10 min, rewashed, and incubated with 4',6-diamidino-2-
phenylindole (DAPI)
 
for 10 min, rewashed with PBS, and distilled water then dried
 
overnight. Coverslips were mounted with Antifade A reagent (Molecular
 
Probes), and 
images were captured with a Zeiss Laser Scanning
 
Microscope (LSM 510, version 2.8 
SPI). For staining of PODs,
 
the procedure was identical except for the use of polyclonal
 
rabbit anti-CBP as the primary antibody (10 µg/ml, Upstate Biotechnology), and Alexa 
fluor 594-conjugated goat anti-rabbit
 








OH) is a derivatized
 
version of the synthetic P/CAF inhibitor H3-CoA-20, in which
 
the C-
terminal sequence ends in the 12 amino acid residues of
 
the cell permeabilizing Tat 
sequence. H3-(Ac)-20-Tat, a control
 
compound, differs from H3-CoA-20-Tat in that the 
CoA moiety
 
is replaced by a hydrogen atom. These compounds were synthesized
 
by the 
solid phase method on a Rainin PS3 peptide synthesizer
 
using the Fmoc (N-(9-
fluorenyl)methoxycarbonyl) strategy, analogous
 
to the previously described method for 
H3-CoA-20 (Lau, Kundu et al. 2000; Poux, Cebrat et al. 2002). The
 
epsilon amino group 
of the lysine residue that corresponds to
 
Lys-14 of histone H3 was protected with the N-
[1(4,4-dimethyl
 
2,6-dioxocyclohexylidene)ethyl] (Dde) group whereas other Lys
 
residues 
were protected with the t-butoxycarbonyl group. Following
 
amino acid couplings and N-
terminal acetylation, the Dde group
 
was removed by mixing the fully protected peptide 
resin with
 





peptide resin was then reacted with 5 equivalents of bromoacetic
 
acid and 5 equivalents 
of diisopropylcarbodiimide for 16 hours at
 
room temperature (or acetic anhydride for 1 
hour for the control
 





(81.5:5:5:5:2.5:1)) for 4 h at room temperature and subsequently
 
precipitated with ice-
cold diethyl ether. Precipitates were
 
collected by centrifugation (3000 rpm, 5 min), the 
supernatants
 
discarded, and the pellets washed two times with cold diethyl
 
ether (30 ml). 
Precipitated peptides were dissolved in 5 ml
 
of water, flash-frozen, lyophilized, and 
purified by preparative
 
reversed phase (C18) high-performance liquid chromatography
 
using a gradient of H2O:CH3CN:0.05% trifluoroacetic acid. The
 
bromoacetylated peptide 
was conjugated with 2 equivalents of
 
CoASH in a minimal volume of aqueous 0.5 M  
trimethylammonium
 
bicarbonate (pH 8) for 16 hours at room temperature, lyophilized,
 
and purified initially by passage over anion exchange chromatography
 
(Dowex 1 x 8–
100) to remove excess CoASH followed by reversed
 
phase high-performance liquid 
chromatography in a gradient of
 
H2O:CH3CN:0.05% trifluoroacetic acid. Peptides were 
confirmed
 
to be >95% pure by high-performance liquid chromatography,
 
and their 
structural identities were confirmed by mass spectrometry.
 
The inhibitory properties of 
both peptides against P/CAF and
 
p300 are shown in Table I. 
DNase and RNase digestion of nuclei 
 Release of nuclear DEK following DNase and RNase treatment was performed as 
described previously with minor modifications (Kappes, Burger et al. 2001).  Cells were 
washed three times with ice cold hypotonic buffer (20 mM HEPES pH 7.4, 20 mM NaCl, 
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5 mM MgCl2) and lysed by Dounce homogenization.  Lysates were incubated for 15 min 
on ice and nuclei were pelleted by centrifugation (5 min, 600 x g).  Nuclei were washed 
and incubated in elution buffer (20 mM HEPES, pH 7.4, 0.5 mM MgCl2, 1 mM ATP, 0.3 
M sucrose, 100 mM NaCl) and were incubated for 30 min at 37 °C with 17 units of 
RNase-free DNase I (Promega) or 40 units of DNase-free RNase A (Roche).  Reactions 
were stopped on ice, and nuclei were pelleted by centrifugation (5 min, 600 x g).  The 
supernatant and pellet containing the released and retained fractions, respectively, were 
collected.   
RNA Immunoprecipitation 
 HeLa cells were infected with either a control adenovirus expressing GFP, or a 
FLAG-tagged DEK encoding adenovirus.  Three days after infection, cells were detached 
with 0.5 mM EDTA and washed with PBS.  Cells were fixed with 1% paraformaldehyde 
for 20 minutes at room temperature.  Fixation was quenched by addition of glycine (pH 
7.0) to a final concentration of 250 mM.  Cells were washed twice with PBS and 
resuspended in RIPA buffer (50 mM Tris-Cl, pH 7.5, 1% Nonidet P-40, 0.5% sodium 
deoxycholate, 0.05% SDS, 1 mM EDTA, 150 mM NaCl) containing protease inhibitors 
(complete, mini, EDTA-free protease inhibitor cocktail tablet, one tablet for 10 mL 
buffer, Roche) and 40 units/mL RNasin (Promega).  Cells were lysed by sonication in 20 
second intervals and complete lysis was verified by microscope.  Lysates were cleared by 
centrifugation (10 min, 16,000xg).  Aliquots were collected for later RNA and protein 
analysis.  Agarose beads conjugated to anti-FLAG M2 monoclonal antibodies (Sigma) 
were added, and samples were incubated for two hours at 4 °C with rotation.  Beads and 
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supernatant were collected separately.  The beads were washed six times with high-
stringency RIPA buffer (50mM Tris-Cl, pH 7.5, 1% Nonidet P-40, 0.1% SDS, 1 mM 
EDTA, 1 M NaCl, 2 M urea, and 0.2 mM phenylmethyl fluoride).  Following the washes, 
beads were resuspended in 50 mM Tris-Cl, pH 7.0, 5 mM EDTA, 10 mM dithiothreitol, 
and 1% SDS.  Lysates were then incubated at 70 °C for 45 min to reverse crosslinks.  
Supernatants were collected and total RNA was purified using the Trizol method 
according to manufacturer’s instructions (Invitrogen).  An aliquot of the supernatant was 
also kept and analyzed by immunoblotting.   RNA yield and composition was determined 
by Total RNA Pico LabChip assay using an Agilent 2100 Bioanalyzer (Agilent 





DEK EXPRESSION INHIBITS SENESCENCE IN MELANOMA 
 
Abstract 
 The human DEK gene is frequently overexpressed in a number of malignancies, 
though the oncogenic contribution of this overexpression has not been identified.  Here, 
we demonstrate for the first time a putative role for DEK in the progression of malignant 
melanoma.  Expression of DEK protein in metastatic melanoma cell lines was found to 
be an average of 30 fold higher than in primary foreskin-derived melanocytes.  Inhibition 
of DEK expression by shRNAs was found to inhibit proliferation of a subset of 
melanoma lines.  Staining for senescence-associated β-galactosidase activity revealed that 
the reduction in cell growth was due to the induction of senescence in these cell lines.  
DEK expression was required to suppress expression of the p21
CIP1
 in all melanoma lines.  
In contrast, another senescence-inducing protein, p16
INK4a
, was not affected by 
knockdown of DEK expression.  Oncogene-induced senescence of normal melanocytes 




 did not result in diminished 
DEK expression.  These results suggest that DEK overexpression is a frequent event in 
melanoma progression and point to a role for DEK in the circumvention of melanoma 





 Malignant melanoma is the most lethal form of skin cancer, and given its 
increasing incidence it is likely to remain a major clinical challenge (Jemal, Siegel et al. 
2008).  Many of the genetic alterations found in melanoma, such as mutation of the 
oncogenes BRAF and NRAS or activation of the AKT pathway, serve to promote cell 
proliferation.  However, rather than inducing tumor formation, introduction of these 
alterations alone into normal melanocytes typically results in senescence (Serrano, Lin et 
al. 1997; Chen, Trotman et al. 2005; Michaloglou, Vredeveld et al. 2005).  It is now 
apparent that multiple tumor suppressive safeguards must be inactivated in addition to 
oncogene activation before a normal melanocyte progresses to overt melanoma.   
 Two principal senescence-inducing tumor suppressor pathways have been 
identified.  The first pathway, p16
INK4a
/pRb, has been discovered to be almost invariably 
inactivated in melanomas, either through deletion, mutation or silencing of p16
INK4a
 itself, 
or through mutations in downstream pathway components (Bartkova, Lukas et al. 1996; 
Walker, Flores et al. 1998).  Conversely, a second principal senescence-inducing tumor 
suppressor, p53, is not commonly mutated or deleted in melanomas, despite being a 
frequent target of inactivation in other neoplasms.  Nevertheless, p53 activity does appear 
to be diminished in melanoma cells through poorly delineated mechanisms 
(Satyamoorthy, Chehab et al. 2000).  It seems likely that melanomas possess heretofore 
unidentified means of evading this formidable tumor suppression checkpoint.   
 Cytogenetic analysis of melanoma also points to the involvement of additional 
oncogenes that may be required for tumor development.  Melanomas display remarkable 
genomic instability that results in a wide array of chromosomal abnormalities.  The 
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frequent gains and losses of specific chromosomes suggest that these regions of 
instability may harbor additional unidentified oncogenes and tumor suppressor genes.  
Alteration of chromosome 6 has frequently been identified as the most common 
cytogenetic change in melanoma (Santos, Zielenska et al. 2007).  In particular, gain of the 
6p arm is one of the few chromosomal aberrations that is prevalent in all types of 
melanoma, including cutaneous (both sun-exposed and non-sun-exposed), acral, mucosal, 
and uveal melanomas (Curtin, Fridlyand et al. 2005).  Furthermore, temporal clustering 
of karyotypic changes in melanoma indicates that 6p gain represents an early event in 
melanoma evolution (Hoglund, Gisselsson et al. 2004).  Although the minimal region of 
6p gain has not been described in melanoma, multiple studies in retinoblastoma and 
bladder cancer have identified a narrow region within 6p22.3 as the minimal region of 6p 
gain in those carcinomas (Chen, Gallie et al. 2001; Evans, Gallie et al. 2004).  This 
region notably contains the putative oncogene DEK.   
 DEK was originally discovered as a part of a chromosomal translocation event 
[t(6;9)(p22;q34)] present in a subset of acute myeloid leukemia (von Lindern, van Baal et 
al. 1992).  Subsequent studies have repeatedly identified DEK as a frequently 
overexpressed gene (independent of the t(6;9) translocation) in a number of neoplasms, 
including retinoblastoma, hepatocellular carcinoma, bladder carcinoma, glioblastoma, 
acute myeloid leukemia, and melanoma, thus implying that DEK may be an oncogene 
(Kondoh, Wakatsuki et al. 1999; Grottke, Mantwill et al. 2000; Kroes, Jastrow et al. 
2000; Larramendy, Niini et al. 2002; Casas, Nagy et al. 2003; Sanchez-Carbayo, Socci et 
al. 2003; Wu, Hoffmann et al. 2005; Carro, Spiga et al. 2006).   
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 DEK has been implicated in several diverse cellular processes including 
chromatin architecture maintenance, mRNA splicing, transcriptional repression, DNA 
damage repair, and cell to cell signaling (Fu, Grosveld et al. 1997; Alexiadis, Waldmann 
et al. 2000; Kappes, Burger et al. 2001; Waldmann, Eckerich et al. 2002; Kappes, 
Scholten et al. 2004; Mor-Vaknin, Punturieri et al. 2006; Sammons, Wan et al. 2006; 
Soares, Zanier et al. 2006; Wise-Draper, Allen et al. 2006; Gamble and Fisher 2007; 
Kappes, Fahrer et al. 2008).  Extensive post-translational modification by 
phosphorylation, acetylation, and poly-(ADP) ribosylation is thought to regulate its 
participation in these disparate cellular processes (Kappes, Damoc et al. 2004; Cleary, 
Sitwala et al. 2005; Gamble and Fisher 2007; Kappes, Fahrer et al. 2008).   
 Despite the clear association of DEK overexpression with malignancy, its 
potential contributions to tumorigenesis have yet to be elucidated.   One possibility is that 
DEK may act to inhibit senescence in transformed cells.  Two reports have demonstrated 
that DEK upregulation by the human papillomavirus (HPV) E7 protein is required to 
inhibit senescence following HPV infection (Wise-Draper, Allen et al. 2005; Johung, 
Goodwin et al. 2007).  The HPV E7 protein enhances DEK expression in a pRB-
dependent manner, as mouse embryonic fibroblasts from triple pRB/p107/p130 knockout 
mice do not upregulate DEK in response to E7.  Furthermore, DEK can inhibit 
senescence even in the absence of HPV infection.  RNAi interference with DEK 
expression was sufficient to induce premature replicative senescence in primary human 
fibroblasts (Johung, Goodwin et al. 2007). 
 We sought to examine DEK’s oncogenic contribution to melanoma.  We find that 
DEK is overexpressed at the protein level in all metastatic melanoma lines tested.  Using 
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lentiviral shRNA vectors, we demonstrate that interference with DEK expression results 
in the arrest of cell proliferation and the induction of senescence.  Furthermore, we find 
that the cyclin dependent kinase inhibitor p21
CIP1
 is induced following knockdown of 
DEK expression in both senescent and non-senescent melanoma lines.  Finally, we 
demonstrate that DEK expression is not diminished following oncogene-induced 
senescence of primary melanocytes.  These results establish DEK as a bona fide 
melanoma oncogene with anti-senescence function.   
 
Results 
DEK protein overexpression in metastatic melanoma.   
 While overexpression of DEK mRNA has frequently been identified in numerous 
malignancies, including melanoma, DEK protein overexpression has been confirmed 
only in retinoblastoma and lung carcinoma (Carro, Spiga et al. 2006; Orlic, Spencer et al. 
2006).  To determine DEK protein expression in melanoma, a diverse panel of metastatic 
melanoma lines, as well as normal melanocytes isolated from two individuals, were 
immunoblotted for DEK (Figure 9A).  DEK was found to be universally overexpressed in 
all melanoma lines tested by an average of about 30 fold compared to normal 
melanocytes as estimated by densitometry (Figure 9B).  DEK expression did not display 
any obvious correlation with other known melanoma genetic features (Table 2).  These 
findings suggest that upregulation of DEK may represent a universal event in the 















Figure 9.  Overexpression of DEK in metastatic melanoma lines. A, immunoblotting 
of a panel of metastatic melanoma lines with monoclonal (mAb) and polyclonal (polyAb) 
anti-DEK antibodies. Two cultures of primary foreskin-derived melanocytes, fm293 and 
fm298, were also included.   β-actin is shown as a loading control.  B, Monoclonal anti-
DEK band densities were quantitated, and relative DEK expression was determined. β-
actin band density was used to adjust for loading, and levels were normalized to fm293 












































shRNA knockdown of DEK expression in melanoma affects cell proliferation.   
 The potential contribution of increased DEK expression to the tumorigenicity of 
melanoma was investigated using lentiviral shRNA vectors targeting DEK expression.  
Although others have previously demonstrated effective knockdown of DEK expression 
using RNAi technology, we found that the anti-DEK antibodies utilized in those studies 
substantially overestimate inhibition of DEK expression (Figure 10A).  Due to the 
extremely high levels of DEK expression in metastatic melanoma, successful RNAi 
interference with DEK required the expression of two shRNAs targeting distinct regions 
of the DEK transcript (Figure 10B and 10C).  A vector that produced two distinct 
shRNAs was used to disrupt expression of DEK in four melanoma cell lines.  
Interestingly, shDEK treatment resulted in a reduction of cell proliferation in the SK-
MEL-28 and SK-MEL-94 melanoma lines, but not in SK-MEL-19 or SK-MEL-29 lines 
(Figure 11).     
Decreased proliferation of shDEK transduced cells is due to senescence 
 Cell death was not observed in any of the melanoma lines following treatment 
with DEK specific shRNA.  However, SK-MEL-28 and SK-MEL-94 cells displayed a 
gradual change in cell morphology.  We next investigated whether the defective 
proliferation and the change in cell morphology were caused by senescence.  Senescent 
cells classically demonstrate β-galactosidase activity that persists in sub-optimal acidic 
(pH 6.0) conditions (Dimri, Lee et al. 1995).  This senescence-associated β-galactosidase 
activity (SA-β-Gal) is a commonly used biomarker of senescent cells.  Staining for SA-β-
Gal activity revealed that this decrease in proliferation was indeed the result of the 


















Figure 10.  Knockdown of DEK expression requires two distinct shRNAs.  A, HeLa 
S3 cells were transduced with the H1-LV lentiviral shRNA vector containing either no 
shRNA (empty), or an shRNA that targets DEK expression (shDEK). DEK expression 
was determined by immunoblotting with monoclonal (mAb DEK) or polyclonal (polyAb 
DEK) antibodies to DEK. B, a modified H1-LV lentiviral vector  that expressed two 
distinct shRNAs targeting DEK was contructed by insertion of a second shRNA sequence 
under the control of the murine U6 promoter (shDEK-2). C, DEK expression was 
detected by immunoblotting following transduction of HeLa S3 cells with a lentiviral 
shRNA vector expressing no shRNA sequence (empty), a single shRNA targeting DEK 








There was a 13-fold and 9-fold increase in the percentage of SA-β-Gal staining cells in 
the shDEK treated SK-MEL-28 and SK-MEL-94 lines, respectively.   SK-MEL-28 cells 
additionally displayed classical senescence morphology, marked by flattening and 
enlargement of cells, while SA-β-Gal positive SK-MEL-94 cells had a less distinct 
morphology.  In contrast, shDEK transduction did not result in any increase in SA-β-Gal 
staining or cellular morphology in SK-MEL-19 or SK-MEL-29 cells (Figure 12C and 
12D).      
Knockdown of DEK expression induces p21
CIP1
 in senescing and non-senescing cells 
 We next examined if inhibition of DEK expression activated either of the two 




.  Although SK-MEL-28 and 
SK-MEL-94 expressed p16
INK4a
, there was no apparent effect of shDEK treatment on 
p16
INK4a
 expression (Figure 13A and 13B).  Additionally, SK-MEL-28 cells are known to 
have an R24C mutation in CDK4, effectively inactivating the p16
INK4a 
tumor suppressive 
pathway (Soengas, Capodieci et al. 2001).  Thus, it appears likely that shDEK-induced 
senescence was not due to p16
INK4a




 was induced 
following knockdown of DEK expression in all four lines.  Interestingly, p53 itself was 
increased in only one of these lines (Figure 13A).  This is consistent with p21
CIP1
-
mediated senescence in human cells, which characteristically does not display p53 
accumulation but does nevertheless exhibit increased p53 activity (Atadja, Wong et al. 
1995; Vaziri, West et al. 1997).  Notably, the one cell line that did accumulate p53, SK-
MEL-28, carries a mutated p53 gene (L145R).  SK-MEL-19 and SK-MEL-29 cells also 
had increased p21
CIP1
 expression, but paradoxically displayed no aberrations in cellular 


















Figure 11.  shRNA interference of DEK affects cell proliferation. A, SK-MEL-28 , B, 
SK-MEL-94, C, SK-MEL-19,  and D, SK-MEL-29 cells were transduced with either a 
lentiviral vector expressing a non-specific shRNA (control) or a vector expressing two 
distinct shRNAs targeting DEK (shDEK).  Cells were counted every three days. Error 





responsiveness to p21CIP1 itself.  In support of this possibility, SK-MEL-19 cells also 
demonstrate a failure to arrest or undergo senescence in response to treatment with the 
p53/MDM2 inhibitor nutlin-3, despite significant expression of p21CIP1 (Verhaegen, 
personal communication).  These findings suggest that DEK expression in melanoma 
may aid in the circumvention of the p53-p21CIP1 senescence pathway. 
DEK expression is stable during oncogene-induced senescence in melanocytes 
 Expression of DEK has previously been shown to diminish in human 
keratinocytes and fibroblasts during replicative senescence.  We tested whether DEK was 
similarly downregulated in response to oncogene-induced senescence in primary 
foreskin-derived melanocytes.  Melanomas almost universally express an oncogenic form 
of either BRAF or NRAS (Brose, Volpe et al. 2002; Maldonado, Fridlyand et al. 2003; 
Omholt, Platz et al. 2003).  However, introduction of these oncogenes into otherwise 
normal primary melanocytes results in the rapid development of senescence.  We used 




, or an empty control vector to 
melanocytes.  Immunofluorescence was performed seven days after transduction to detect 





transduced cells exhibited signs of senescence such as flattened morphology and the 





 both continued to express DEK despite the induction of 
senescence (Figure 14B and 14C).  This increase in DEK expression does not appear to 
be due to non-specific effects of lentiviral transduction, as cells transduced with the 
empty lentiviral vector did not have enhanced DEK expression (Figure 14A).  DEK 









Figure 12.  Senescence associated β-galactosidase activity of shDEK-transduced 
melanoma lines. A, SK-MEL-28 , B, SK-MEL-94, C, SK-MEL-19,  and D, SK-MEL-29 
cells were transduced with either a lentiviral vector expressing a non-specific shRNA 
(Control shRNA) or a vector expressing two distinct shRNAs targeting DEK (shDEK).  
Fifteen days after transduction, cells were fixed and stained for senescence associated β-
galactosidase activity. Phase-contrast micrographs demonstrating changes in cell 
morphology and SA-β-Gal staining are shown. The number in the upper right corner of 
each micrograph indicates the percentage of cells that stained positive for senescence 












 transduced cells (Figure 15).  Notably, DEK 
did not appear to co-localize with senescence-associated heterochromatic foci. 
Discussion 
 Using lentiviral shRNA interference with DEK expression, we identify an 
important oncogenic function for DEK in melanoma.  We show that disruption of DEK 
expression results in the gradual onset of cellular senescence in a subset of melanomas.  
Importantly, this is the first demonstration of an anti-senescence function for DEK in an 
HPV-negative malignancy.   
 All metastatic melanomas we examined were found to overexpress DEK protein 
to varying degrees.  There are two likely explanations for the high levels of DEK 
expression.  First, it is possible that DEK expression is augmented by a gain in gene copy 
number.  This has been shown to be true in retinoblastoma and bladder carcinoma, where 
increased DEK expression appears to be due to genomic gain at the DEK locus (6p22.3) 
(Evans, Gallie et al. 2004; Grasemann, Gratias et al. 2005; Orlic, Spencer et al. 2006).  
Additionally, in retinoblastoma deregulation of DEK may also be due to 6p chromosomal 
translocations (Paderova, Orlic-Milacic et al. 2007).   The possibility that DEK 
overexpression is due to chromosomal alterations is supported by the observation that 
gains in the 6p chromosome represent one of the most frequent chromosomal 
abnormalities in melanoma, with one study finding that 63% of primary melanomas and 
50% of metastatic melanomas possess 6p chromosomal gains (Balazs, Adam et al. 2001; 
Curtin, Fridlyand et al. 2005; Santos, Zielenska et al. 2007).  A second possible 
mechanism of DEK overexpression is through dysregulation of the E2F family of 









Figure 13.  Immunoblotting of shDEK-transduced melanoma lines for senescence 
markers. A, SK-MEL-28 , B, SK-MEL-94, C, SK-MEL-19,  and D, SK-MEL-29 cells 
were transduced with either a lentiviral vector expressing a non-specific shRNA (Control 
shRNA) or a vector expressing two distinct shRNAs targeting DEK (shDEK).  Whole cell 
lysates were collected every third day.  Immunoblotting results are shown for DEK, p53, 
p21CIP1, and p16INK4a. GFP is shown as a marker of viral transduction. β-actin is 


































































































Figure 14.  DEK is expressed by melanocytes during oncogene-induced senescence. 
Primary human melanocytes were isolated and transduced with a lentiviral vector 
expressing only GFP (top panels) or GFP and either BRAFV600E (middle panels) or 
NRASQ61R (bottom panels).  Seven days after transduction cells were fixed and DEK 
expression was visualized by immunofluorescence.  (arrowheads – Non-transduced cells, 



















Figure 15.  DEK does not co-localize with senescence associated heterochromatin 
foci. Primary human melanocytes were isolated and transduced with a lentiviral vector 
expressing either BRAFV600E (top panels) or NRASQ61R (bottom panels).  Seven days 
after transduction cells were fixed and DEK expression was visualized by 










































































YY1 and importantly the E2F family of transcription factors (Sitwala, Adams et al. 2002; 
Carro, Spiga et al. 2006).  E2F activity is regulated through its binding to pRb, which is 
in turn regulated by p16
INK4a
.  As mentioned above, melanomas almost invariably have 
defects in the regulation of this pathway.  The inactivation of the P16
INK4a
/pRB pathway 
in melanoma results in the release of E2F from pRB.  Thus, melanomas demonstrate high 
E2F transcriptional activity (Halaban, Cheng et al. 2000).  Thus, the near universal 
dysregulation of the p16
INK4a
 in melanoma may be the cause of their increased DEK 
expression.  In support of this possibility, it has been shown that ectopic expression of 
p16
INK4a
 or a constitutively active form of pRB does indeed repress DEK production 
(Vernell, Helin et al. 2003).  Regardless of the mechanism responsible, the frequent 
overexpression of DEK implies a significant role in melanoma progression. 
 What could this role be?  Our data point to a function in the suppression of 
senescence.  We found that interfering with this abundant DEK expression resulted in the 
gradual induction of senescence in some melanomas.  Consistent with p21
CIP1
-mediated 
senescence, the onset of senescence corresponded with p21
CIP1
 expression, though not 
always with an increase in total p53.  Replicative senescence of primary human cells does 
not generally correspond with an accumulation of p53 protein but does critically rely on 
expression of both p53 and p21
CIP1
 (Vaziri, West et al. 1997; Webley, Bond et al. 2000).  
This observation is reconciled by findings indicating that although the amount of total 
p53 is not altered, its activity is substantially increased during replicative senescence 
(Vaziri, West et al. 1997).  This increase in p53 activity can be traced to increased levels 
of phosphorylation of serine15 and threonine18 (Webley, Bond et al. 2000).  Although 
we did not directly test the requirement of p53 in the development of senescence 
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following interference with DEK expression, the induction of p21
CIP1
 strongly suggests 
the involvement of p53.  Several groups have proposed p53-independent induction of 
p21
CIP1
 in various systems, however, most of these claims are based on the erroneous 
assumptions that mutated p53 forms cannot activate p21
CIP1
 and that p53 activity is 
always accompanied by accumulation of p53 protein.   
 One potential explanation of the anti-senescence function of DEK is that DEK 
may repress basal p53 transcriptional activity.  DEK has been shown to repress p53 
transcriptional activation of multiple p53-target gene promoters, including 
p21
CIP1
(Sammons, Wan et al. 2006; Wise-Draper, Allen et al. 2006).  Therefore, high 
levels of DEK in melanoma cells may serve to directly repress transcriptional p53 
activity on the p21
CIP1
 promoter in melanoma cells.  Interference with DEK expression 
may release this repression, resulting in a steady accumulation of p21
CIP1
.  Another 
possible explanation for the induction of senescence in cells lacking DEK is that DEK 
may prevent the activation of p53 in replication-stressed or oncogene-stressed cells by 
alleviating or masking these stresses.  Telomere shortening/uncapping and the 
accumulation of DNA damage are two major stresses that accumulate with cell division 
and are prominent triggers of replicative senescence.  Both of these stresses trigger a 
DNA damage response that ultimately results in p53-mediated senescence (Ben-Porath 
and Weinberg 2005; Collado, Blasco et al. 2007).  In addition, recent research has 
demonstrated that the phenomenon of oncogene-induced senescence is actually a 
response to DNA damage resulting from stalling of replication forks in rapidly dividing 
cells (Di Micco, Fumagalli et al. 2006).   Thus, the major signals of p16
INK4a
-independent 
senescence all appear to be involve activation and signaling of the DNA damage repair 
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machinery and p53.  We have recently shown that DEK plays a protective role in 
repairing DNA damage, raising the possibilty that overexpression of DEK in melanoma 
cells represses senescence by alleviating DNA damage signals (Kappes, Fahrer et al. 
2008). 
 Our findings have particular significance for understanding the evasion of p53-
mediated senescence by melanoma cells.  In contrast to p16
INK4a
/pRB senescence, the 
circumvention of p53-mediated senescence in melanoma is not well understood.  p53 is 
the most frequently mutated or deleted gene in cancer, but it is rarely a target of 
melanoma mutation.  Nonetheless, melanoma displays defective p53 activity 
(Satyamoorthy, Chehab et al. 2000; Gray-Schopfer, Cheong et al. 2006).  Because of the 
extremely high frequency of genetic inactivation of the p53-regulatory protein ARF, the 
evasion of p53-mediated senescence is commonly ascribed to the inactivation of ARF.  
However, attributing significance to the frequent inactivation of ARF is complicated by 
the fact that the ARF gene shares its locus, CDKN2A, with another important melanoma 
tumor suppressor, p16
INK4a
.  Thus, deletion or methylation of the CDK2NA locus may 
simply be a reflection of the importance of p16
INK4a
 inactivation in melanoma 
development.  Indeed, the incidence of point mutations affecting only p16
INK4a
 is much 
greater than those affecting only ARF, suggesting that the primary target of deletion or 
methylation of CDKN2a is p16
INK4a
 (Bennett 2008).  Additionally, while ARF has been 
shown to play an important role in the development of senescence in rodents, studies of 
senescence in human cells consistently demonstrate a lesser role for ARF (Wei, Hemmer 
et al. 2001; Brookes, Rowe et al. 2002; Voorhoeve and Agami 2003).   
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 Surprisingly, we found that in a model of melanocyte oncogene-induced 
senescence, DEK expression was not diminished concomitantly with the onset of 
senescence.  This is in contrast to previous reports of depletion of DEK in replicative 
senescence of fibroblasts and keratinocytes.  The discrepancy may due to differences 
between those cell types and melanocytes, or it may reflect a differential role for DEK in 
oncogene-induced senescence as opposed to replicative senescence.  At a minimum, 
these results demonstrate that cells can undergo senescence in the presence of DEK 
expression.  It is also noteworthy, given our discovery of an interaction between DEK 
and heterochromatin protein 1α (HP1α), that unlike HP1α, DEK does not colocalize with 
senescence associated heterochromatic foci (Narita, Nunez et al. 2003; Kappes, 
Khodadoust et al., in preparation).   
 These results suggest that overexpression of DEK may be an important 
mechanism for evasion of senescence in melanoma cells.  The frequency of DEK 
overexpression raises the possibility that this overexpression may be a requisite event in 
the development of melanoma.  Moreover, as DEK is a frequently overexpressed gene in 
a variety of malignancies, these results may be of significance in the study of other tumor 
types as well.   
 
Materials and Methods 
Cell culture   
 All melanoma cell lines were cultured in DMEM (Life Technologies, Rockville, 
MD) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin.  
Human melanocytes were isolated from
 
human neonatal foreskins as described 
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(Verhaegen, Bauer et al. 2006) and maintained in
 
Medium 254 supplemented with 12-O-
tetradecanoylphorbol-13-acetate
 




Extract preparation and protein immunoblots 
 Total cell lysates were obtained by Laemmli extraction, separated by SDS-PAGE, 
and transferred to Immobilon-P membranes (Millipore, Bedford, MA).  Protein 
concentrations were determined using the BCA Protein Assay (Pierce, Rockford, IL).  
Monoclonal antibodies to DEK were obtained from BD Biosciences (Franklin Lake, NJ), 
β-actin from Sigma Chemical (St. Louis, MO), and p53 from Novacostra Laboratories 
(Newcastle upon Tyne, UK). Polyclonal antibodies to DEK were produced as previously 
described (Kappes, Damoc et al. 2004).  Unless otherwise specified, DEK was detected 
in immunoblots using polyclonal anti-DEK antibodies.  Detection was performed using 
ECL Western blotting substrate from Pierce (Rockford, IL).  Protein expression was 
quantified using Scion image
 
densitometry software (Scion Corporation, Frederick, MD). 
Cell proliferation and senescence-associated β-galactosidase staining 
 Cell cultures were split every three days and counted manually by 
hemocytometer.    Cells were washed in PBS, fixed for 3-5 min (room temperature) in 
2% formaldehyde/ 0.2% glutaraldehyde (or 3% formaldehyde), washed, and incubated at 
37°C (no CO2) with fresh senescence associated (3-Gal (SA-,3-Gal) stain solution: 1 mg 
of 5-bromo-4-chloro-3-indolyl P3-D-galactoside (X-Gal) per ml (stock = 20 mg of 
dimethylformamide per ml)/40 mM citric acid/sodium phosphate, pH 6.0/5 mM 
potassium ferrocyanide/5 mM potassium ferricyanide/150 mM NaCl/2 mM MgCl2. 
Staining was evident in 2-4 hr, and maximal in 12-16 hr. 
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Lentiviral shRNA constructs   
 The H1-LV vector was used to produce shRNAs targeting DEK.  The shDEK-1 
vector used the human H1 promoter to drive expression of an shRNA targeting a 
sequence in the 3’ untranslated region of the human DEK transcript (nucleotides 1615-35, 
GenBank NM_003472.2).   The shDEK-2 vector was constructed by inserting a second 
Pol III promoter and shRNA immediately 5’ of the H1 promoter.  This insertion 
contained the murine U6 promoter expressing a second shRNA targeting a coding region 





 expression lentiviral vectors has been 
described previously (Denoyelle, Abou-Rjaily et al. 2006).  Lentivirus production and 
infection was performed as described previously (Verhaegen, Bauer et al. 2006).  
Transduction efficiency of H1-LV and FG-12 derived lentiviral vectors was estimated by 
detection of GFP expression (driven by the human ubiquitin c promoter) by fluorescence 
microscopy or flow cytometry and was routinely greater than 95%.   Cells transduced 
with the PLKO.1-DEK832 vector were selected for 3 days in 2 µg/mL puromycin.    
Immunofluorescence 
 Melanocytes were cultured and infected on chamber slides.  Immunofluorescence 
staining for DEK was performed.  Three phosphate-buffered saline (PBS)
 
washes were 
performed in between each of the following steps;
 
when indicated, PBS washes contained 
0.1% saponin. Cells were
 
washed and fixed for 10 min in 4% paraformaldehyde. Fixed 
cells
 
were washed, blocked for at least 1 hour with 0.2% bovine serum
 
albumin in PBS, 
rewashed with PBS/saponin, and incubated for
 





in PBS/saponin.  Cells were then rewashed
 
in PBS/saponin and 
reblocked with goat serum in PBS/saponin
 
at a 1:50 dilution for 1 hour, followed by 
PBS/saponin washing
 
and a 1 hour incubation with Alexa fluor 594-conjugated goat anti-
mouse
 
IgG (20 µg/ml; Molecular Probes) in PBS/saponin. Slides were washed with 
PBS/saponin, refixed
 
for 10 min, rewashed with PBS, and distilled water then dried. 
Coverslips were mounted with Prolong Gold reagent containing DAPI (Molecular
 
Probes), and images were captured with a Zeiss Laser Scanning
 






DEK PROMOTES CHEMORESISTANCE IN MELANOMA THROUGH 
UPREGULATION OF MCL-1 EXPRESSION 
 
Abstract 
 Metastatic melanoma has been shown to frequently overexpress the oncogene 
DEK.  We have recently described that DEK expression is required to avoid senescence 
in a subset of metastatic melanoma cell lines.  Here, we address the potential oncogenic 
contribution of DEK in melanoma lines that express high levels of DEK, but do not 
senesce in response to inhibition of DEK expression.  In these lines, DEK expression 
confers remarkable chemoresistance to both doxorubicin and TW-37, a BH3 mimetic 
compound.  Interference with DEK expression did not result in aberrations in the p53 
response to doxorubicin but did cause reduced expression of the anti-apoptotic protein 
Mcl-1.  Notably, expression of other related proteins, Bcl-2 and Bcl-XL, were unaffected.  
Although Mcl-1 protein levels are often regulated at the level of protein stability, 
diminished Mcl-1 expression in DEK-deficient melanoma cells was not due to changes in 
Mcl-1 protein stability but instead was a result of defective Mcl-1 production.  
Quantitative RT-PCR analysis and luciferase reporter assays of the mcl-1 promoter 
revealed that inhibition of DEK expression resulted in reduced mcl-1 promoter activity 
 
 87 
and hence reduced levels of mcl-1 transcript.  Finally, Mcl-1 expression was shown to be 
a critical determinant of doxorubicin resistance in melanoma.  These findings describe a 
second oncogenic function of DEK in melanoma cells, as a promoter of chemoresistance.  
These results also demonstrate a novel mechanism of Mcl-1 dysregulation in melanoma 
at the level of transcription. 
Introduction 
 Melanoma is the most lethal form of skin cancer, and its increasing incidence 
indicates that it will pose a growing clinical challenge (Jemal, Siegel et al. 2008).  
Although primary melanoma can be successfully treated with surgery at early stages, 
metastatic melanoma carries a grim prognosis.  Metastatic melanoma responds poorly to 
current therapeutic modalities, include radiotherapy and chemotherapy (Gogas, Kirkwood 
et al. 2007).  The notorious chemoresistance of melanoma to conventional 
chemotherapies has stimulated research into novel molecularly targeted therapies.  
Although several newly developed, rationally-designed pharmacologic agents have 
shown promise, their clinical efficacy has yet to be proven. 
 Malignant melanoma is one of the most chemoresistant cancers, and a myriad of 
mechanisms employed by melanoma have been identified that contribute to this 
phenotype (Soengas and Lowe 2003; Chin, Garraway et al. 2006).  These mechanisms 
can be crudely divided into two categories: suppression of genes that promote apoptosis 
and enhancement of those that promote survival.  Many pro-apoptotic mediators of both 
the intrinsic and extrinsic pathways of apoptosis, such as p14ARF, Apaf-1, and TRAIL-
R, have been shown to be frequently downregulated in melanoma.  Conversely, 
melanomas commonly display enhanced expression of anti-apoptotic proteins, including 
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Bcl-2 family members (Bcl-2, Bcl-XL, and Mcl-1), FLIP, and MITF   (Irmler, Thome et 
al. 1997; Selzer, Schlagbauer-Wadl et al. 1998; Chin, Garraway et al. 2006; Eberle, 
Kurbanov et al. 2007; Wolter, Verhaegen et al. 2007).  The dysregulation of some of 
these genes can be traced to genetic and/or epigenetic alterations.  For example, Apaf-1 
has been shown to be inactivated by methylation of the gene locus, while amplification of 
chromosome 3p14 has been implicated in overexpression of MITF (Soengas, Capodieci 
et al. 2001; Chin, Garraway et al. 2006; Jonsson, Dahl et al. 2007).  However, 
corresponding genetic abnormalities are lacking for most proposed mechanisms of 
melanoma chemoresistance. 
 Alteration of chromosome 6 has frequently been identified as the most common 
cytogenetic change in melanoma (Santos, Zielenska et al. 2007).  In particular, gain of the 
6p arm is one of the few chromosomal aberrations that is prevalent in all types of 
melanoma, including cutaneous (both sun-exposed and non-sun-exposed), acral, mucosal, 
and uveal melanomas (Curtin, Fridlyand et al. 2005).  We have previously identified the 
product of a putative oncogene located in the 6p chromosome arm, DEK, as a frequently 
overexpressed protein in metastatic melanoma.  Interference with DEK expression 
resulted in the induction of senescence in a subset of metastatic melanoma lines.  
Additionally, we found a target of p53, p21
CIP1
, to be induced following knockdown of 
DEK in both senescing and non-senescing lines, suggesting enhanced p53 activity in cells 
lacking DEK. 
 Although DEK was overexpressed in all melanoma lines examined, we found the 
degree of this overexpression to be variable.  Surprisingly, we found that interference 
with DEK expression in the two melanoma lines with the greatest expression of DEK did 
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not result in senescence or any other abnormalities in cell proliferation.  Previously, DEK 
has been shown to act as an inhibitor of apoptosis in HeLa cervical cancer cells (Wise-
Draper, Allen et al. 2006).  Depletion of DEK in these cells resulted in spontaneous 
apoptosis in a p53-dependent manner.  DEK expression inhibits p53 transcriptional 
activity (Sammons, Wan et al. 2006; Wise-Draper, Allen et al. 2006).   Thus, in addition 
to repressing senescence, DEK may also act as an anti-apoptotic factor in DEK-
overexpressing cancer cells. 
 We examined the possibility that DEK expression in melanoma promotes 
chemoresistance.  We found that DEK expression did indeed confer substantial 
chemoresistance to both the DNA damaging agent doxorubicin and the BH3 mimetic 
compound TW-37.  Interestingly, the ability to inhibit senescence did not involve p53 
accumulation or activity.  Rather, DEK promoted expression of the anti-apoptotic protein 
Mcl-1, but not the related proteins Bcl-2 or Bcl-XL.  We show that Mcl-1 protein stability 
is not affected by DEK expression.  Instead, DEK appears to regulate Mcl-1 expression at 
a transcriptional level by promoting activation of the Mcl-1 promoter.  Finally, we 
demonstrate that Mcl-1 expression, but not Bcl-XL, is a critical determinate of 
chemoresistance.  Our findings present a novel second oncogenic function for DEK in the 
setting of melanoma: promotion of chemoresistance.  These results also identify a 
previously unknown regulatory mechanism of Mcl-1 expression that may have 
implications in dysregulation of Mcl-1 in other cancers beyond melanoma. 
Results 




Previously, we have shown that interference with DEK expression results in 
senescence in a subset of metastatic melanoma lines.  Surprisingly, the two cell lines with 
the greatest expression of DEK (SK-MEL-19 and SK-MEL-29) did not exhibit any 
defects in proliferation following shDEK treatment.  Because DEK has previously been 
described as an anti-apoptotic factor in HeLa cells, we hypothesized that DEK may 
nevertheless contribute to the chemoresistance of these metastatic melanoma lines. 
Indeed, DEK-knockdown in these lines did result in markedly increased sensitivity to the 
anthracycline doxorubicin (Figure 16A and 16B).   
Because we have recently shown that DEK is required for effective DNA damage 
repair of damage caused by certain genotoxic agents (Kappes, Fahrer et al. 2008), we 
sought to determine if the increased sensitivity to apoptotic stimuli in DEK-knockdown 
cells was limited to DNA damaging agents.  To test the sensitivity of DEK knockdown 
cells to a non-genotoxic apoptotic agent we utilized the recently developed BH3 mimetic 
TW-37.  TW-37 directly stimulates the mitochrondial apoptosis pathway by binding the 
Bcl-2 family of anti-apoptotic proteins.  TW-37, unlike many BH3 mimetics, exhibits a 
high affinity for Mcl-1, in addition to Bcl-2 and Bcl-XL (Wang, Nikolovska-Coleska et al. 
2006).  Cells lacking DEK exhibited greater sensitivity to the TW-37, indicating that 
chemosensitization in response to interference with DEK expression is not limited to 
DNA damaging agents (Figure 16C and 16D).  It should be noted that although DEK-
knockdown cells were more sensitive to TW-37, the difference was not as pronounced as 
the increased sensitivity to doxorubicin.  This may be the result of dual protective effects 
of DEK in aiding DNA repair as well as repressing the mitochondrial apoptotic pathway 















Figure 16.  Interference with DEK expression sensitizes SK-MEL-19 metastatic 
melanoma cells to pro-apoptotic stimuli.  A, cells were transduced with either a 
lentiviral vector expressing a non-specific shRNA (control shRNA), a vector expressing a 
single shRNA targeting DEK (shDEK-1), or a vector expressing two distinct shRNAs 
targeting DEK (shDEK-2).  72 hours after infection, cells were treated with doxorubicin 
for 30 hours, and then stained with DAPI.  Condensed and fragmented nuclei were 
counted and divided by total nuclei to determine the percent of dead cells.  The inset 
illustrates the inhibition of DEK expression as determined by immunoblotting. B, 
fluorescence microscopy illustrating cell nuclear morphology after treatment with 0.3 
µg/mL doxorubicin for 30 hrs in cells infected with a control shRNA expressing vector 
(left) or a vector expressing two distinct shRNAs targeting DEK (right).  C, sensitivity to 
the BH3 mimetic compound TW-37 was determined as in A, with the exception that cells 
were treated with TW-37 for 48 hours.  D, fluorescence microscopy illustrating cell 
nuclear morphology after treatment with 15µM TW-37 in cells infected with a control 
shRNA expressing vector (left) or a vector expressing two distinct shRNAs targeting 






melanoma results in broad chemoresistance to genotoxic stress as well as mitochondrial 
targeted therapies. 
Interference with DEK expression does not cause aberrations in the p53 response to 
doxorubicin 
DEK has previously been reported to mediate anti-apoptotic effects through 
destabilization of p53 protein and inhibition of p53 activity (Sammons, Wan et al. 2006; 
Wise-Draper, Allen et al. 2006).  Therefore, we next examined whether the increased 
sensitivity in DEK-knockdown cells was due to increased p53 accumulation and activity.  
Surprisingly, DEK-knockdown SK-MEL-19 cells displayed no detectable aberrations in 
p53 accumulation nor in activation of p53, as measured by phosphorylation of serine 15 
in response to doxorubicin (Figure 17).  Additionally, induction of p21
CIP1
 in response to 
doxorubicin was slightly diminished, not enhanced as would be predicted if DEK were 
inhibiting p53 activity.  Thus, the chemoresistance conferred by DEK does not appear to 
be related to p53 stability or activity. 
DEK-knockdown cells have diminished Mcl-1 expression   
The increased susceptibility of DEK-knockdown cells to TW-37 suggested the 
possible involvement of the Bcl-2 family of anti-apoptotic proteins.  Indeed, 
immunoblotting revealed decreased expression of Mcl-1 in DEK-deficient cells, though 
not of other closely related members, Bcl-2 and Bcl-XL (Figure 17).  This decrease was 
most notable approximately 30-36 hours following exposure to doxorubicin, although 
levels of Mcl-1 were diminished even in non-treated DEK-knockdown cells.  Because 
Mcl-1 is a known target of caspase cleavage (Herrant, Jacquel et al. 2004)(Gomez-

















Figure 17.  Knockdown of DEK decreases Mcl-1 expression, but does not affect the 
p53 response to doxorubicin.  A, SK-MEL-19 cells were transduced with either a 
lentiviral vector expressing a non-specific shRNA (control shRNA) or a vector expressing 
two distinct shRNAs targeting DEK (shDEK).  Cells were treated with 0.2 µg/mL 
doxorubicin and collected at the indicated times.  Expression of p53, phosphorylated p53 
(serine 15), p21CIP1, Bcl-2, Bcl-XL, Mcl-1, caspase-3, and β-actin was determined by 
immunoblotting.  The graphs below show the relative expression of Bcl-2 (left panel), 
Bcl-XL (middle panel) and Mcl-1 (right panel) following doxorubicin treatment as 
estimated by band densitometry.  Expression is shown relative to that of untreated 
control-transduced cells.  
 
 






































expression in doxorubicin-treated, DEK-knockdown cells was caspase-dependent.  
Inhibition of caspase activity with the pan-caspase inhibitor z-VAD-fmk eliminated 
cleavage of caspase-3, but had only a minimal effect on the levels of Mcl-1 in shDEK-
treated cells, indicating that the reduction in Mcl-1 is not due to caspase activity (Figure 
18).  In addition to SK-MEL-19 cells, we found that the reduction of Mcl-1 expression 
following interference with DEK expression could also be seen in SK-MEL-29 cells 
(Figure 19).  Importantly, the reduction of Mcl-1 was not due to non-specific effects of 
the lentiviral vector or DEK-targeted shRNA, as the same effects could be reproduced 
with a third distinct shRNA targeting DEK and expressed in a different vector system 
(Figure 19).    
Decreased Mcl-1 in shDEK treated cells is not due to increased Mcl-1 degradation 
 We next attempted to determine the cause of the decrease in Mcl-1 expression in 
cells lacking DEK.  Unlike other Bcl-2 family members, Mcl-1 is very labile and rapidly 
turned over in the cell through ubiquitination and subsequent proteasomal degradation.  
Thus, a major mechanism of Mcl-1 regulation is the modulation of Mcl-1 protein 
degradation.  To determine if the decrease in Mcl-1 protein in DEK-knockdown cells was 
due to enhanced proteasomal degradation of Mcl-1, cells were treated with the 
proteasome inhibitor bortezomib.  Bortezomib has been shown to be extremely effective 
in blocking Mcl-1 degradation, and treatment of melanoma cells with bortezomib has 
been shown to result in rapid accumulation of Mcl-1 protein (Fernandez, Verhaegen et al. 
2005; Qin, Ziffra et al. 2005; Qin, Xin et al. 2006; Wolter, Verhaegen et al. 2007).  While 
Mcl-1 accumulated in both cells containing and cells lacking DEK, the rate of 















Figure 18.  Diminished Mcl-1 expression in doxorubicin shDEK-transduced cells is 
not caspase-3 dependent. Control and shDEK-transduced SK-MEL-19 cells were 
treated with 0.2 µg/mL doxorubicin alone or doxorubicin in the presence of 50 µM of the 
pan-caspase inhibitor z-VAD-fmk. Immunoblotting was used to determine the expression 




suggested that the reduction of Mcl-1 in DEK-knockdown cells was not due to an 
increase in Mcl-1 degradation.  To assess the stability of Mcl-1 protein in DEK-
knockdown cells, cycloheximide, a translational inhibitor, was used to inhibit de novo 
Mcl-1 production, and Mcl-1 levels were determined by immunoblotting.  To better 
visualize the decrease in Mcl-1 expression, cells were first pre-treated with bortezomib to 
augment Mcl-1 levels, then the bortezomib was washed out, and cells were incubated in 
cycloheximide.  Mcl-1 was degraded at a similar rate in both control and shDEK-treated 
cells, although the initial amount of Mcl-1 was reduced in shDEK-treated cells (Figure 
20B).  Taken together, these results implied that the presence of DEK does not affect 
Mcl-1 protein stability but does enhance the production of Mcl-1 protein.   
Reduction of Mcl-1 expression is due to decreased Mcl-1 transcription 
 Since the production but not the stability of Mcl-1 protein appeared to be altered 
in DEK-knockdown cells, we next examined if these cells had reduced levels of Mcl-1 
transcript (Figure 21A).  Indeed, quantitative RT-PCR analysis revealed shDEK-
transduced cells had an almost 50% reduction of Mcl-1 mRNA as compared to control 
transduced cells.  Luciferase reporter gene assays were next used to determine the activity 
of the human Mcl-1 promoter in shDEK-transduced cells.  We found that shDEK-
transduced cells exhibited markedly reduced Mcl-1 promoter activity (Figure 21B).  
These results show that the decreased Mcl-1 expression in DEK-knockdown cells is 















Figure 19.  Diminished Mcl-1 expression in shDEK-transduced SK-MEL-19 and 
SK-MEL-29 cells is not shRNA or vector specific. SK-MEL-19 (left) and SK-MEL-29 
(right) cells were transduced with a lentivirus expressing either a control shRNA 
sequence, a single shRNA targeting DEK (shDEK-1), or two distinct shRNAs targeting 
DEK (shDEK-2).  96 hours after infection, cells were collected and their lysates were 
immunoblotted for DEK and Mcl-1 expression.  To ensure that the decrease in Mcl-1 
expression was not due to non-specific effects of the lentiviral vector, a third DEK-
targeting lentivirus (shDEK-3) using a different lentiviral vector and expressing a distinct 















Figure 20.  Knockdown of DEK decreases Mcl-1 production, but does not affect 
Mcl-1 protein stability  A, Transduced SK-MEL-19 cells were treated for the indicated 
times with 25 nM bortezomib (Bort)  Following treatment, cells were collected and 
lysates were immunoblotted for Mcl-1, DEK, Bcl-2, and β-actin (left).  Densitometry was 
used to quantitate Mcl-1 expression (right).  Expression is shown relative to non-treated 
control-infected cells.  B, Transduced SK-MEL-19 cells were treated for 5 hours with 25 
nM of the proteasome inhibitor bortezomib.  Cells were then washed to remove 
bortezomib and incubated with cycloheximide (CHX) to block protein translation for the 
indicated times.  Following treatment cells were collected and immunoblotted as in A 

















Figure 21.  Decreased activity of the mcl-1 promoter in shDEK-transduced cells. A, 
mcl-1 mRNA expression of control and shDEK treated SK-MEL-19 cells was determined 
by quantitative real-time RT-PCR using mcl-1 specific primers.  mcl-1 mRNA expression 
was normalized to that of β–actin.  B, control and shDEK transduced SK-MEL-19 cells 
were transfected with either the the promoterless pGL2 basic plasmid or a plasmid 
expressing the firefly luciferase gene under the control of the human mcl-1 promoter (-
213/+10 bp).  Cells were lysed and luciferase activity was determined 30 hours after 
transfection. The average luciferase activity of three experiments is shown relative to that 
of control transduced cells transfected with the pGL2 basic plasmid.  Error bars represent 





Mcl-1 expression determines doxorubicin sensitivity 
Finally, we investigated whether the increased sensitivity to chemotherapeutic agents 
of cells lacking DEK could be attributed to their reduction in Mcl-1 expression.  
Although Mcl-1 has been shown to enhance resistance to several chemotherapeutic 
agents and apoptotic stimuli, its contribution to doxorubicin resistance in melanoma has 
not been directly investigated.  Interference with Mcl-1 expression resulted in a 
remarkable increase in sensitivity to doxorubicin in both control transduced and shDEK 
transduced cells (Figure 22A).  In contrast, interference with Bcl-XL expression resulted 
in only marginally increased sensitivity (Figure 22B).  Thus, Mcl-1 is a particularly 
potent mediator of doxorubicin resistance.  To determine if overexpression of Mcl-1 
could rescue DEK-knockdown cells from doxorubicin cytotoxicity, a lentiviral vector 
expressing human Mcl-1 was constructed.  Secondary transduction of DEK-knockdown 
cells with this vector indeed did restore doxorubicin resistance (Figure 23A).  
Interestingly, these cells had almost identical total levels of Mcl-1 protein as control 
transduced cells (Figure 23A, inset lanes 1 and 4) and displayed nearly identical 
sensitivity to doxorubicin (Figure 23A). Additionally, cells with normal DEK expression 
achieved even greater resistance to doxorubicin upon Mcl-1 overexpression (Figure 
23A).  Importantly, while shDEK treated cells demonstrated diminished levels of 
endogenous Mcl-1, expression of Flag-tagged Mcl-1 driven by the lentiviral CMV 
promoter was not affected (Figure 23A, inset lanes 3 and 4).  This is further evidence 
that, as evinced above, cells lacking DEK do not display defects in Mcl-1 protein 
stability, but rather are deficient in Mcl-1 transcription.   Again, Bcl-XL did not seem to 
confer equivalent resistance to doxorubicin, as Bcl-XL overexpression failed to rescue 
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shDEK cells from doxorubicin cytotoxicity (Figure 23B).   These results demonstrate that 
the marked sensitivity to doxorubicin of melanoma cells lacking DEK is attributable to 
their reduced Mcl-1 expression.   
Discussion 
 Using shRNA to interfere with DEK expression, we previously demonstrated that 
continuous DEK expression in a subset of metastatic melanomas is required to avoid the 
induction of senescence.  Here, we show that DEK expression can additionally confer 
remarkable chemoresistance.  Interestingly, the anti-apoptotic function of DEK in 
melanoma did not appear to be related to the p53-suppressing effect previously seen in 
HeLa cervical carcinoma cells.  Rather, the chemoresistance activity of DEK was 
attributable to a novel function in the control of Mcl-1 transcription. 
 Mcl-1 has emerged as a particularly potent member of the Bcl-2 family of anti-
apoptotic proteins.  Previous studies have described Mcl-1 overexpression in melanoma 
(Selzer, Schlagbauer-Wadl et al. 1998; Tang, Tron et al. 1998; Zhuang, Lee et al. 2007; 
Wong, Khosravi et al. 2008).  The importance of Mcl-1 in melanoma treatment is 
underscored by the observation that Mcl-1 expression correlates with metastases and poor 
prognosis whereas Bcl-2 does not (Fecker, Geilen et al. 2006; Zhuang, Lee et al. 2007).  
The expression of Mcl-1 by melanoma cells importantly has been implicated in resistance 
to many treatments, including several recently developed targeted therapies.  Mcl-1 is a 
critical determinate of sensitivity in response to proteasome inhibition by bortezomib, and 
to MEK inhibition by U0126 (Qin, Xin et al. 2006; Nguyen, Marcellus et al. 2007; Wang, 
Jiang et al. 2007; Wolter, Verhaegen et al. 2007).  Additionally, the ability to survive 













Figure 22.  Mcl-1, but not Bcl-XL, expression confers doxorubicin chemoresistance 
in melanoma. A, SK-MEL-19 cells were transduced with either a control or shDEK 
lentiviral vector.  Cells were subsequently transduced with either an empty lentiviral 
vector or a vector expressing an Mcl-1 targeting shRNA.  72 hours after the second viral 
infection, cells were treated with the indicated concentration of doxorubicin for 30 hrs.  
Following treatment, cells were stained with DAPI and apoptotic cells were counted by 
fluorescence microscopy.  B, cells were treated as in A, with the exception that the second 
















Figure 23.  Mcl-1 expression, but not Bcl-XL, expression restores doxorubicin 
chemoresistance to shDEK-transduced melanoma cells. A, SK-MEL-19 cells were 
transduced with either a control or shDEK lentiviral vector.  Cells were subsequently 
transduced with either an empty lentiviral vector or a vector expressing Flag-tagged Mcl-
1.  72 hours after the second viral infection, cells were treated with the indicated 
concentration of doxorubicin for 30 hrs.  Following treatment, cells were stained with 
DAPI and apoptotic cells were counted by fluorescence microscopy.  B, cells were 
treated as in A, with the exception that the second lentiviral infection was performed with 





depend on Mcl-1(Nguyen, Marcellus et al. 2007).  This is because ABT-737, like many 
first generation BH3 mimetics, displays selective affinity for Bcl-2 and Bcl-XL, but not 
Mcl-1 (Oltersdorf, Elmore et al. 2005).  Indeed, Mcl-1 exhibits important differences 
from these related proteins.  Specifically, Mcl-1 has a unique BH3-only protein affinity 
profile (Youle and Strasser 2008), with one particularly important feature being its ability 
to bind NOXA but not BAD (Chen, Willis et al. 2005). Another unique feature of Mcl-1 
is its lability.  Because of its short half life, Mcl-1 is effectively regulated at the post-
translational level.    
 Whereas post-translational regulation of Mcl-1 has been well characterized, 
studies of transcriptional regulation have given a less clear picture.  The mcl-1 promoter 
is responsive to STAT signaling, and also can be repressed by two E2F transcription 
factors, E2F1 and E2F2 (Croxton, Ma et al. 2002; Croxton, Ma et al. 2002).  Recently, 
the mcl-1 promoter was also identified as a target of p53 repression (Pietrzak and 
Puzianowska-Kuznicka 2008).  Our findings show that DEK promotes activity of the 
mcl-1 promoter.  Although we do not demonstrate direct binding of DEK to the mcl-1 
promoter, this would appear to be the most likely explanation of our findings.  DEK has 
previously been shown to function as a transcriptional activator (as well as a repressor) 
and can localize to transcriptionally active areas (Campillos, Garcia et al. 2003; Hu, Illges 
et al. 2005; Hu, Scholten et al. 2007).  It is noteworthy that the regulation of Mcl-1 
expression by DEK was observed only in the melanoma lines with the greatest expression 
of DEK.  It may be that this activity of DEK is only observed in cells with extremely 
abundant DEK expression.  Our attempts to address this possibility by stable 
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overexpression of DEK in melanocytes and melanoma lines were unsuccessful, 
presumably due a to negative feedback response on endogenous DEK production.   
 Our previous study of the function of DEK in melanoma demonstrated that only a 
subset of melanoma cells senesced in response to knockdown of DEK.  Interestingly, 
even melanoma lines that did not senesce in response to interference with DEK 
nonetheless displayed induction of p21
CIP1
.  Because of the universal response of p21
CIP1
 
to DEK interference, we speculate that inhibition of p21
CIP1
 may in fact be the primary 
function of enhanced DEK expression.  In this scenario, the upregulation of DEK 
expression is initially required to bypass p21
CIP1
-mediated cell arrest, and 
chemoresistance develops as an inherent consequence of the circumvention of the 
senescence response by overexpression of DEK.  One puzzling feature of metastatic 
melanoma chemoresistance is its intrinsic nature (Soengas and Lowe 2003).  In other 
words, chemoresistance does not develop as a result of acquired alterations during and 
after exposure to treatment but is rather an inherent characteristic of even untreated 
melanoma.  If overexpression of DEK is indeed a frequently employed mechanism of 
bypassing the senescence response, the ability of DEK to also regulate Mcl-1 expression 
may partially explain the remarkable intrinsic chemoresistance of metastatic melanoma.    
 These results functionally implicate DEK as a melanoma oncogene that displays 
both anti-senescence and anti-apoptotic activity.  Furthermore, we establish DEK, a gene 
frequently overexpressed in a number of malignancies, as a novel regulator of Mcl-1 
transcriptional regulation and hence as a modulator of chemoresitance.  Our findings 
suggest that overexpression of DEK may be a frequent and significant event in the 
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development of melanoma, and these data warrant the further study of DEK as a potential 
target in the pursuit of effective treatments for melanoma. 
Material and Methods 
Cell culture   
 All melanoma cell lines were cultured in DMEM (Life Technologies, Rockville, 
MD) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin.  
Human melanocytes were isolated from
 
human neonatal foreskins as described 
(Verhaegen, Bauer et al. 2006) and maintained in
 
Medium 254 supplemented with 12-O-
tetradecanoylphorbol-13-acetate
 





 Doxorubicin hydrochloride, cycloheximide and 4',6-diamidino-2-phenylindole 
(DAPI) were purchased from Sigma Chemical (St. Louis, MO).  Bortezomib was 
obtained from Millennium Pharmaceuticals (Cambridge, MA). zVAD-fmk was 
purchased from Calbiochem (Cambridge, MA).  TW-37 synthesis has been described 
previously (Wang, Nikolovska-Coleska et al. 2006).   
Extract preparation and protein immunoblots  
Adherent and non-adherent cells were collected.  Total cell lysates were obtained by 
Laemmli extraction, separated by SDS-PAGE, and transferred to Immobilon-P 
membranes (Millipore, Bedford, MA).  Protein concentrations were determined using the 
BCA Protein Assay (Pierce, Rockford, IL).  Antibodies to Bcl-XL and monoclonal 
antibodies to DEK were obtained from BD Biosciences (Franklin Lake, NJ), β-actin from 
Sigma Chemical (St. Louis, MO), p53 from Novacostra Laboratories (Newcastle upon 
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Tyne, UK), Bcl-2 from DAKO Diagnostics (Glostrup, Denmark), Mcl-1 from Santa Cruz 
Biotechnology (Santa Cruz, CA), caspase-3 and phospho-p53-ser
15 
from Cell Signaling 
Technologies (Beverly, MA).  Polyclonal antibodies to DEK were produced as 
previously described (Kappes, Damoc et al. 2004).  Unless otherwise specified, DEK was 
detected in immunoblots using polyclonal anti-DEK antibodies.  Detection was 
performed using ECL Western blotting substrate from Pierce (Rockford, IL).  Protein 
expression was quantified using Scion image
 
densitometry software (Scion Corporation, 
Frederick, MD). 
Cell viability   
 Adherent and non-adherent cells were collected and pooled at the indicated times 
after treatment.  Cells were washed in PBS, fixed with 3.7% paraformaldehyde, and 
stained with DAPI.  Samples were then mounted unto glass slides, and nuclear 
condensation and fragmentation were assessed by fluorescence microscopy using an 
Olympus BX-51 upright microscope.  Image capture was performed electronically using 
an Olympus DP-70 high resolution digital camera.  
Lentiviral shRNA constructs   
Construction of lentiviral shRNA vectors targeting Bcl-2, Bcl-XL, and Mcl-1 has been 
described previously (Verhaegen, Bauer et al. 2006).  The H1-LV vector was used to 
produce shRNAs targeting DEK.  The shDEK-1 vector used the human H1 promoter to 
drive expression of an shRNA targeting a sequence in the 3’ untranslated region of the 
human DEK transcript (nucleotides 1615-35, GenBank NM_003472.2).   The shDEK-2 
vector was constructed by inserting a second Pol III promoter and shRNA immediately 5’ 
of the H1 promoter.  This insertion contained the murine U6 promoter expressing a 
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second shRNA targeting a coding region of the DEK transcript (nucleotides 1118-1141, 
GenBank NM_003472.2).   Finally, a third lentiviral vector targeting DEK expression 
based on the PLKO.1 vector, PLKO.1-DEK832, was purchased from the Sigma 
Chemicals (St. Louis, MO).  This vector targets a third region of the human DEK 
transcript distinct from the shRNA targets listed above.  Lentivirus production and 
infection was performed as described previously (Verhaegen, Bauer et al. 2006).  When 
cells were sequentially infected with two lentiviral vectors, the second infection was 
performed 72 hours after the initial infection.  Transduction efficiency of H1-LV derived 
lentiviral vectors was estimated by detection of GFP expression (driven by the human 
ubiquitin c promoter) by fluorescence microscopy or flow cytometry and was routinely 
greater than 95%.   Cells transduced with the PLKO.1-DEK832 vector were selected for 
3 days in 2 µg/mL puromycin. 
Mcl-1 and Bcl-XL expression lentivirus 
The coding region of human Mcl-1 mRNA was amplified by RT-PCR from SK-
MEL-19 cells.  An N-terminal FLAG-tag was cloned in frame with the coding region of 
the cDNA, and this construct was inserted under control of the CMV promoter into the 
FG12-eGFP lentiviral vector. The FG9EF1a Bcl-XL vector was a gift from Colin Duckett 
and expresses Bcl-XL under the control of the EF1a promoter.   Lentivirus production and 
infection were performed as described previously (Denoyelle, Abou-Rjaily et al. 2006).   
Quantitative real-time RT-PCR  
Total RNA was purified from cells using the TRIZOL method  according to 
manufacturer’s instructions (Invitrogen, Carlsbad, CA).  The RNA was further purified 
using the Qiagen RNeasy mini kit (Qiagen, Chatworth, CA).  Quantitative real-time RT-
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PCR was performed using the Quantitect Sybr Green RT-PCR kit (Qiagen, Chatworth, 
CA) using the following primers:  mcl1 forward – ATGCTTCGGAAACTGGACAT;  
mcl1 reverse – TCCTGATGCCACCTTCTAGG; β-actin forward - 
CGCCCAGCACGATGAAA ; β-actin reverse - CCGCCGATCCACACAGA.  Real-time 
RT-PCR was performed and analyzed on a Bio-Rad iCycler (Bio-Rad, Hercules, CA).  
Expression of mcl-1 was normalized to that of β–actin.  The assay included a
 
no-template 
control and a standard curve of six dilutions for both mcl-1 and β–actin.
  
Results are given 
as the average of three experiments ± SE, and each sample was amplified and analyzed in 
triplicate.   
Luciferase reporter gene assays 
 The human mcl-1 promoter reporter plasmid -213/+10, which drives expression of 
firefly luciferase, was a generous gift from Dr. Douglas Cress.  Cells were transfected 
using Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA) according to manufacturer’s 
instructions.  Cells were co-transfected with the pRL-TK plasmid (Promega Corp., 
Madison, WI), which drives expression of renilla luciferase, as an internal transfection 
control. Thirty hours later cells were lysed and the lysates were assayed for firefly and 
renilla luciferase activity using the Dual Luciferase Reporter Assay System (Promega 
Corp., Madison, WI).  Luminescence was detected with a Tecan GENios plate reader 
(Phenix, Austria).  Data are presented as the mean ± SE of three experiments.   
Statistics 
Statistical analyses of the quantitative real-time RT-PCR and luciferase reporter assay 






DEK and mRNA processing 
 In Chapter II we demonstrate that the sub-nuclear localization of DEK is modified 
by acetylation.  Our observation that DEK accumulates in introchromatin granule clusters 
(IGCs) following acetylation suggests that acetylation is a regulatory mechanism of DEK 
activity.  The finding that DEK can enter IGCs, and that its migration into IGCs is 
enhanced during transcriptional inhibition strongly suggests a role in RNA processing.  In 
fact, the mere presence of a protein in IGCs has been suggested to be diagnostic for 
interactions with mRNA (Lamond and Spector 2003).  However, the significance of DEK 
migration into IGCs is unclear.  Although they are rich in RNA processing factors, IGCs 
are not an active place of RNA processing (Fakan, Leser et al. 1984; Zeng, Kim et al. 
1997; Cmarko, Verschure et al. 1999).  In agreement with this, we find that the migration 
of DEK into IGCs is not accompanied by an increase in interactions with RNA (Chapter 
II, Figure 7).  One hypothesis is that the IGCs represent a storage and assembly area for 
the formation of splicing complexes (Misteli and Spector 1997).  In this model, inactive 
splicing factors cycle to the IGC where they reassemble splicing complexes components 
and subsequently “bud” off from the IGC.  It is possible that DEK behaves in a similar 




 The link between DEK and RNA processing has been tenuous, highlighted by the 
fact that the investigators who initially described the association of DEK with splicing 
factors have themselves since abandoned the notion that DEK is a true member of the 
splicing machinery (Reichert, Le Hir et al. 2002).  Even with their use of a cross-reactive 
anti-DEK antisera, the original studies implicating DEK with this process never identified 
a direct interaction between DEK and RNA nor did they find a requirement for DEK in 
active splicing complexes (Le Hir, Izaurralde et al. 2000; McGarvey, Rosonina et al. 
2000).  Indeed, we also were unable to identify any in vivo RNA targets of DEK by RNA 
immunoprecipitation (Chapter II, Figure 8).  Nevertheless, there are still some data that 
suggest involvement of DEK in this process.  The initial association of DEK with 
splicing complexes was identified by mass spectrometry in a purification scheme free of 
the controversial antisera, making it unlikely that its association was simply an artifact.  
Additionally, we and others have found that a small but consistent fraction of DEK is 
released upon treatment with RNase (Chapter II, Figure 7) (Kappes, Burger et al. 2001).   
 The subsequent discovery that DEK could act to proofread 3’ splice sites suggests 
that DEK does have an active function in pre-mRNA processing (Soares, Zanier et al. 
2006).  However, it is difficult to reconcile this proposed function with the previous 
findings showing both an absence of DEK in splicing complexes and the ability of 
U2AF35 to mediate efficient 3’ splice site recognition in the absence of DEK (Wu, 
Romfo et al. 1999; Guth, Tange et al. 2001; Reichert, Le Hir et al. 2002; Kataoka and 
Dreyfuss 2004).  This might be partially explained by the requirement of phosphorylation 
of DEK for functional activity.  Although we demonstrate here that acetylation does not 
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promote interactions between DEK and RNA (Chapter II, Figure 7), it appears likely that 
the participation of DEK in RNA processing is regulated through phosphorylation.  Thus, 
only a fraction of total cellular DEK may actually be involved in these RNA interactions 
increasing the difficulty of detection in many experimental systems.  The authors propose 
that DEK is required for the recognition of the 3’ splice site.  However, it has previously 
been demonstrated that the factors required for effective splice site recognition vary 
depending on the RNA target (Reed 1989; Wu, Romfo et al. 1999; Guth, Tange et al. 
2001).  It is possible that the involvement of DEK in splice site recognition is limited to 
only a select subset of pre-mRNA targets, and this could account for the failure to 
identify a consistent function for DEK in splicing.  In summary, there is reasonable 
evidence linking DEK to RNA processing, but additional work is needed to validate and 
extend these results before concluding that DEK is a component of the cellular RNA 
processing machinery. 
DEK and Melanoma 
 Chapters III and IV describe two tumorigenic functions of DEK in the context of 
melanoma: inhibition of senescence and inhibition of apoptosis.  Our finding that DEK 
was ubiquitously overexpressed in metastatic melanoma lines raises the possibility that 
DEK may play an essential role in the progression of melanoma (Chapter III, Figure 9).   
 One of the most puzzling results regarding the function of DEK in melanoma is 
that interference with DEK expression produced two seemingly mutually exclusive 
phenotypes.  That is, cells that underwent senescence did not display changes in Mcl-1 
expression, and cells that downregulated Mcl-1 did not senesce.  Why are these two 
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outcomes exclusive, and what melanoma characteristics are responsible for determining 
these outcomes?     
 Melanomas display remarkable heterogeneity, and thus the different responses to 
inhibition of DEK are not entirely unexpected.  These two phenotypes may represent 
distinct roles for DEK in molecularly disparate melanomas.  Considerable effort has been 
spent in the identification of molecular signatures of melanoma.  It has become clear that 
melanomas tend to target several common pathways for activation or suppression.  
However, the precise genetic alterations used to achieve the same functional result vary 
from melanoma to melanoma.  For example, the mitogen activated protein kinase 
(MAPK) pathway is frequently activated in melanoma by mutation of either BRAF or 
NRAS (Eskandarpour, Hashemi et al. 2003; Smalley and Herlyn 2004).  Although these 
mutations both target the MAPK pathway, they are not equivalent.  As a consequence, 
BRAF mutations tend to associate with specific complementary mutations and NRAS 
mutations with a different set of alterations (Pavey, Johansson et al. 2004; Curtin, 
Fridlyand et al. 2005; Haqq, Nosrati et al. 2005; Johansson, Pavey et al. 2007).  One of 
the best described genetic differences between melanomas possessing either BRAF or 
NRAS mutations is the expression of PTEN (phosphatase and tensin homolog).  PTEN is 
an important negative regulator of another key signaling pathway in melanoma, the AKT 
pathway.  Like the MAPK pathway, the AKT signal transduction pathway is frequently 
activated in melanoma (Dai, Martinka et al. 2005; Govindarajan, Sligh et al. 2007).  
Melanomas with mutations in BRAF (which does not affect AKT signaling) frequently 
also display loss or mutation of PTEN (Tsao, Goel et al. 2004; Goel, Lazar et al. 2006).  
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In contrast, because active NRAS has a secondary effect of activating AKT signaling, 
tumors with NRAS mutations do not exhibit mutations or deletions of PTEN.   
 Interestingly, although the four melanoma lines examined in this work are all 
known to express the mutant form of BRAF (BRAF
V600E
), they differ in their expression 
of PTEN (data not shown).  Specifically, the lines SK-MEL-19 and SK-MEL-29 both 
express PTEN, while the SK-MEL-28 and SK-MEL-94 lines do not.  As presented in 
Chapters III and IV, SK-MEL-19 and SK-MEL-29 lines also downregulate Mcl-1 in 
response to DEK knockdown.  Because these lines express functional PTEN, there is no 
deregulation of AKT signaling, unlike in most melanomas.  This is noteworthy because 
of the prominent role of the AKT pathway in the regulation of Mcl-1 protein stability.  In 
what is thought to be a major Mcl-1 regulatory mechanism, active AKT signaling 
protects Mcl-1 from ubiquitination and degradation (Zhong, Gao et al. 2005; Maurer, 
Charvet et al. 2006).  The majority of melanomas display constitutive activation of AKT 
(through either mutation of NRAS or loss of PTEN function), and therefore would be 
predicted to have increased Mcl-1 protein stability.  However, a subset of melanomas that 
express both BRAF
V600E
 and wild type PTEN do not benefit from active AKT signaling, 
and thus Mcl-1 protein in these cells would be predicted to have a shorter half-life.  Thus, 
it is possible that the extremely high expression of DEK in this class of melanoma 
lacking AKT activity evolves as a mechanism to compensate for decreased Mcl-1 half-
life.    
 Because melanoma is such a genetically heterogeneous cancer, the finding that 
DEK expression is ubiquitous in metastatic melanoma is in itself of interest.  The most 
frequent mutation in melanoma is the inactivation of the p16
INK4a
 gene (Bartkova, Lukas 
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et al. 1996).  Even in cases where this gene is intact and not silenced by methylation, 
downstream components of the p16
INK4a
/pRB pathway are frequently found to be mutated 
(Walker, Flores et al. 1998).  Thus, it has been postulated that this is a requisite event in 
the progression of melanoma.  The finding that DEK is so frequently overexpressed in 
melanoma may similarly reflect its requirement for progression, or it may simply be a 
consequence of the universal inactivation of p16
INK4a
 in this cancer. 
 To better assess the significance of DEK in melanoma, it will be necessary to also 
investigate its expression in nevi and primary melanoma lesions, in addition to a larger 
set of metastatic melanomas.  Melanomas typically arise from benign nevi, most 
commonly in response to chronic exposure to ultraviolet light.  Tumor growth is initially 
radial, but as the melanoma progesses this changes to vertical growth.  The transition to 
vertical growth appears to be accompanied by the potential for metastasis (Clark, Elder et 
al. 1989; Crotty and Menzies 2004).  It is increasingly evident that melanocytes within 
benign nevi are in a state of oncogene-induced senescence.  Melanocytes residing within 
nevi frequently harbor mutations of either BRAF (80%) or NRAS (5-15%) yet do not 
proliferate (Daniotti, Oggionni et al. 2004; Thomas, Alexander et al. 2004).  This lack of 
progression is due to p16
INK4a
/pRB mediated senescence.  Accordingly, these lesions 
stain positively for both p16
INK4a
 and senescence-associated β-galactosidase activity 
(Michaloglou, Vredeveld et al. 2005; Gray-Schopfer, Cheong et al. 2006).  The 
inactivation of p16
INK4a
 through various mechanisms allows progression of melanoma 
formation.  Similarly, the transitions from radial growth to vertical growth to metastatic 
melanoma are also marked by a number of frequent alterations (Nyormoi and Bar-Eli 
2003; Haqq, Nosrati et al. 2005; Govindarajan, Sligh et al. 2007; Magnoni, Tenedini et al. 
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2007; Sousa and Espreafico 2008).    The results presented here demonstrate that in the 
progression from benign nevus to metastatic melanoma, DEK is upregulated, but they do 
not indicate at which stage(s) this upregulation occurs.  Examination of DEK expression 
in a well-sized panel of primary and metastatic melanomas, by immunohistochemistry for 
example, would be of great benefit in further elucidating the contribution of DEK to 
melanoma pathogenesis.  Additionally, confirmation of a cytogenetic correlation of 6p 
gain with DEK expression would strongly support the notion that DEK expression is a 
required event for melanoma progression. 
While we have demonstrated that the contribution of DEK expression to 
melanoma chemoresistance is due to regulation of Mcl-1, we did not identify the 
mechanism through which DEK acts to oppose senescence.  Recent data from our group 
provide some insight into how DEK may function to inhibit senescence.  We have 
discovered that DEK is required for the efficient DNA repair of double strand breaks 
(DSB) (Kappes, Fahrer et al. 2008).  As discussed in Chapter III, DNA damage signaling 
is involved in the induction of senescence in response to oncogene-induced stress, 
telomere uncapping, and accumulation of DNA damage.  Melanomas appear to exhibit 
some signs of DNA damage such as γ–H2AX foci and DNA DSBs, suggesting that 
senescence-inducing signals are present in these cells (Gorgoulis, Vassiliou et al. 2005; 
Warters, Adamson et al. 2005).  However, melanoma cells do not respond with p53-
dependent G1 arrest (Gorgoulis, Vassiliou et al. 2005).  We hypothesize that the recently 
discovered DNA repair activity of DEK may be responsible for its apparent function as 
an inhibitor of senescence.  Microarray analysis of 60 primary melanomas revealed that 
those melanomas that later gave rise to metastasis display increased expression of 
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components of DNA repair pathways (Kauffmann, Rosselli et al. 2008).  The 
overexpression of DNA repair pathway genes in melanomas with metastatic potential 
was somewhat counterintuitive because patients with inherited defects in DNA repair 
proteins, such as xeroderma pigmentosum, have an increased incidence of melanoma (Li, 
Hu et al. 2006).  However, while deficiency in DNA repair genes may promote the 
genomic instability that initially gives rise to melanoma, functioning DNA repair 
pathways promote metastatic potential (Sarasin and Kauffmann 2008).  This suggests that 
although a certain degree of genomic instability is necessary for initial transformation, 
metastasis requires the ability to withstand increased DNA damage stress.  By promoting 
DNA repair, DEK may act to permit transition from primary to metastatic melanoma.     
We additionally have found that DEK is an essential factor required for higher-
order chromatin structure, potentially by actively participating with HP1 (Kappes, 
Khodadoust et al., in preparation).  The participation of DEK in DNA repair and higher 
order chromatin structure may be interconnected.  Recent discovery of a function of the 
heterochromatin protein 1β (HP1β) in DNA repair may be of particular relevance to DEK 
(Ayoub, Jeyasekharan et al. 2008).  HP1β is phosphorylated in response to DNA damage.  
This phosphorylation of HP1β causes its release from methylated histone H3 (H3K9me), 
and consequently, greater chromatin accessibility.  Subsequently, H2AX is 
phosphorylated, which recruits DNA repair factors to the lesion.  Mutant HP1β lacking 
the essential phosphorylation site remains bound to chromatin and inhibits the 
phosphorylation of H2AX.  Notably, the kinase responsible for HP1β phosphorylation, 
CK2, is the primary kinase known to phosphorylate DEK.  It has been shown that DEK is 
not recruited to sites of DNA damage suggesting that DEK is not a repair factor per se, 
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but it is interesting to speculate that DEK may be a damage sensing factor analogous to 
HP1β that promotes repair by altering chromatin in response to double strand breaks 
(Scholten 2004).    
 Although the results presented here certainly raise many new questions, they 
provide a useful starting point for further investigation of the function of DEK in cancer.  
The continued study of DEK in the context of melanoma promises to contribute to our 






Adams, B. S., H. C. Cha, J. Cleary, T. Haiying, H. Wang, K. Sitwala and D. M. 
Markovitz (2003). "DEK binding to class II MHC Y-box sequences is gene- and 
allele-specific." Arthritis Res Ther 5(4): R226-33. 
Adams, P. D. (2007). "Remodeling of chromatin structure in senescent cells and its 
potential impact on tumor suppression and aging." Gene 397(1-2): 84-93. 
Ageberg, M., U. Gullberg and A. Lindmark (2006). "The involvement of cellular 
proliferation status in the expression of the human proto-oncogene DEK." 
Haematologica 91(2): 268-9. 
Alexiadis, V., T. Waldmann, J. Andersen, M. Mann, R. Knippers and C. Gruss (2000). 
"The protein encoded by the proto-oncogene DEK changes the topology of 
chromatin and reduces the efficiency of DNA replication in a chromatin-specific 
manner." Genes Dev 14(11): 1308-12. 
Amiard, S., M. Doudeau, S. Pinte, A. Poulet, C. Lenain, C. Faivre-Moskalenko, D. 
Angelov, N. Hug, A. Vindigni, P. Bouvet, J. Paoletti, E. Gilson and M. J. Giraud-
Panis (2007). "A topological mechanism for TRF2-enhanced strand invasion." 
Nat Struct Mol Biol 14(2): 147-54. 
Ayoub, N., A. D. Jeyasekharan, J. A. Bernal and A. R. Venkitaraman (2008). "HP1-beta 
mobilization promotes chromatin changes that initiate the DNA damage 
response." Nature. 
Bancaud, A., N. Conde e Silva, M. Barbi, G. Wagner, J. F. Allemand, J. Mozziconacci, 
C. Lavelle, V. Croquette, J. M. Victor, A. Prunell and J. L. Viovy (2006). 
"Structural plasticity of single chromatin fibers revealed by torsional 
manipulation." Nat Struct Mol Biol 13(5): 444-50. 
 
 120 
Barlev, N. A., L. Liu, N. H. Chehab, K. Mansfield, K. G. Harris, T. D. Halazonetis and S. 
L. Berger (2001). "Acetylation of p53 activates transcription through recruitment 
of coactivators/histone acetyltransferases." Mol Cell 8(6): 1243-54. 
Bartkova, J., J. Lukas, P. Guldberg, J. Alsner, A. F. Kirkin, J. Zeuthen and J. Bartek 
(1996). "The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently 
altered in melanoma pathogenesis." Cancer Res 56(23): 5475-83. 
Bennett, D. C. (2008). "How to make a melanoma: what do we know of the primary 
clonal events?" Pigment Cell Melanoma Res 21(1): 27-38. 
Bohm, F., F. Kappes, I. Scholten, N. Richter, H. Matsuo, R. Knippers and T. Waldmann 
(2005). "The SAF-box domain of chromatin protein DEK." Nucleic Acids Res 
33(3): 1101-10. 
Boyes, J., P. Byfield, Y. Nakatani and V. Ogryzko (1998). "Regulation of activity of the 
transcription factor GATA-1 by acetylation." Nature 396(6711): 594-8. 
Campillos, M., M. A. Garcia, F. Valdivieso and J. Vazquez (2003). "Transcriptional 
activation by AP-2alpha is modulated by the oncogene DEK." Nucleic Acids Res 
31(5): 1571-5. 
Carro, M. S., F. M. Spiga, M. Quarto, V. Di Ninni, S. Volorio, M. Alcalay and H. Muller 
(2006). "DEK Expression is controlled by E2F and deregulated in diverse tumor 
types." Cell Cycle 5(11): 1202-7. 
Cavellan, E., P. Asp, P. Percipalle and A. K. Farrants (2006). "The WSTF-SNF2h 
chromatin remodeling complex interacts with several nuclear proteins in 
transcription." J Biol Chem 281(24): 16264-71. 
Chaput, N., C. Flament, S. Viaud, J. Taieb, S. Roux, A. Spatz, F. Andre, J. B. LePecq, M. 
Boussac, J. Garin, S. Amigorena, C. Thery and L. Zitvogel (2006). "Dendritic cell 




Chen, L., W. Fischle, E. Verdin and W. C. Greene (2001). "Duration of nuclear NF-
kappaB action regulated by reversible acetylation." Science 293(5535): 1653-7. 
Chen, L., S. N. Willis, A. Wei, B. J. Smith, J. I. Fletcher, M. G. Hinds, P. M. Colman, C. 
L. Day, J. M. Adams and D. C. Huang (2005). "Differential targeting of 
prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary 
apoptotic function." Mol Cell 17(3): 393-403. 
Chin, L., L. A. Garraway and D. E. Fisher (2006). "Malignant melanoma: genetics and 
therapeutics in the genomic era." Genes Dev 20(16): 2149-82. 
Clark, W. H., Jr., D. E. Elder, D. t. Guerry, L. E. Braitman, B. J. Trock, D. Schultz, M. 
Synnestvedt and A. C. Halpern (1989). "Model predicting survival in stage I 
melanoma based on tumor progression." J Natl Cancer Inst 81(24): 1893-904. 
Cmarko, D., P. J. Verschure, T. E. Martin, M. E. Dahmus, S. Krause, X. D. Fu, R. van 
Driel and S. Fakan (1999). "Ultrastructural analysis of transcription and splicing 
in the cell nucleus after bromo-UTP microinjection." Mol Biol Cell 10(1): 211-23. 
Crotty, K. A. and S. W. Menzies (2004). "Dermoscopy and its role in diagnosing 
melanocytic lesions: a guide for pathologists." Pathology 36(5): 470-7. 
Curtin, J. A., J. Fridlyand, T. Kageshita, H. N. Patel, K. J. Busam, H. Kutzner, K. H. Cho, 
S. Aiba, E. B. Brocker, P. E. LeBoit, D. Pinkel and B. C. Bastian (2005). "Distinct 
sets of genetic alterations in melanoma." N Engl J Med 353(20): 2135-47. 
Dai, D. L., M. Martinka and G. Li (2005). "Prognostic significance of activated Akt 
expression in melanoma: a clinicopathologic study of 292 cases." J Clin Oncol 
23(7): 1473-82. 
Daniotti, M., M. Oggionni, T. Ranzani, V. Vallacchi, V. Campi, D. Di Stasi, G. D. Torre, 
F. Perrone, C. Luoni, S. Suardi, M. Frattini, S. Pilotti, A. Anichini, G. Tragni, G. 
Parmiani, M. A. Pierotti and M. Rodolfo (2004). "BRAF alterations are associated 




Denoyelle, C., G. Abou-Rjaily, V. Bezrookove, M. Verhaegen, T. M. Johnson, D. R. 
Fullen, J. N. Pointer, S. B. Gruber, L. D. Su, M. A. Nikiforov, R. J. Kaufman, B. 
C. Bastian and M. S. Soengas (2006). "Anti-oncogenic role of the endoplasmic 
reticulum differentially activated by mutations in the MAPK pathway." Nat Cell 
Biol 8(10): 1053-63. 
Devany, M., F. Kappes, K. M. Chen, D. M. Markovitz and H. Matsuo (2008). "Solution 
NMR structure of the N-terminal domain of the human DEK protein." Protein Sci 
17(2): 205-15. 
Devany, M., N. P. Kotharu and H. Matsuo (2004). "Solution NMR structure of the C-
terminal domain of the human protein DEK." Protein Sci 13(8): 2252-9. 
Di Micco, R., M. Fumagalli, A. Cicalese, S. Piccinin, P. Gasparini, C. Luise, C. Schurra, 
M. Garre, P. G. Nuciforo, A. Bensimon, R. Maestro, P. G. Pelicci and F. d'Adda 
di Fagagna (2006). "Oncogene-induced senescence is a DNA damage response 
triggered by DNA hyper-replication." Nature 444(7119): 638-42. 
Dijkers, P. F., R. H. Medema, J. W. Lammers, L. Koenderman and P. J. Coffer (2000). 
"Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the 
forkhead transcription factor FKHR-L1." Curr Biol 10(19): 1201-4. 
Dimri, G. P., X. Lee, G. Basile, M. Acosta, G. Scott, C. Roskelley, E. E. Medrano, M. 
Linskens, I. Rubelj, O. Pereira-Smith and et al. (1995). "A biomarker that 
identifies senescent human cells in culture and in aging skin in vivo." Proc Natl 
Acad Sci U S A 92(20): 9363-7. 
Dingwall, C. and R. A. Laskey (1991). "Nuclear targeting sequences--a consensus?" 
Trends Biochem Sci 16(12): 478-81. 




Eberle, J., B. M. Kurbanov, A. M. Hossini, U. Trefzer and L. F. Fecker (2007). 
"Overcoming apoptosis deficiency of melanoma-hope for new therapeutic 
approaches." Drug Resist Updat 10(6): 218-34. 
Eskandarpour, M., J. Hashemi, L. Kanter, U. Ringborg, A. Platz and J. Hansson (2003). 
"Frequency of UV-inducible NRAS mutations in melanomas of patients with 
germline CDKN2A mutations." J Natl Cancer Inst 95(11): 790-8. 
Eskiw, C. H., G. Dellaire and D. P. Bazett-Jones (2004). "Chromatin contributes to 
structural integrity of promyelocytic leukemia bodies through a SUMO-1-
independent mechanism." J Biol Chem 279(10): 9577-85. 
Fakan, S., G. Leser and T. E. Martin (1984). "Ultrastructural distribution of nuclear 
ribonucleoproteins as visualized by immunocytochemistry on thin sections." J 
Cell Biol 98(1): 358-63. 
Faulkner, N. E., J. M. Hilfinger and D. M. Markovitz (2001). "Protein phosphatase 2A 
activates the HIV-2 promoter through enhancer elements that include the pets 
site." J Biol Chem 276(28): 25804-12. 
Fecker, L. F., C. C. Geilen, G. Tchernev, U. Trefzer, C. Assaf, B. M. Kurbanov, C. 
Schwarz, P. T. Daniel and J. Eberle (2006). "Loss of proapoptotic Bcl-2-related 
multidomain proteins in primary melanomas is associated with poor prognosis." J 
Invest Dermatol 126(6): 1366-71. 
Fu, G. K., G. Grosveld and D. M. Markovitz (1997). "DEK, an autoantigen involved in a 
chromosomal translocation in acute myelogenous leukemia, binds to the HIV-2 
enhancer." Proc Natl Acad Sci U S A 94(5): 1811-5. 
Fu, G. K. and D. M. Markovitz (1996). "Purification of the pets factor. A nuclear protein 
that binds to the inducible TG-rich element of the human immunodeficiency virus 
type 2 enhancer." J Biol Chem 271(32): 19599-605. 
Gamble, M. J. and R. P. Fisher (2007). "SET and PARP1 remove DEK from chromatin to 
permit access by the transcription machinery." Nat Struct Mol Biol 14(6): 548-55. 
 
 124 
Goel, V. K., A. J. Lazar, C. L. Warneke, M. S. Redston and F. G. Haluska (2006). 
"Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous 
melanoma." J Invest Dermatol 126(1): 154-60. 
Gogas, H. J., J. M. Kirkwood and V. K. Sondak (2007). "Chemotherapy for metastatic 
melanoma: time for a change?" Cancer 109(3): 455-64. 
Gorgoulis, V. G., L. V. Vassiliou, P. Karakaidos, P. Zacharatos, A. Kotsinas, T. Liloglou, 
M. Venere, R. A. Ditullio, Jr., N. G. Kastrinakis, B. Levy, D. Kletsas, A. Yoneta, 
M. Herlyn, C. Kittas and T. D. Halazonetis (2005). "Activation of the DNA 
damage checkpoint and genomic instability in human precancerous lesions." 
Nature 434(7035): 907-13. 
Govindarajan, B., J. E. Sligh, B. J. Vincent, M. Li, J. A. Canter, B. J. Nickoloff, R. J. 
Rodenburg, J. A. Smeitink, L. Oberley, Y. Zhang, J. Slingerland, R. S. Arnold, J. 
D. Lambeth, C. Cohen, L. Hilenski, K. Griendling, M. Martinez-Diez, J. M. 
Cuezva and J. L. Arbiser (2007). "Overexpression of Akt converts radial growth 
melanoma to vertical growth melanoma." J Clin Invest 117(3): 719-29. 
Grasemann, C., S. Gratias, H. Stephan, A. Schuler, A. Schramm, L. Klein-Hitpass, H. 
Rieder, S. Schneider, F. Kappes, A. Eggert and D. R. Lohmann (2005). "Gains 
and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in 
retinoblastoma." Oncogene 24(42): 6441-9. 
Gray-Schopfer, V. C., S. C. Cheong, H. Chong, J. Chow, T. Moss, Z. A. Abdel-Malek, R. 
Marais, D. Wynford-Thomas and D. C. Bennett (2006). "Cellular senescence in 
naevi and immortalisation in melanoma: a role for p16?" Br J Cancer 95(4): 496-
505. 
Griffith, J. D., L. Comeau, S. Rosenfield, R. M. Stansel, A. Bianchi, H. Moss and T. de 
Lange (1999). "Mammalian telomeres end in a large duplex loop." Cell 97(4): 
503-14. 
Guth, S., T. O. Tange, E. Kellenberger and J. Valcarcel (2001). "Dual function for 
U2AF(35) in AG-dependent pre-mRNA splicing." Mol Cell Biol 21(22): 7673-81. 
 
 125 
Hagstrom, K. A. and B. J. Meyer (2003). "Condensin and cohesin: more than 
chromosome compactor and glue." Nat Rev Genet 4(7): 520-34. 
Haqq, C., M. Nosrati, D. Sudilovsky, J. Crothers, D. Khodabakhsh, B. L. Pulliam, S. 
Federman, J. R. Miller, 3rd, R. E. Allen, M. I. Singer, S. P. Leong, B. M. Ljung, 
R. W. Sagebiel and M. Kashani-Sabet (2005). "The gene expression signatures of 
melanoma progression." Proc Natl Acad Sci U S A 102(17): 6092-7. 
Hawley-Nelson, P., K. H. Vousden, N. L. Hubbert, D. R. Lowy and J. T. Schiller (1989). 
"HPV16 E6 and E7 proteins cooperate to immortalize human foreskin 
keratinocytes." EMBO J 8(12): 3905-10. 
Hayakawa, F., M. Towatari, Y. Ozawa, A. Tomita, M. L. Privalsky and H. Saito (2004). 
"Functional regulation of GATA-2 by acetylation." J Leukoc Biol 75(3): 529-40. 
Hoglund, M., D. Gisselsson, G. B. Hansen, V. A. White, T. Sall, F. Mitelman and D. 
Horsman (2004). "Dissecting karyotypic patterns in malignant melanomas: 
temporal clustering of losses and gains in melanoma karyotypic evolution." Int J 
Cancer 108(1): 57-65. 
Horton, P., K. J. Park, T. Obayashi, N. Fujita, H. Harada, C. J. Adams-Collier and K. 
Nakai (2007). "WoLF PSORT: protein localization predictor." Nucleic Acids Res 
35(Web Server issue): W585-7. 
Hough, R. E., J. R. Goepel, H. E. Alcock, B. W. Hancock, P. C. Lorigan and D. W. 
Hammond (2001). "Copy number gain at 12q12-14 may be important in the 
transformation from follicular lymphoma to diffuse large B cell lymphoma." Br J 
Cancer 84(4): 499-503. 
Hu, H. G., H. Illges, C. Gruss and R. Knippers (2005). "Distribution of the chromatin 
protein DEK distinguishes active and inactive CD21/CR2 gene in pre- and mature 
B lymphocytes." Int Immunol 17(6): 789-96. 
 
 126 
Hu, H. G., I. Scholten, C. Gruss and R. Knippers (2007). "The distribution of the DEK 
protein in mammalian chromatin." Biochem Biophys Res Commun 358(4): 1008-
14. 
Irmler, M., M. Thome, M. Hahne, P. Schneider, K. Hofmann, V. Steiner, J. L. Bodmer, 
M. Schroter, K. Burns, C. Mattmann, D. Rimoldi, L. E. French and J. Tschopp 
(1997). "Inhibition of death receptor signals by cellular FLIP." Nature 388(6638): 
190-5. 
Jemal, A., R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray and M. J. Thun (2008). "Cancer 
statistics, 2008." CA Cancer J Clin 58(2): 71-96. 
Johansson, P., S. Pavey and N. Hayward (2007). "Confirmation of a BRAF mutation-
associated gene expression signature in melanoma." Pigment Cell Res 20(3): 216-
21. 
Johung, K., E. C. Goodwin and D. DiMaio (2007). "Human papillomavirus E7 repression 
in cervical carcinoma cells initiates a transcriptional cascade driven by the 
retinoblastoma family, resulting in senescence." J Virol 81(5): 2102-16. 
Jonsson, G., C. Dahl, J. Staaf, T. Sandberg, P. O. Bendahl, M. Ringner, P. Guldberg and 
A. Borg (2007). "Genomic profiling of malignant melanoma using tiling-
resolution arrayCGH." Oncogene 26(32): 4738-48. 
JR, P. o., D. G. Norman, J. Bramham, M. E. Bianchi and D. M. Lilley (1998). "HMG box 
proteins bind to four-way DNA junctions in their open conformation." EMBO J 
17(3): 817-26. 
Kappes, F., K. Burger, M. Baack, F. O. Fackelmayer and C. Gruss (2001). "Subcellular 
localization of the human proto-oncogene protein DEK." J Biol Chem 276(28): 
26317-23. 
Kappes, F., C. Damoc, R. Knippers, M. Przybylski, L. A. Pinna and C. Gruss (2004). 
"Phosphorylation by protein kinase CK2 changes the DNA binding properties of 
the human chromatin protein DEK." Mol Cell Biol 24(13): 6011-20. 
 
 127 
Kappes, F., J. Fahrer, M. S. Khodadoust, A. Tabbert, C. Strasser, N. Mor-Vaknin, M. 
Moreno-Villanueva, A. Burkle, D. M. Markovitz and E. Ferrando-May (2008). 
"DEK is a poly(ADP-ribose)-acceptor in apoptosis and mediates resistance to 
genotoxic stress." Mol Cell Biol. 
Kappes, F., I. Scholten, N. Richter, C. Gruss and T. Waldmann (2004). "Functional 
domains of the ubiquitous chromatin protein DEK." Mol Cell Biol 24(13): 6000-
10. 
Kataoka, N. and G. Dreyfuss (2004). "A simple whole cell lysate system for in vitro 
splicing reveals a stepwise assembly of the exon-exon junction complex." J Biol 
Chem 279(8): 7009-13. 
Kauffmann, A., F. Rosselli, V. Lazar, V. Winnepenninckx, A. Mansuet-Lupo, P. Dessen, 
J. J. van den Oord, A. Spatz and A. Sarasin (2008). "High expression of DNA 
repair pathways is associated with metastasis in melanoma patients." Oncogene 
27(5): 565-73. 
Kouzine, F., S. Sanford, Z. Elisha-Feil and D. Levens (2008). "The functional response of 
upstream DNA to dynamic supercoiling in vivo." Nat Struct Mol Biol 15(2): 146-
54. 
Lamond, A. I. and W. C. Earnshaw (1998). "Structure and function in the nucleus." 
Science 280(5363): 547-53. 
Lamond, A. I. and D. L. Spector (2003). "Nuclear speckles: a model for nuclear 
organelles." Nat Rev Mol Cell Biol 4(8): 605-12. 
Lau, O. D., T. K. Kundu, R. E. Soccio, S. Ait-Si-Ali, E. M. Khalil, A. Vassilev, A. P. 
Wolffe, Y. Nakatani, R. G. Roeder and P. A. Cole (2000). "HATs off: selective 




Le Hir, H., D. Gatfield, E. Izaurralde and M. J. Moore (2001). "The exon-exon junction 
complex provides a binding platform for factors involved in mRNA export and 
nonsense-mediated mRNA decay." EMBO J 20(17): 4987-97. 
Le Hir, H., E. Izaurralde, L. E. Maquat and M. J. Moore (2000). "The spliceosome 
deposits multiple proteins 20-24 nucleotides upstream of mRNA exon-exon 
junctions." EMBO J 19(24): 6860-9. 
Li, C., Z. Hu, Z. Liu, L. E. Wang, S. S. Strom, J. E. Gershenwald, J. E. Lee, M. I. Ross, 
P. F. Mansfield, J. N. Cormier, V. G. Prieto, M. Duvic, E. A. Grimm and Q. Wei 
(2006). "Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk 
of cutaneous melanoma: a case-control analysis." Cancer Epidemiol Biomarkers 
Prev 15(12): 2526-32. 
Lowe, S. W., E. Cepero and G. Evan (2004). "Intrinsic tumour suppression." Nature 
432(7015): 307-15. 
Magnoni, C., E. Tenedini, F. Ferrari, L. Benassi, C. Bernardi, G. Gualdi, G. Bertazzoni, 
E. Roncaglia, L. Fantoni, R. Manfredini, S. Bicciato, S. Ferrari, A. Giannetti and 
E. Tagliafico (2007). "Transcriptional profiles in melanocytes from clinically 
unaffected skin distinguish the neoplastic growth pattern in patients with 
melanoma." Br J Dermatol 156(1): 62-71. 
Markovitz, D. M., M. J. Smith, J. Hilfinger, M. C. Hannibal, B. Petryniak and G. J. Nabel 
(1992). "Activation of the human immunodeficiency virus type 2 enhancer is 
dependent on purine box and kappa B regulatory elements." J Virol 66(9): 5479-
84. 
Marzio, G., C. Wagener, M. I. Gutierrez, P. Cartwright, K. Helin and M. Giacca (2000). 
"E2F family members are differentially regulated by reversible acetylation." J 
Biol Chem 275(15): 10887-92. 
Maurer, U., C. Charvet, A. S. Wagman, E. Dejardin and D. R. Green (2006). "Glycogen 
synthase kinase-3 regulates mitochondrial outer membrane permeabilization and 
apoptosis by destabilization of MCL-1." Mol Cell 21(6): 749-60. 
 
 129 
McGarvey, T., E. Rosonina, S. McCracken, Q. Li, R. Arnaout, E. Mientjes, J. A. 
Nickerson, D. Awrey, J. Greenblatt, G. Grosveld and B. J. Blencowe (2000). "The 
acute myeloid leukemia-associated protein, DEK, forms a splicing-dependent 
interaction with exon-product complexes." J Cell Biol 150(2): 309-20. 
Meyn, M. S., J. M. Lu-Kuo and L. B. Herzing (1993). "Expression cloning of multiple 
human cDNAs that complement the phenotypic defects of ataxia-telangiectasia 
group D fibroblasts." Am J Hum Genet 53(6): 1206-16. 
Michaloglou, C., L. C. Vredeveld, M. S. Soengas, C. Denoyelle, T. Kuilman, C. M. van 
der Horst, D. M. Majoor, J. W. Shay, W. J. Mooi and D. S. Peeper (2005). 
"BRAFE600-associated senescence-like cell cycle arrest of human naevi." Nature 
436(7051): 720-4. 
Misteli, T. and D. L. Spector (1997). "Protein phosphorylation and the nuclear 
organization of pre-mRNA splicing." Trends Cell Biol 7(4): 135-8. 
Mor-Vaknin, N., A. Punturieri, K. Sitwala, N. Faulkner, M. Legendre, M. S. Khodadoust, 
F. Kappes, J. H. Ruth, A. Koch, D. Glass, L. Petruzzelli, B. S. Adams and D. M. 
Markovitz (2006). "The DEK nuclear autoantigen is a secreted chemotactic 
factor." Mol Cell Biol 26(24): 9484-96. 
Nakano, K. and K. H. Vousden (2001). "PUMA, a novel proapoptotic gene, is induced by 
p53." Mol Cell 7(3): 683-94. 
Nguyen, M., R. C. Marcellus, A. Roulston, M. Watson, L. Serfass, S. R. Murthy 
Madiraju, D. Goulet, J. Viallet, L. Belec, X. Billot, S. Acoca, E. Purisima, A. 
Wiegmans, L. Cluse, R. W. Johnstone, P. Beauparlant and G. C. Shore (2007). 
"Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes 
MCL-1-mediated resistance to apoptosis." Proc Natl Acad Sci U S A 104(49): 
19512-7. 
Nyormoi, O. and M. Bar-Eli (2003). "Transcriptional regulation of metastasis-related 
genes in human melanoma." Clin Exp Metastasis 20(3): 251-63. 
 
 130 
Oda, E., R. Ohki, H. Murasawa, J. Nemoto, T. Shibue, T. Yamashita, T. Tokino, T. 
Taniguchi and N. Tanaka (2000). "Noxa, a BH3-only member of the Bcl-2 family 
and candidate mediator of p53-induced apoptosis." Science 288(5468): 1053-8. 
Oltersdorf, T., S. W. Elmore, A. R. Shoemaker, R. C. Armstrong, D. J. Augeri, B. A. 
Belli, M. Bruncko, T. L. Deckwerth, J. Dinges, P. J. Hajduk, M. K. Joseph, S. 
Kitada, S. J. Korsmeyer, A. R. Kunzer, A. Letai, C. Li, M. J. Mitten, D. G. 
Nettesheim, S. Ng, P. M. Nimmer, J. M. O'Connor, A. Oleksijew, A. M. Petros, J. 
C. Reed, W. Shen, S. K. Tahir, C. B. Thompson, K. J. Tomaselli, B. Wang, M. D. 
Wendt, H. Zhang, S. W. Fesik and S. H. Rosenberg (2005). "An inhibitor of Bcl-2 
family proteins induces regression of solid tumours." Nature 435(7042): 677-81. 
Orlic, M., C. E. Spencer, L. Wang and B. L. Gallie (2006). "Expression analysis of 6p22 
genomic gain in retinoblastoma." Genes Chromosomes Cancer 45(1): 72-82. 
Paderova, J., M. Orlic-Milacic, M. Yoshimoto, G. da Cunha Santos, B. Gallie and J. A. 
Squire (2007). "Novel 6p rearrangements and recurrent translocation breakpoints 
in retinoblastoma cell lines identified by spectral karyotyping and mBAND 
analyses." Cancer Genet Cytogenet 179(2): 102-11. 
Pavey, S., P. Johansson, L. Packer, J. Taylor, M. Stark, P. M. Pollock, G. J. Walker, G. 
M. Boyle, U. Harper, S. J. Cozzi, K. Hansen, L. Yudt, C. Schmidt, P. Hersey, K. 
A. Ellem, M. G. O'Rourke, P. G. Parsons, P. Meltzer, M. Ringner and N. K. 
Hayward (2004). "Microarray expression profiling in melanoma reveals a BRAF 
mutation signature." Oncogene 23(23): 4060-7. 
Petkova, V., M. J. Romanowski, I. Sulijoadikusumo, D. Rohne, P. Kang, T. Shenk and A. 
Usheva (2001). "Interaction between YY1 and the retinoblastoma protein. 
Regulation of cell cycle progression in differentiated cells." J Biol Chem 276(11): 
7932-6. 
Pietrzak, M. and M. Puzianowska-Kuznicka (2008). "p53-dependent repression of the 
human MCL-1 gene encoding an anti-apoptotic member of the BCL-2 family: the 
role of Sp1 and of basic transcription factor binding sites in the MCL-1 
promoter." Biol Chem. 
 
 131 
Poux, A. N., M. Cebrat, C. M. Kim, P. A. Cole and R. Marmorstein (2002). "Structure of 
the GCN5 histone acetyltransferase bound to a bisubstrate inhibitor." Proc Natl 
Acad Sci U S A 99(22): 14065-70. 
Puthalakath, H., L. A. O'Reilly, P. Gunn, L. Lee, P. N. Kelly, N. D. Huntington, P. D. 
Hughes, E. M. Michalak, J. McKimm-Breschkin, N. Motoyama, T. Gotoh, S. 
Akira, P. Bouillet and A. Strasser (2007). "ER stress triggers apoptosis by 
activating BH3-only protein Bim." Cell 129(7): 1337-49. 
Qin, J. Z., H. Xin, L. A. Sitailo, M. F. Denning and B. J. Nickoloff (2006). "Enhanced 
killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA." Cancer 
Res 66(19): 9636-45. 
Raposo, G., H. W. Nijman, W. Stoorvogel, R. Liejendekker, C. V. Harding, C. J. Melief 
and H. J. Geuze (1996). "B lymphocytes secrete antigen-presenting vesicles." J 
Exp Med 183(3): 1161-72. 
Reed, R. (1989). "The organization of 3' splice-site sequences in mammalian introns." 
Genes Dev 3(12B): 2113-23. 
Reichert, V. L., H. Le Hir, M. S. Jurica and M. J. Moore (2002). "5' exon interactions 
within the human spliceosome establish a framework for exon junction complex 
structure and assembly." Genes Dev 16(21): 2778-91. 
Romig, H., F. O. Fackelmayer, A. Renz, U. Ramsperger and A. Richter (1992). 
"Characterization of SAF-A, a novel nuclear DNA binding protein from HeLa 
cells with high affinity for nuclear matrix/scaffold attachment DNA elements." 
EMBO J 11(9): 3431-40. 
Saha, A., J. Wittmeyer and B. R. Cairns (2006). "Chromatin remodelling: the industrial 
revolution of DNA around histones." Nat Rev Mol Cell Biol 7(6): 437-47. 
Sammons, M., S. S. Wan, N. L. Vogel, E. J. Mientjes, G. Grosveld and B. P. Ashburner 
(2006). "Negative regulation of the RelA/p65 transactivation function by the 
product of the DEK proto-oncogene." J Biol Chem 281(37): 26802-12. 
 
 132 
Santos, G. C., M. Zielenska, M. Prasad and J. A. Squire (2007). "Chromosome 6p 
amplification and cancer progression." J Clin Pathol 60(1): 1-7. 
Sarasin, A. and A. Kauffmann (2008). "Overexpression of DNA repair genes is 
associated with metastasis: A new hypothesis." Mutat Res. 
Satyamoorthy, K., N. H. Chehab, M. J. Waterman, M. C. Lien, W. S. El-Deiry, M. 
Herlyn and T. D. Halazonetis (2000). "Aberrant regulation and function of wild-
type p53 in radioresistant melanoma cells." Cell Growth Differ 11(9): 467-74. 
Scholten, I. (2004). Characterisation of the proto-oncoprotein DEK. Konstanz, University 
of Konstanz. 
Scholzen, T. and J. Gerdes (2000). "The Ki-67 protein: from the known and the 
unknown." J Cell Physiol 182(3): 311-22. 
Schubert, S., S. Horstmann, T. Bartusel and K. H. Klempnauer (2004). "The cooperation 
of B-Myb with the coactivator p300 is orchestrated by cyclins A and D1." 
Oncogene 23(7): 1392-404. 
Selzer, E., H. Schlagbauer-Wadl, I. Okamoto, H. Pehamberger, R. Potter and B. Jansen 
(1998). "Expression of Bcl-2 family members in human melanocytes, in 
melanoma metastases and in melanoma cell lines." Melanoma Res 8(3): 197-203. 
Serrano, M., A. W. Lin, M. E. McCurrach, D. Beach and S. W. Lowe (1997). "Oncogenic 
ras provokes premature cell senescence associated with accumulation of p53 and 
p16INK4a." Cell 88(5): 593-602. 
Sierakowska, H., K. R. Williams, I. S. Szer and W. Szer (1993). "The putative 
oncoprotein DEK, part of a chimera protein associated with acute myeloid 




Sitwala, K. V., K. Adams and D. M. Markovitz (2002). "YY1 and NF-Y binding sites 
regulate the transcriptional activity of the dek and dek-can promoter." Oncogene 
21(57): 8862-70. 
Smalley, K. S. and M. Herlyn (2004). "Loitering with intent: new evidence for the role of 
BRAF mutations in the proliferation of melanocytic lesions." J Invest Dermatol 
123(4): xvi-xvii. 
Soares, L. M., K. Zanier, C. Mackereth, M. Sattler and J. Valcarcel (2006). "Intron 
removal requires proofreading of U2AF/3' splice site recognition by DEK." 
Science 312(5782): 1961-5. 
Soengas, M. S., P. Capodieci, D. Polsky, J. Mora, M. Esteller, X. Opitz-Araya, R. 
McCombie, J. G. Herman, W. L. Gerald, Y. A. Lazebnik, C. Cordon-Cardo and S. 
W. Lowe (2001). "Inactivation of the apoptosis effector Apaf-1 in malignant 
melanoma." Nature 409(6817): 207-11. 
Sousa, J. F. and E. M. Espreafico (2008). "Suppression subtractive hybridization profiles 
of radial growth phase and metastatic melanoma cell lines reveal novel potential 
targets." BMC Cancer 8: 19. 
Spilianakis, C., J. Papamatheakis and A. Kretsovali (2000). "Acetylation by PCAF 
enhances CIITA nuclear accumulation and transactivation of major 
histocompatibility complex class II genes." Mol Cell Biol 20(22): 8489-98. 
Stansel, R. M., T. de Lange and J. D. Griffith (2001). "T-loop assembly in vitro involves 
binding of TRF2 near the 3' telomeric overhang." EMBO J 20(19): 5532-40. 
Sterner, D. E. and S. L. Berger (2000). "Acetylation of histones and transcription-related 
factors." Microbiol Mol Biol Rev 64(2): 435-59. 
Tarkkanen, M., I. Elomaa, C. Blomqvist, A. H. Kivioja, P. Kellokumpu-Lehtinen, T. 
Bohling, J. Valle and S. Knuutila (1999). "DNA sequence copy number increase 
at 8q: a potential new prognostic marker in high-grade osteosarcoma." Int J 
Cancer 84(2): 114-21. 
 
 134 
Thomas, N. E., A. Alexander, S. N. Edmiston, E. Parrish, R. C. Millikan, M. Berwick, P. 
Groben, D. W. Ollila, D. Mattingly and K. Conway (2004). "Tandem BRAF 
mutations in primary invasive melanomas." J Invest Dermatol 122(5): 1245-50. 
Tomita, A., M. Towatari, S. Tsuzuki, F. Hayakawa, H. Kosugi, K. Tamai, T. Miyazaki, 
T. Kinoshita and H. Saito (2000). "c-Myb acetylation at the carboxyl-terminal 
conserved domain by transcriptional co-activator p300." Oncogene 19(3): 444-51. 
Tsao, H., V. Goel, H. Wu, G. Yang and F. G. Haluska (2004). "Genetic interaction 
between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in 
melanoma." J Invest Dermatol 122(2): 337-41. 
Varga-Weisz, P., K. van Holde and J. Zlatanova (1993). "Preferential binding of histone 
H1 to four-way helical junction DNA." J Biol Chem 268(28): 20699-700. 
Vernell, R., K. Helin and H. Muller (2003). "Identification of target genes of the 
p16INK4A-pRB-E2F pathway." J Biol Chem 278(46): 46124-37. 
Waldmann, T., C. Eckerich, M. Baack and C. Gruss (2002). "The ubiquitous chromatin 
protein DEK alters the structure of DNA by introducing positive supercoils." J 
Biol Chem 277(28): 24988-94. 
Waldmann, T., I. Scholten, F. Kappes, H. G. Hu and R. Knippers (2004). "The DEK 
protein--an abundant and ubiquitous constituent of mammalian chromatin." Gene 
343(1): 1-9. 
Walker, G. J., J. F. Flores, J. M. Glendening, A. H. Lin, I. D. Markl and J. W. Fountain 
(1998). "Virtually 100% of melanoma cell lines harbor alterations at the DNA 
level within CDKN2A, CDKN2B, or one of their downstream targets." Genes 
Chromosomes Cancer 22(2): 157-63. 
Wang, M. D., M. J. Schnitzer, H. Yin, R. Landick, J. Gelles and S. M. Block (1998). 




Wang, Y. F., C. C. Jiang, K. A. Kiejda, S. Gillespie, X. D. Zhang and P. Hersey (2007). 
"Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-
independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-
1." Clin Cancer Res 13(16): 4934-42. 
Warters, R. L., P. J. Adamson, C. D. Pond and S. A. Leachman (2005). "Melanoma cells 
express elevated levels of phosphorylated histone H2AX foci." J Invest Dermatol 
124(4): 807-17. 
Webley, K., J. A. Bond, C. J. Jones, J. P. Blaydes, A. Craig, T. Hupp and D. Wynford-
Thomas (2000). "Posttranslational modifications of p53 in replicative senescence 
overlapping but distinct from those induced by DNA damage." Mol Cell Biol 
20(8): 2803-8. 
Wise-Draper, T. M., H. V. Allen, E. E. Jones, K. B. Habash, H. Matsuo and S. I. Wells 
(2006). "Apoptosis inhibition by the human DEK oncoprotein involves 
interference with p53 functions." Mol Cell Biol 26(20): 7506-19. 
Wise-Draper, T. M., H. V. Allen, M. N. Thobe, E. E. Jones, K. B. Habash, K. Munger 
and S. I. Wells (2005). "The human DEK proto-oncogene is a senescence 
inhibitor and an upregulated target of high-risk human papillomavirus E7." J 
Virol 79(22): 14309-17. 
Wolter, K. G., M. Verhaegen, Y. Fernandez, Z. Nikolovska-Coleska, M. Riblett, C. M. de 
la Vega, S. Wang and M. S. Soengas (2007). "Therapeutic window for melanoma 
treatment provided by selective effects of the proteasome on Bcl-2 proteins." Cell 
Death Differ 14(9): 1605-16. 
Wu, S., C. M. Romfo, T. W. Nilsen and M. R. Green (1999). "Functional recognition of 
the 3' splice site AG by the splicing factor U2AF35." Nature 402(6763): 832-5. 
Xue, Y., F. Zhou, C. Fu, Y. Xu and X. Yao (2006). "SUMOsp: a web server for 
sumoylation site prediction." Nucleic Acids Res 34(Web Server issue): W254-7. 
 
 136 
Youle, R. J. and A. Strasser (2008). "The BCL-2 protein family: opposing activities that 
mediate cell death." Nat Rev Mol Cell Biol 9(1): 47-59. 
Yu, J., L. Zhang, P. M. Hwang, K. W. Kinzler and B. Vogelstein (2001). "PUMA induces 
the rapid apoptosis of colorectal cancer cells." Mol Cell 7(3): 673-82. 
Zeng, C., E. Kim, S. L. Warren and S. M. Berget (1997). "Dynamic relocation of 
transcription and splicing factors dependent upon transcriptional activity." EMBO 
J 16(6): 1401-12. 
Zha, J., H. Harada, E. Yang, J. Jockel and S. J. Korsmeyer (1996). "Serine 
phosphorylation of death agonist BAD in response to survival factor results in 
binding to 14-3-3 not BCL-X(L)." Cell 87(4): 619-28. 
Zhang, R., W. Chen and P. D. Adams (2007). "Molecular dissection of formation of 
senescence-associated heterochromatin foci." Mol Cell Biol 27(6): 2343-58. 
Zhong, Q., W. Gao, F. Du and X. Wang (2005). "Mule/ARF-BP1, a BH3-only E3 
ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates 
apoptosis." Cell 121(7): 1085-95. 
Zhou, Z., L. J. Licklider, S. P. Gygi and R. Reed (2002). "Comprehensive proteomic 
analysis of the human spliceosome." Nature 419(6903): 182-5. 
Zhuang, L., C. S. Lee, R. A. Scolyer, S. W. McCarthy, X. D. Zhang, J. F. Thompson and 
P. Hersey (2007). "Mcl-1, Bcl-XL and Stat3 expression are associated with 
progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during 
progression of melanoma." Mod Pathol 20(4): 416-26. 
Zlatanova, J. and K. van Holde (1998). "Binding to four-way junction DNA: a common 
property of architectural proteins?" FASEB J 12(6): 421-31. 
 
 
